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Executive summary
The 19th meeting of the WHO Expert Committee on the Selection and Use of 
Essential Medicines took place in Geneva, Switzerland, from 8 to 12 April 2013. 
The report was approved by the Committee on 1 October 2013. The purpose of 
the meeting was to review and update the 17th WHO Model List of Essential 
Medicines (EML) and the 3rd WHO Model List of Essential Medicines for 
Children (EMLc). The Expert Committee members and temporary advisers 
who participated in the meeting are listed in the report, together with their 
declarations of interest.
In accordance with its approved procedures1 the Expert Committee 
evaluated the scientific evidence on the comparative effectiveness, safety and 
cost–effectiveness of medicines to update the EML and the EMLc. The Expert 
Committee considered 52 applications and 15 reviews and:
 ■ approved the addition of 17 new medicines to the EML (10 to the 
core list and seven to the complementary list);
 ■ approved the deletion of one medicine from the EML;
 ■ approved new indications for three medicines already listed on 
the EML;
 ■ approved the addition of a new dosage form or strength for four 
medicines already on the EML;
 ■ approved the moving of two medicines from the complementary list 
to the core list, and one from the core list to the complementary list;
 ■ rejected nine applications for the addition of medicines to the EML 
and deferred a decision in the case of a further two applications;
 ■ approved two medicines for neonatal care.
The following are some of the main recommendations in order of their 
appearance on the Model List.
Section 2. Analgesics, antipyretics, non-steroidal anti-inflammatory medicines 
(NSAIMS), medicines used to treat gout, and disease-modifying agents in 
rheumatoid disorders (DMARDs): The section was renamed “Medicines for 
pain and palliative care” to emphasize the importance of the medicines used in 
palliative care. The Expert Committee recognized the importance of palliative 
care not only in cancer but also in HIV/AIDS, multidrug-resistant tuberculosis 
and severe congenital diseases. Therefore it moved these medicines from 
Section 8 (Antineoplastic, immunosuppressives and medicines used in palliative 
1  See: http://www.who.int/selection_medicines/committees/subcommittee/2/eeb1098%5b1%5d.pdf.
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care) to Section 2 in both the EML and the EMLc. Medicines needed for the 
treatment of other common symptoms in palliative care – such as anorexia, 
nausea, constipation and diarrhoea – were also included in Section 2. A new 
section on “Medicines for diseases of joints” (Section 30) was created to list 
the treatments for gout and the disease-modifying agents used in rheumatoid 
disorders and juvenile joint diseases that were deleted from Section 2.
Section 6.4. Antiviral medicines: The Expert Committee considered the 
applications submitted for addition, deletion and modification of antiretrovirals 
and noted the ongoing work on Consolidated guidelines on the use of antiretroviral 
drugs for treating and preventing HIV infection: recommendations for a public 
health approach scheduled for publication in June 2013. In consultation with 
the relevant departments in WHO, the Expert Committee decided to defer the 
applications until the guidelines had been published.
Section 6.4.3. Other antivirals: Pegylated interferon alpha (2a or 2b) was added 
for the treatment of hepatitis C (in combination with ribavarin), for obtaining 
a sustainable virological response. Although this combination is now being 
used with direct-acting antivirals in some countries, the Expert Committee 
noted the high level of expertise and specialized facilities needed for safe and 
effective use of interferons, as well as the high cost, and therefore included it in 
the complementary list.
In the same section, the Expert Committee considered the application 
for deletion of oseltamivir. The Expert Committee reviewed all the evidence 
available to it and decided to retain oseltamivir in the list, with only the restricted 
indication of treatment of potentially severe or complicated illness due to 
confirmed or suspected influenza virus infection, in accordance with WHO 
treatment guidelines.
Section 6.5.3.1. Antimalarial medicines, curative treatment: The Expert Committee 
added artesunate + mefloquine fixed-dose combination tablets for the treatment 
of malaria in adults and children in line with current WHO treatment guidelines. 
In making its decision, the Expert Committee noted that both medicines were 
listed separately in the EML and the EMLc, and that evaluation in clinical trials had 
shown similar comparative efficacy of the separate tablets and the combination. 
Some products containing the fixed-dose combination have been approved by 
the United Nations prequalification programme administered by WHO. With 
this addition, three of the five fixed-dose combinations recommended by WHO 
for the treatment of malaria are included in the core list.
Section 8.2. Cytotoxic and adjuvant medicines: After considering the applications 
for the addition of imatinib and trastuzumab, the Expert Committee decided that 
an urgent review of this subsection was needed, using a process and structure 
Executive Summary
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similar to that used for the same section in the EMLc. This process would require 
identification in adults of the treatable tumours of public health relevance and 
identification of the medicines required to treat those tumours, within the 
context of a stepwise development of cancer care systems in the overall context 
of health system development. The Expert Committee considered the two 
applications in detail and noted the high quality of evidence showing relevant 
clinical benefits in support of both imatinib and trastuzumab but deferred the 
final specifications of the medicines and their inclusion until the review of the 
section of cytotoxics is completed.
Section 11. Blood products and plasma substitutes: After considering the 
application for the addition of whole blood and red blood cells, the Expert 
Committee decided to restructure this section. The heading was changed to 
“Blood products of human origin and plasma substitutes”. Subsection 11.1 was 
retitled “Blood and blood components” to include fresh–frozen plasma, red blood 
cells, platelets and whole blood. Subsection 11.2 was renamed “Plasma-derived 
medicinal products” with a Subsection 11.2.1 on “Human immunoglobulins” and 
a Subsection 11.2.2 on “Blood coagulation factors”. The title of Subsection 11.3 
was changed to “Plasma substitutes”.
Section 21. Ophthalmological preparations: Bevacizumab injection was added to 
the complementary list in a new section of the EML (Section 21.6: Anti-vascular 
endothelial growth factor (VEGF) preparations). Neovascular age-related macular 
degeneration is a leading cause of blindness in persons over 50 years of age and 
bevacizumab has been shown to be effective with an acceptable risk profile. The 
Expert Committee recommended the addition of bevacizumab, while noting 
the precautions needed for intravitreal administration.
Section 22.1. Oxytocics: The application for deletion of misoprostol was 
based  on interpretation of the data presented to the previous meeting of 
the Expert Committee. After considering the available evidence, the Expert 
Committee decided to retain misoprostol, restating that it was for the prevention 
of postpartum haemorrhage where oxytocin is not available or cannot be 
safely used.
Section 24.1. Medicines used in psychotic disorders: Risperidone was added to 
the core list as an alternative to chlorpromazine or haloperidol, and clozapine 
was added to the complementary list. The Expert Committee considered 
the application for risperidone and decided to list this second-generation 
antipsychotic on the basis of its efficacy, adverse effects, availability and cost. 
Clozapine was added to the complementary list for individuals with psychosis 
who do not respond to other antipsychotics, provided that laboratory facilities 
are available for regular monitoring of white blood cells.
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Section 29. Specific medicines for neonatal care: Chlorhexidine 7.1% solution 
or gel delivering 4% was added to the core list for use in umbilical cord care in 
community settings. A new subsection (Section 29.2: Medicines administered 
to the mother) was added. Dexamethasone was included for accelerated fetal 
lung maturation in anticipated preterm birth; the efficacy of steroids for this 
condition had been conclusively demonstrated. While alternative steroids 
with similar efficacy were available, dexamethasone was considered the most 
appropriate product in terms of availability and cost.
Other medicines added were: loperamide, loratadine (for adults only 
in the context of palliative care), hyoscine butyl bromide, gliclazide (to replace 
glibenclamide), azithromycin eye drops, latanoprost eye drops and ofloxacin 
eye drops, which were added to the core list; and fomepizole, hydromorphone, 
oxycodone and protionamide which were added to the complementary list.
The Expert Committee deleted dithranol, which is used topically for the 
treatment of psoriasis. The adverse effects could be severe and, when compared 
with other treatments, the relative efficacy was poor.
The Expert Committee did not approve the following proposals 
for addition of medicines: colchicine, naproxen, bedaquiline, a fixed-dose 
combination of isoniazid + pyridoxine + sulfamethoxazole + trimethoprim 
(because there is currently no marketed product), a new formulation of 
ferrous salt + folic acid, a fixed-dose combination for secondary prevention of 
cardiovascular disease, ketorolac eye drops, ketotifen eye drops, and montelukast.
The Expert Committee also noted that, given the increasing number of 
applications, the limited time available at Expert Committee meetings and the 
need to coordinate with the development of WHO guidelines, more frequent 
meetings and alternative methods such as virtual meetings are required to 
respond in a timely manner to new clinical developments.
All applications and documents considered by the Expert Committee 
remain available on the WHO website for the meeting.2
Further information on the current EML (the 18th edition) and the 
EMLc (the 4th edition) can be found on the WHO website.3
2  See: http://www.who.int/selection_medicines/committees/expert/19.
3  See: http://www.who.int/medicines/publications/essentialmedicines.
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blood products, but would not contribute to any decisions on these applications.
Dr Liliana de Lima declared being the Executive Director of the International Association 
for Hospice and Palliative Care. As this organization was an applicant in relation to the 
palliative care listings, Dr de Lima was recused from involvement in the consideration of 
these applications. Dr de Lima also disclosed her involvement in various WHO committees, 
including those dealing with ensuring balance in controlled substances policies and 
paediatric pain.
Mr Andrew Gray disclosed remunerated consultancies for UNAIDS and WHO relating 
to the preparation of a strategic report on development and cooperation in the 
pharmaceutical sectors in Brazil, the Russian Federation, India, China and South Africa 
(the BRICS countries), in relation to medicines for HIV/AIDS, tuberculosis and malaria and 
priority medicines for noncommunicable diseases, and the preparation of a systematic 
review and position paper on the interchangeability of lamivudine and emtricitabine. 
Mr Gray declared having received support from Fresenius Kabi and Pfizer for continuing 
education presentations unrelated to any specific products. He also disclosed that 
he was involved as a consultant pharmacist to the Centre for the AIDS Programme of 
Research in South Africa (CAPRISA), which was a site for National Institute of Health 
trials (AIDS Clinical Trials Group and International Maternal Pediatric Adolescent AIDS 
Clinical Trials Group networks). The networks received donated trial medication from 
various manufacturers, including Abbott, Boehringer Ingelheim, Bristol Myers Squibb, 
Gilead, GlaxoSmithKline, Merck Sharpe & Dohme, and Roche. In addition, he had been 
a co-investigator in a USAID and LifeLab-funded phase IIb clinical trial of a microbicide 
containing tenofovir (active ingredient supplied by Gilead, and packed by Conrad). 
Mr Gray further disclosed that he was a member of an expert committee of the South 
African Medicines Control Council.
Dr Suzanne Hill disclosed being a former staff member of WHO, and in that context 
having been the principal investigator of the Bill & Melinda Gates Foundation-funded 
Better Medicines for Children project, which had been completed. Dr Hill disclosed that 
she was chairperson of the Australian Pharmaceutical Benefit Advisory Committee, in 
which capacity she had made public statements on general issues related to medicines.
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Dr Alar Irs disclosed being employed by the Estonian State Agency of Medicines and 
being a member of various scientific committees of the European Medicines Agency.
Apart from where specifically mentioned, none of these disclosures was considered 
material to the work of the Expert Committee and no actions were necessary in relation 
to the involvement of any of these members.
Professor Hany Abdel-Aleem, Professor Lisa Bero, Dr Youping Li, Professor Johannes 
Löwer, Dr Nicola Magrini and Dr Shalini Sri Ranganathan reported no conflicts of interest.
The temporary advisers present declared the following interests
Dr Kuruvilla Prasad Mathews disclosed having previously been a member of a committee 
constituted by the Office of the Drug Controller General – New Drugs Division, New Delhi 
(part of the Indian Ministry of Health).
Dr Eva W. Njenga disclosed having received travel support from Eli Lilly and Novo Nordisk 
to attend conferences in 2011 and 2012.
Dr Le Van Truyen disclosed being the chairman of the Scientific Board of the Vietnam 
Institute of Dietary Supplements (VIDS).
Professor Gitanjali Batmanabane disclosed having previously worked for the Better 
Medicines for Children project in the WHO Regional Office for South-East Asia.
None of these disclosures was considered material to the work of the Expert Committee 
and no actions were necessary in relation to the involvement of any of these temporary 
advisers.
Dr Gilles Sama Kwende disclosed no potential conflicts of interest.
In addition, the Secretary of the Expert Committee, Dr Krisantha Weerasuriya, disclosed 
that he had been a member of the Scientific Advisory Committee of the Drugs for Neglected 
Diseases initiative (DNDi) since 2007. On the advice of the WHO Legal department, Dr 
Weerasuriya was recused from all discussion of any applications submitted by DNDi.
11. Introduction
The 19th meeting of the World Health Organization (WHO) Expert Committee 
on the Selection and Use of Essential Medicines was held from 8 to 12 March 
2013, in Geneva, Switzerland.
The meeting was opened on behalf of the Director-General of WHO 
by Dr Marie-Paule Kieny, Assistant Director-General for Health Systems and 
Innovation. Dr Kieny welcomed the participants to the meeting and summarized 
the history of the WHO Model List of Essential Medicines (EML), beginning 
with the request of Member States in the 1970s for a list of “important medicines”. 
The Essential Medicines concept was elaborated in 1975 and the first WHO EML 
was developed by the first meeting of the Expert Committee on the Selection 
of Essential Medicines in 1977. At its second meeting the Expert Committee 
decided that its focus should be “the Selection and Use of Essential Medicines”, 
thus emphasizing that selection of medicines is by itself insufficient and that it 
should always be accompanied by consideration of the use of those medicines. 
The 19th meeting of the Expert Committee revised the 17th Model List of 
Essential Medicines, which would then become the 18th EML.
Dr Kieny highlighted three changes that had taken place since 1977. 
The first change was the evolution from an expert opinion-based process to an 
evidence-based one. Second, the EML had gone from a list that was selected 
from existing medicines to a list that also recommended specific indications and, 
where necessary, proposed what new formulations should be available on the 
basis of health-care needs. Third, the Expert Committee had progressed from 
a consultation of experts to a wider consultative process involving the global 
health community.
The wide spectrum of applications was highlighted, ranging from 
dexamethasone used since the 1970s for pregnant women at risk of preterm 
labour to improve the lung maturity in the unborn child to monoclonal antibodies 
for the treatment of cancer. The EML provided support for the Millennium 
Development Goals, especially in relation to the fourth goal (reducing child 
mortality rates), the fifth goal (improving maternal health) and the sixth goal 
(combating HIV, malaria and other diseases).
Dr Kieny noted that Expert Committee members are selected from 
panels of experts that are nominated from many organizations and governments. 
Expert Panel and Expert Committee members are required to provide advice as 
individuals, however, and may not take directions from any external organization 
or government. She thanked the members for their participation and expressed 
appreciation for their deliberations.
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2. Open session
The open session of the meeting was chaired by Dr Marie-Paule Kieny, WHO 
Assistant Director-General for Health Systems and Innovation, on behalf of the 
Director-General, and was attended by several interested parties. Participants 
were welcomed by Mr Kees de Joncheere, Director of the Department of Essential 
Medicines and Health Products.
The Secretary of the Expert Committee, Dr Krisantha Weerasuriya, 
provided a brief update on activities since the last meeting of the Expert 
Committee. Dr Weerasuriya described the dissemination of the report of the 
18th meeting of the Expert Committee, efforts to ensure access to priority life‐
saving medicines for women and children, the Better Medicines for Children 
Project and the WHO Model Formulary. Ms Hanne Bak Pedersen of the WHO 
Regional Office for Europe drew attention to the need for a similar process for the 
evidence-based selection of essential medical devices, including diagnostic tests. 
Dr Hill, a member of the Expert Committee, noted that all countries, including 
high-income countries, are facing significant challenges with new and expensive 
medicines. International efforts to ensure affordable prices for such products are 
urgently needed. Work in the area of public health, innovation and intellectual 
property has been ongoing for several years, but progress has been slow.
The following presentations, of relevance to the agenda of the Expert 
Committee, were made by interested parties:
 ■ Dr Willem Scholten (Consultant, Medicines and Controlled 
Substances, Geneva, Switzerland) – “Messages on WHO essential 
medicines: pivotal for access to pain management”
 ■ Professor Lukas Radbruch (Incoming Chair of the International 
Association for Hospice and Palliative Care, Houston, TX, USA; 
Director, Department of Palliative Medicine, University Hospital 
Bonn, Germany) – “Relieving suffering: essential medicines in 
palliative care”
 ■ Dr Leslie Lehmann (Clinical Director, Pediatric Hematopoietic Stem 
Cell Transplant Program, Dana/Farber/Children’s Hospital Cancer 
Center, Boston; Assistant Professor of Pediatrics, Harvard Medical 
School, Boston, MA, USA) in collaboration with Ms Julie Torode 
(Deputy CEO, Union for International Cancer Control, Geneva, 
Switzerland) and Ms Mélanie Samsom (Global Advocacy Specialist, 
Union for International Cancer Control, Geneva, Switzerland) – 
“The case for support: addressing the needs of cancer patients 
worldwide in the WHO Model Essential Medicines List”
Open session
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 ■ Professor Tom Harrison and Professor Juan Luis Rodriguez Tudela 
(Global Action Fund for Fungal Infections, Geneva, Switzerland) - 
“Essential antifungals”
 ■ Dr Harvey G. Klein (Department of Transfusion Medicine, Clinical 
Center, National Institutes of Health, Bethesda, MD, USA) – “Blood 
is an essential medicine”
 ■ Dr Gilles Folléa (Executive Director, European Blood Alliance, 
Brussels, Belgium) – “Addition of whole blood and red blood cells 
on the WHO essential medicine lists: an assessment of pros and 
cons from the European Blood Alliance”
 ■ Dr Che Kit Lin (Chief Executive and Medical Director, Hong 
Kong Red Cross Blood Transfusion Service, Hong Kong, China) – 
“Statement from international transfusion medicine experts”.
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3. General items
3.1 Defining public health relevance
WHO currently defines essential medicines as follows:
“Essential medicines are those that satisfy the priority health care needs 
of the population”.
Essential medicines are selected with due regard to their public health relevance, 
evidence of efficacy and safety, and comparative cost–effectiveness.
The public health relevance of a medicine has been variously described 
by previous Expert Committees meetings as including:
 ■ the incidence and prevalence of the disease;
 ■ the burden of disease, based on formal Global Burden of Disease 
estimates, disability-adjusted life-years or other evaluations;
 ■ region-specific needs (e.g. medicines for visceral leishmaniasis are 
on the EML but this disease is prevalent in only two WHO regions);
 ■ evidence of potential impact or high effectiveness (e.g. if a medicine 
is highly effective in relation to relevant outcomes – in terms of 
magnitude of effects or capacity to cure or control – for a particular 
condition, it has been more likely to be accepted as essential even if 
the target disease is relatively uncommon (e.g. recombinant surfactant 
in acute respiratory distress syndrome in infants);
 ■ the potential political impact of identifying a medicine as essential 
for advocacy purposes.
The Expert Committee previously considered the question of drugs for 
orphan diseases in 2007. Although a proposal to add a separate list of drugs for 
rare diseases was debated at that time, the Expert Committee did not accept the 
proposal. Cost–effectiveness criteria were suggested as an alternative approach, 
but experience in high-income countries with “orphan drugs” suggested that total 
expenditure on very expensive medicines for very rare disorders can become 
unaffordable very rapidly.
To date the Expert Committee has not set rigid rules for defining when a 
proposal for a particular medicine satisfies the criterion of public health relevance. 
However, several applications before the 19th meeting were for conditions that 
challenged the Expert Committee’s interpretation of public health relevance. 
These included, but were not limited to, imatinib for chronic myeloid leukaemia 
and colchicine for familial Mediterranean fever.
A potentially useful consideration is described in the report by Kanavos 
et al. on value-based pricing (1). The authors note, with respect to antiretrovirals:
General items
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“HIV treatment is a special case, where, in the face of a new global 
pandemic affecting both rich and poor populations, new products were 
priced at levels affordable in the context of rich world health care delivery 
(i.e. to include R&D costs and/or investment returns sufficient to justify 
continuing highly risked research expenditures). As was obvious from a 
very early stage in the pandemic, these were unaffordable in the areas of 
greatest need. Hence special intervention before the normal processes of 
patent expiry and mass commodity level production had occurred was 
required, leading to considerable controversy.”
Arguably, adding a medicine to the WHO EML might precipitate a “special 
intervention” before the normal processes of patent expiry and could be used as 
an advocacy tool to reduce the price of the medicine. This would be an additional 
consideration regarding the public health relevance of the medicine.
As in its previous meetings, the Expert Committee relied on a case-
by-case consideration of public health relevance and potential health impact 
in evaluating applications for inclusion in the EML. The Expert Committee 
confirmed that it would need to be convinced in each case primarily on the basis 
of the incidence and prevalence of the disease being addressed (even if limited 
to a single geographical region) and evidence of the burden of disease, and that 
it would also take into account the value represented in terms of effectiveness, as 
well as the potential for advocacy purposes. The Expert Committee decided that 
any simple, mechanical cut-off point based on any one of these considerations 
would not be consistent with its established principles.
3.2 Medicines information as a global public good
Since the start of effective regulation of medicines in the early 1960s, the usual 
system for licensing a new medicine has been for a sponsor of a product to 
nominate an indication for use, and for this indication or claim to become the 
basis for a review by regulatory authorities. Over time, additional indications 
may develop and be proposed for licensing – or not – on the basis of commercial 
and clinical considerations. Once a product is off-patent, however, the original 
sponsor’s responsibility for keeping the indications consistent with clinical 
evidence and medical practice seems to end. Safety-related changes to product 
documentation may occur in some systems but generally the product-specific 
information document is no longer adequately maintained. Ensuring correct 
and updated information on a medicine is not only a regulatory issue but is also 
relevant to the medicine’s rational and appropriate use.
Some commercial or not-for-profit drug information sources – such as 
the British National Formulary or Micromedex (a commercial drug information 
source) – may provide information on the newer, unapproved indications, 
contraindications and adverse effects. However, the information that is published 
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by these organizations does not have the same legal and regulatory basis as a 
product information sheet supported by a manufacturer or product sponsor.
Examples of medicines for which the original information is now obsolete 
include cytotoxics such as dacarbazine (in some countries contraindicated in 
the Summary of Product Characteristics (SPC) for Hodgkin lymphoma, for 
which it is a standard of care), methotrexate (used for multiple autoimmune and 
inflammatory disorders), and changed indications for anti-inflammatory drugs 
such as colchicine. In relation to medicines for children, indications and dosing 
regimens are often off-label, although increasingly there is evidence to support 
some uses (e.g. first-line drugs for tuberculosis) or doses.
The difficulty at national level is to determine who should take 
responsibility for maintaining “old” product SPCs. Depending on the national 
legislation relating to the supply of medicines, the production of new labelling 
may also require assuming legal liability. Given that the majority of medicine 
regulatory authorities now depend on application fees from industry to support 
their activities, the resources available to noncommercial entities to update 
such documents are nearly always scarce. While the capacity to prepare such a 
dossier may exist in many pharmaceutical companies, such resources may not 
be available to an academic group acting in the public interest.
The Expert Committee considered the potential role of WHO in 
supporting countries in maintaining up-to-date product information documents. 
One option could be to use the WHO Essential Medicines process to identify 
essential medicines for which the product information documents do not reflect 
the most recent clinical evidence and clinical practice. By working globally it 
might be possible to organize collaboration with groups such as the Cochrane 
Collaboration to summarize the clinical evidence and make it generally 
available. Although there would still need to be national processes in place to 
manage the legal requirements, a global approach to maintaining information 
about a medicine could be seen as a global public health good. Such documents 
could be particularly useful for drug regulatory authorities in low- and middle-
income countries.
The Expert Committee noted that it had previously considered 
evidence of efficacy and safety and demonstrable public health importance as 
the main criteria for inclusion in the EML, rather than the indications having 
been approved by regulatory authorities in national settings (e.g. ribavirin 
for haemorrhagic fever). The Expert Committee noted that the inclusion of 
indications in regulatory documents (such as the label or SPC) was nearly always 
based on the request of the sponsor/applicant. The Expert Committee was 
therefore in favour of an expanded role for WHO in ensuring that indications 
for which evidence exists are recognized in product information documents. The 
Expert Committee recommended that this issue be raised with the International 
Conference of Drug Regulatory Authorities (ICDRA).
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3.3 Other
The Expert Committee encouraged the Secretariat to evaluate different options 
for convening the Committee and for modifying the Committee processes 
for updating the EML. The Expert Committee noted the necessity for more 
frequent meetings, making use of facilities such as video-conferencing and 
teleconferencing. The Expert Committee also noted the large number of 
applications to be considered at its 19th meeting and suggested that the Secretariat 
should consider whether there is a maximum number of applications that it is 
feasible to consider in a single meeting.
The Expert Committee recalled the decision made at the 17th meeting 
with respect to applications for medicines for children, namely: “In its report, 
the Subcommittee concluded that it had satisfied its terms of reference and 
recommended, in principle, that the Subcommittee be dissolved. The Expert 
Committee agreed and made the recommendation to the Executive Board and 
the Director-General that the Subcommittee had fulfilled its terms of reference 
regarding the development and revision of the WHO Model List of Essential 
Medicines for Children and should now be dissolved. Future Expert Committees 
should, however, include adequate expertise to consider medicines for children 
and maintain the EMLc.”
The Expert Committee noted that the numbers of applications for adult 
and paediatric medicines considered at the 19th meeting were almost equal, but 
that the composition of the Committee did not reflect this distribution. It was felt 
that there is a need to ensure adequate expertise when convening future Expert 
Committees. A possible alternative would be to re-establish the Subcommittee 
as part of an overall reform of the working methods of the Expert Committee.
The Expert Committee also drew attention to another comment from 
the report of the 17th meeting: “The Committee recognized the importance 
of coordinating the maintenance and further development of the two lists, for 
example, by requiring that use in children and adults be considered in every 
application for inclusion in the Model List. If the applicant leaves either aspect out, 
the Secretariat should request this omission to be addressed by the applicant or 
other party as appropriate.” It was felt that the applications submitted to the 19th 
meeting did not uniformly consider adult and child indications when relevant.
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4. Applications only for paediatric medicines
Section 1: Anaesthetics
Anaesthetics (review) – Children
The 18th meeting of the Expert Committee posed the question: “What 
anaesthetics can be safely used in neonates?” A review on this topic, limited to 
general anaesthetics, was prepared by Dr Elizabeth Zisovska, Skopje, the former 
Yugoslav Republic of Macedonia.
Expert reviews were provided by Dr Gitanjali Batmanabane and Dr Gilles 
Sama Kwende.
Several studies in immature animal models were reviewed and there 
was some evidence of degenerative effects of several anaesthetics on neuronal 
structure. However, the relevance of these effects to neonates was not clear (2, 3). 
It was noted that many general anaesthetics are not licensed for children, and 
especially neonates. The reasons for this are complex but may be related to the 
lack of data on safety or toxicity in children, again especially in neonates.
There are physiological and pharmacological differences between 
neonates and children as well as between children and adults, which have been 
partially reflected in modifications of dose (4). In neonates there is good evidence 
that inadequate pain relief is associated with negative short-term and long-term 
effects. Neonatal boys who were circumcised without analgesia had a more 
pronounced pain reaction to later immunization injections compared with those 
who had received active analgesia with a mixture of lidocaine and prilocaine 
(5, 6). Hence adequate pain relief and anaesthesia appear to be important for 
the neonate.
The goals of anaesthesia in neonates are largely the same as in adults and 
children (7), namely:
 ■ minimization of physiological, humoral and behavioural signs 
of distress;
 ■ reduction of pain;
 ■ ablation of consciousness;
 ■ maximization of perioperative outcomes.
The major issue is lack of appropriate studies – and therefore lack of 
evidence – in neonates. This is a common problem with medicines for children. 
Hence any extrapolation from adult data needs to be reviewed when data from 
neonates become available.
The review proposed:
 ■ Halothane should not be the preferred inhalational anaesthetic 
in neonates, and an age restriction of above 1 month should be 
included in the listing.
Applications only for paediatric medicines
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 ■ Isoflurane is safe in neonates for induction and maintenance and 
should therefore be retained in the WHO Model List of Essential 
Medicines for Children (EMLc).
 ■ Nitrous oxide and oxygen should both be retained in the EMLc.
 ■ Ketamine should be retained in the EMLc, although a paediatric 
formulation would be useful to improve safety during administration.
 ■ The use of propofol should be restricted to patients aged over 
1 month.
 ■ Thiopental should be added to the EMLc as it is licensed for use 
in neonates.
Having considered the review, the Expert Committee recommended no 
additions to the list but agreed to add clarifications on age restrictions where 
these have been specified by regulatory authorities. Propofol was approved for 
induction but not for maintenance in neonates. Since thiopental is licensed for 
use in neonates, this fact should be mentioned in the list. The Expert Committee 
noted the declining use of halothane but felt that, in the absence of alternatives, 
it remains an accessible option in some settings.
Section 2: Non-steroidal anti-inflammatory medicines (NSAIMs) 
and medicines used to treat gout and disease-modifying agents 
in rheumatoid disorders (DMARDs)
2.2: Opioid analgesics
Hydromorphone (addition) – Children
Oxycodone (addition) – Children
Two applications were submitted by Dr Willem Scholten, former team leader 
(until 31 October 2012), Access to Controlled Medicines, WHO. The first 
application was for the addition of hydromorphone and oxycodone, as examples 
of the opioid class, to the EMLc.
Expert reviews were provided by Dr Gitanjali Batmanabane and Dr Le 
Van Truyen.
These two applications were based on recommendations in the WHO 
Guidelines on the pharmacological treatment of persisting pain in children with 
medical illnesses, published in 2012, and the WHO policy guidelines Ensuring 
balance in national policies on controlled substances: guidance for availability 
and accessibility of controlled medicines (8, 9). The listing was requested as a 
footnote to the square box appended to the morphine listing, which would read 
as “Examples for alternative opioids for morphine. Two or more alternatives 
should be available in addition to morphine.”
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The WHO documents advise that two or more opioids should be made 
available to allow switching of opioids and/or route of administration in children 
in the presence of inadequate analgesic effect and/or intolerable side-effects. 
However, the application itself stated that there is a need for comparative trials of 
opioids in terms of effectiveness, adverse effects and feasibility of use in children 
with persistent pain due to medical illnesses. No evidence was provided on 
specific subsets of patients responding to a second opioid when there has been 
no response to the first. There was also no estimate of the proportion of children 
who might have a poor response to morphine. The bulk of the evidence presented 
in relation to both the hydromorphone and oxycodone applications dealt with 
acute pain in children.
There is high availability of oxycodone (though less of hydromorphone) 
in high-income countries, with multiple formulations being marketed. However, 
no listing was provided of the formulations that are available in low- and middle-
income countries.
The Expert Committee recommended that a square box symbol be added 
to the listing for morphine, with a note that alternatives would be limited to 
hydromorphone and oxycodone.
Morphine (new formulation) – Children
The second application submitted by Dr Willem Scholten, team leader (until 31 
October 2012), Access to Controlled Medicines, WHO, was for the addition of 
morphine granules and tablets (both slow-release) to the EMLc. The application 
also requested that the terminology be standardized as slow-release and requested 
that dosage and formulae for morphine oral solution should be published as an 
annex to the published meeting report in the WHO Technical Report Series.
Expert reviews were provided by Dr Abdol Majid Cheraghali and Dr Le 
Van Truyen.
The WHO Guidelines on the pharmacological treatment of persisting pain 
in children with medical illnesses recommend morphine as the first-line strong 
opioid treatment for persisting moderate to severe pain (8). The application 
stated that insufficient formulations and strengths of morphine were available 
to treat pain in paediatric groups ranging from infants to children of 12 years of 
age. Therefore, it was proposed that slow-release granules, which would allow 
morphine to be administered as liquid in very small doses for infants, should 
be added to the EMLc. The advantage of slow-release morphine is longer dose 
intervals, which could improve patient compliance by decreasing dose frequency. 
Additional points relate to the inter-individual variation in the response to 
morphine and the need for titration for pain relief. As there is no upper dosage 
limit for opioid analgesics, the application also noted the need for high-end 
strengths of morphine to be added to the EMLc.
Applications only for paediatric medicines
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The Expert Committee noted that the available studies that support the 
use of oral morphine in cancer have been conducted in adults. Thus there is a 
need for comparative trials of opioids in terms of effectiveness, side-effects and 
feasibility of use in children with persisting pain due to medical illness.
The Expert Committee noted requests that the standard term “slow-
release” should be used rather than “controlled-release”, “modified-release” and 
“prolonged-release” and recommended that this term be implemented in the 
EMLc section on morphine. However, it was felt that use of the same approach 
in other sections would require a review of the applicability of this terminology 
for the full range of preparations in all therapeutic areas.
The Expert Committee recommended the addition of morphine granules 
and slow-release tablets to the EMLc and noted the dosage recommendations 
in the WHO guidelines (8) and in the formulas for morphine oral solution 
included in the highlights for pharmacists in Persisting pain in children, 
published in 2012 (8).
Section 6: Anti-infective medicines
6.2: Antibacterials
6.2.4: Antituberculosis medicines
Second-line antituberculosis medicines (review) – Children
An application to review second-line antituberculosis medicines was prepared 
by staff of the Desmond Tutu TB Centre, Department of Paediatrics and Child 
Health, Faculty of Medicine and Health Sciences, Stellenbosch University, 
Tygerberg, South Africa.
Expert reviews were prepared by Dr Lisa Bero and Dr Gitanjali 
Batmanabane. Comments were received from Médecins Sans Frontières (MSF).
Assuming that 10–15% of the disease burden is in children, a conservative 
estimate of 63 000 prevalent cases of multidrug-resistant tuberculosis (MDR-TB) 
per year in children can be made. Possibly due to challenges in confirming the 
diagnosis in younger ages, lack of awareness of the disease, limited experience in 
its management, and lack of access to child-friendly or otherwise adequate drugs, 
few children are being diagnosed and treated for MDR-TB and there is a paucity 
of published experience on paediatric MDR-TB.
WHO categorizes the antituberculosis drugs in five groups (10, 11). 
Group 1 is “First-line oral agents” (e.g. isoniazid, rifampicin), Group 2 is 
“Injectable agents” (e.g. kanamycin, amikacin), Group 3 is “Fluoroquinolones”, 
Group 4 is “Oral bacteriostatic second-line agents” (e.g. ethionamide, cycloserine) 
and Group 5 is “Agents with unclear efficacy or concerns regarding usage” 
(e.g. clofazimine, linezolid). WHO guidelines recommend including a second-
line injectable agent from Group 2 and a fluoroquinolone from Group 3, with 
additional drugs from Groups 4 and 5 to create a treatment regimen with at 
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least 4–5 active drugs (10). These guidelines are generally consistent with those 
recommended by other organizations (12).
The Expert Committee noted that the evaluation of the efficacy of 
antituberculosis drugs has generally relied on microbiological, and not clinical, 
end-points. Due to differences in the pathophysiology of tuberculosis in children 
– especially the paucibacillary nature of the majority of paediatric disease – and 
difficulties with obtaining sputum specimens, the evaluation of microbiological 
end-points in children is challenging. Evidence to inform the selection of agents 
for treating MDR-TB (defined as disease caused by Mycobacterium tuberculosis 
resistant to at least rifampicin and isoniazid) in children is essentially limited 
to outcome data from treatment cohorts and these confirm the efficacy of the 
medicines in Groups 2–4.
The efficacy of ofloxacin, levofloxacin, and moxifloxacin against MDR-TB 
has been extensively evaluated in vitro, in both animals and humans. Although 
multiple systematic reviews did not identify any randomized trials in MDR-TB, 
they synthesized the data from many observational studies. A recent individual 
patient data (IPD) meta-analysis used reports identified in these systematic 
reviews to provide a more detailed analysis (13). This review included data from 
9153 patients drawn from 32 observational cohorts, and reported improved 
treatment success with the use of a later-generation fluoroquinole (FLQ) versus 
no FLQ (adjusted odds ratio, aOR: 2.8; 95% confidence interval, CI: 1.3–6.1) 
and versus ofloxacin (aOR: 2.1, 95% CI: 1.2–3.9), and with the use of ofloxacin 
versus no FLQ (aOR: 2.0, 95% CI: 1.2–3.3). In a retrospective observational 
study comparing ofloxacin and levofloxacin for MDR-TB treatment in adults, 
levofloxacin was more efficacious, with increased treatment success in ofloxacin-
susceptible isolates (96.2% for levofloxacin versus 87.5% for ofloxacin) and in 
ofloxacin-resistant isolates (78.6% for levofloxacin versus 45.5% for ofloxacin) 
(14). A systematic review of adults with extensively drug-resistant tuberculosis 
(XDR-TB) reported that use of later-generation FLQs was associated with 
improved outcomes (15).
In a systematic review of children treated for MDR-TB, FLQs were an 
important component of the treatment regimen in all included studies, which 
had a pooled treatment success of 81.7% (16). More recently, in a cohort of 
children with MDR-TB in which an FLQ was a key component of the treatment 
regimen, 137 of 149 (92%) achieved a cure or probable cure (17).
The FLQs are generally well tolerated by adults receiving the prolonged 
treatment required for MDR-TB. Data on extended administration of FLQs 
to children have not demonstrated serious adverse effects. Despite a lack of 
randomized trials of the FLQs in the treatment of MDR-TB in adults or children, 
their strong bactericidal and sterilizing activity, favourable pharmacokinetics and 
toxicity profile have made them an important component of existing MDR-TB 
treatment regimens. WHO’s Rapid advice: treatment of tuberculosis in children, 
Applications only for paediatric medicines
13
published in 2010, makes a strong recommendation for the use of FLQs in 
the treatment of drug-resistant TB but did not specify which of the FLQs are 
preferred in children (18). Additional data are needed with regard to paediatric 
dosing of the FLQs in MDR-TB, particularly in the case of levofloxacin and 
moxifloxacin. Pharmacokinetic data to inform the most appropriate dosing in 
children are urgently needed and are likely to be forthcoming from ongoing 
studies. Existing formulations of these drugs are difficult to dose appropriately 
and to administer to children.
All three injectable medicines – kanamycin, amikacin and capreomycin 
– are currently included in the EMLc. There are few data on use in children 
although, in a subgroup analysis in a systematic review of paediatric MDR-TB, 
treatment success was higher in studies in which patients received injectables 
compared with studies where they were not commonly used (87.2% versus 
62.6%, P = 0.02) (16).
Ethionamide (ETH) is already included in the EMLc. ETH and 
protionamide (PTH) have shown bactericidal activity in vitro against 
M. tuberculosis, with PTH minimum inhibitory concentrations usually reported as 
either equal to or half that of ETH. In a trial in adults that compared ETH 500 mg 
in two divided doses with PTH 500 mg in two divided doses, in combination 
with isoniazid and streptomycin, there was no difference in treatment efficacy, 
with 98% and 96% of patients respectively having negative cultures at six months 
(19). In an IPD meta-analysis of 9153 patients with MDR-TB, the use of ETH or 
PTH was associated with increased odds of treatment success versus failure or 
relapse (aOR: 1.7, 95% CI: 1.3–2.3) and versus failure, relapse or death (aOR: 1.7, 
95% CI: 1.4–2.1) (13). ETH was a component of the usual treatment regimens in 
all the cohorts included in a recent systematic review of children with MDR-TB, 
which reported a pooled treatment success of 81.7% (16). There is expected to be 
complete cross-resistance between ETH and PTH.
Cycloserine is already included in the EMLc. There are questions about 
the efficacy of cycloserine, and neurotoxicity is an important adverse event 
in the treatment of MDR-TB in adults (20). Published paediatric experience 
consists of two small series in the 1960s which described the use of cycloserine in 
combination with isoniazid in the treatment of 29 children and which reported 
generally good outcomes and few adverse effects (21, 22). Because of the limited 
choices available for treatment, cycloserine remains an important option in the 
treatment of MDR-TB.
There is very little English-language literature on the use of terizidone 
(TZD) for tuberculosis. In combination with other drugs, TZD at a dose of 
250 mg three times daily was shown to be well tolerated and effective for the 
treatment of urogenital tuberculosis in 51 adults (23).
Para-aminosalicylic acid (PAS) is already included in the EMLc. Although 
not a potent drug, its efficacy against M. tuberculosis has been well established 
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in adults, particularly in protecting companion drugs against resistance. On 
the basis of existing data, experience and recommendations, many children 
with MDR-TB will be successfully treated without PAS, although for children 
with additional drug resistance, including pre-XDR or XDR-TB, drug options 
are much more limited and PAS will be an important component of treatment 
regimens in that context.
The in vitro activity of linezolid against M. tuberculosis has been 
consistently demonstrated. Emerging data in adults and children have also 
shown it to be effective in difficult cases of drug-resistant tuberculosis, with good 
long-term outcomes. Two systematic reviews in 2012 reported on the safety and 
efficacy of linezolid for the treatment of drug-resistant tuberculosis in adults. The 
first included 11 studies representing 148 patients (24). The pooled percentage of 
patients with treatment success was 67.9% (95% CI: 58–79%). The second review 
included 207 patients in 12 studies, of which many but not all were the same 
studies as those of the first review (25). Of 121 patients with definite treatment 
outcomes, 82% (95% CI: 74–88%) had successful treatment outcomes, with 93% 
(95% CI: 86–97%) having sputum smear conversion and 93% (95% CI: 87–97%) 
having culture conversion. Two more recent cohorts have reported similar 
findings (26, 27). All 16 children on linezolid had culture conversion, most within 
1–3 months, and 14 of 16 (87.5%) had a successful long-term outcome, with one 
lost to follow-up and one death (respiratory failure, culture-negative at the time of 
death). There are no formal recommendations for paediatric dosing of linezolid 
for MDR-TB. Because of the high cost, toxicity and good clinical outcomes with 
existing treatment regimens for children with MDR-TB, routine use of linezolid 
is not supported.
Clofazimine – with its pharmacological characteristics, ability to 
concentrate in macrophages, potential sterilizing activity, lack of cross-resistance 
with other agents and apparent inability to foster resistance – is a potentially 
attractive option for treatment of drug-resistant tuberculosis. In one study 
in adults, a four-month intensive phase containing kanamycin, gatifloxacin, 
clofazimine, ethambutol, high-dose isoniazid, pyrazinamide and protionamide, 
followed by a five-month continuation phase containing gatifloxacin, ethambutol, 
pyrazinamide and clofazimine, resulted in 87.8% cure with only 0.5% relapsing 
(28). Additional support for clofazimine includes the report of a cohort of adults 
with XDR-TB in which more than 60% of patients had a successful treatment 
outcome with a clofazimine-containing regimen (29). The WHO 2008 guidelines 
(11) recommend the use of Group 5 drugs, of which clofazimine is one, only 
when a regimen containing four drugs with likely activity cannot be created from 
Groups 1–4. No other specific recommendation regarding clofazimine is made.
On the basis of WHO guideline recommendations, public health needs 
and available evidence on efficacy and safety, the Expert Committee recommended 
the following changes to update the complementary list in the EMLc:
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 ■ Ofloxacin should be replaced by levofloxacin, with an asterisk note to 
indicate that ofloxacin and moxifloxacin may be used as alternatives.
 ■ Ethionamide should be retained, but with an asterisk note to indicate 
that protionamide may be used as an alternative.
The Expert Committee noted that child-friendly formulations are 
urgently needed for some of the second-line antituberculosis medicines to 
improve dosing and adherence.
No other changes were made as there were insufficient data to justify the 
inclusion of clofazimine or linezolid. Cycloserine would also be retained, without 
mention of terizidone. No changes were made to the existing listings on amikacin, 
capreomycin, kanamycin and para-aminosalicylic acid.
Streptomycin injections (to be moved to the complementary list) – Children
An application to move streptomycin to the complementary list for children was 
prepared by the Stop TB Department, WHO.
Expert reviews were prepared by Dr Lisa Bero and Dr Gitanjali 
Batmanabane. Comments were received from Médecins Sans Frontières.
Overall, evidence for the efficacy of streptomycin for the treatment 
of tuberculosis in children is lacking. There is toxicity (ototoxicity and 
nephrotoxicity) associated with all aminoglycosides. In addition, streptomycin 
can be administered only by injection.
According to WHO’s Rapid advice: treatment of tuberculosis in children 
(18), streptomycin should not be used as part of first-line treatment regimens for 
children with pulmonary tuberculosis or tuberculous peripheral lymphadenitis. 
Streptomycin use is reserved for those with MDR-TB with known susceptibility 
to this medicine.
The Expert Committee accordingly decided to place streptomycin in the 
complementary list of the EMLc. Its use for MDR-TB will require specialist care 
and facilities.
6.4: Antiviral medicines 
6.4.2: Antiretrovirals
Abacavir (new formulation); Abacavir + lamivudine (addition);  
Efavirenz (new formulation); Lamivudine + nevirapine + zidovudine (new formulation);  
Lamivudine + stavudine (new formulation; Lamivudine + zidovudine (new formulation);  
Nevirapine (new formulation)
Applications for additions and changes in formulations to update both the EML 
and EMLc were submitted by the Clinton Health Access Initiative, with the 
support of the HIV Department of WHO. At the time of the meeting, the current 
WHO guidelines for the treatment of both adults and children living with HIV/
AIDS were those issued in 2010 (30).
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Expert reviews were prepared by Dr Eva Njenga and Dr Liliana de Lima.
The Expert Committee received a progress report on the updating of the 
guidelines, which were expected to be completed by mid-2013. The Committee 
noted that proposals originally submitted in the application were subsequently 
amended by the HIV Department, reflecting ongoing work on the 2013 guidelines. 
However, as these guidelines (for both adults and children) were as yet incomplete, 
and had yet to be approved by WHO’s Guidelines Review Committee, the Expert 
Committee was reluctant to make any changes to the EML at this point.
Instead, the Expert Committee recommended that there should be 
an extraordinary meeting (possibly electronically) to consider a limited list 
of applications, specifically to align the EML with the expected 2013 WHO 
guidelines, before the planned Committee meeting in 2015. Nonetheless, the 
Expert Committee underscored the established principle that the mention of a 
medicine in an approved WHO guideline did not automatically guarantee its 
inclusion in the EML. Each such application would still be considered on its 
own merits and in accordance with the principles that inform the selection of 
essential medicines.
6.5: Antiprotozoal medicines
6.5.5: Antitrypanosomal medicines
6.5.5.1: African trypanosomiasis
Nifurtimox tablets (addition) – Children
An application for the addition of nifurtimox tablets to the EMLc was submitted 
by the Drugs for Neglected Diseases initiative (DNDi), Geneva, Switzerland.
Expert reviews were prepared by Dr Eva Njenga and Dr Gilles Sama 
Kwende.
Human African trypanosomiasis is transmitted by tsetse flies which are 
present in 36 sub-Saharan African countries. Of those, 13 countries have reported 
cases of sleeping sickness since 2000, with a declining trend. Treatment strategies 
have played a major role in this decline. Children account for approximately 25% 
of the total cases reported.
Nifurtimox–eflornithine combination therapy (NECT) is as effective as 
eflornithine alone for treating second-stage African trypanosomiasis but also has 
safety advantages and is easier to administer (infusion every 12 hours for 7 days 
versus every 6 hours for 14 days). Both are listed in the EML. Data from the seven 
most affected countries show that 59% of adult patients were treated with the 
combination in 2010 (31) and 86% in 2011. Listing of both medicines in the EML 
has helped to scale up access to NECT.
Eflornithine is already listed in the EMLc for second-stage African 
trypanosomiasis. Nifurtimox is listed in the EMLc only for American 
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trypanosomiasis, but is listed for both American and African trypanosomiasis 
in the EML.
Additional data are now available on children and hence this application 
was submitted to include nifurtimox in the EMLc to facilitate the combination 
therapy for sleeping sickness. There are no randomized controlled trials to assess 
the combination of nifurtimox and eflornithine specifically in children. A clinical 
trial (multicentre, open-label, phase IIIb) to assess NECT in field conditions was 
conducted in six sites in the Democratic Republic of the Congo. Of a total of 
629 patients included in the trial, 100 were children below 12 years of age, 14 were 
pregnant women and 33 were breastfeeding mothers. Ninety-eight percent of the 
629 patients were alive and well on discharge (32). With 24-month follow-up, 
similar cure rates were shown in children and adults, with close to 89% alive 
and well.
A cohort study of patients from Médecins sans Frontières (MSF) 
treatment centres, including 120 children, also showed good results (33). Adverse 
reactions were common (60–90%) but severe events were relatively rare. A 
pharmacovigilance study of NECT reported adverse effects, the commonest being 
vomiting/nausea and abdominal pain followed by headache, musculoskeletal 
pains and vertigo. Adverse events in children were similar to those in adults but 
the major adverse events were less frequent (34).
Both NECT and eflornithine monotherapy have similar health-system 
requirements, such as the need for intravenous infusion in a hospital setting. 
Nifurtimox is supplied free of charge according to an agreement with 
WHO and, in practice, it is less costly to procure the combination than the 
individual components.
Considering the public health need for this combination in the affected 
countries and the data on effectiveness and safety particularly in children, the 
Expert Committee recommended that nifurtimox be added to the EMLc. It was 
noted that this would also help countries to scale up treatment programmes for 
Trypanosoma brucei gambiense second-stage infection.
6.5.5.2: American trypanosomiasis
Benznidazole tablets (new formulation) – Children
An application for adding the 12.5-mg benznidazole tablet presentation was 
received from the Drugs for Neglected Diseases initiative (DNDi), Rio de Janeiro, 
Brazil. Another application to add the 50-mg scored tablet was received from 
the Department for Control of Neglected Tropical Diseases, WHO, based on the 
same considerations as those for the 12.5-mg tablet.
Expert reviews were prepared by Dr Gilles Sama Kwende and Dr Eva 
Njenga.
A recent WHO report estimated that 10 million people worldwide 
are infected by Trypanosoma cruzi, mostly in the endemic areas of 21 Latin 
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American countries, but also in non-endemic countries as a consequence of 
population mobility (35). Most infections occur during childhood, and there 
are also congenital infections. However, until recently the only registered dosage 
form of benznidazole, the first-line treatment for Chagas disease, was a 100-mg 
tablet suitable for adults.
Despite the heterogeneity of studies presented in terms of objectives, 
geographical location, age ranges, numbers of children included, therapeutic 
schemes used, duration of post-treatment monitoring and the cure control tests 
deployed, there is clear evidence of the efficacy of benznidazole for the treatment 
of children infected by Trypanosoma cruzi, including those less than a year old, 
and this evidence suggests that greater efficacy is associated with early treatment. 
Seroconversion rates vary from 87% at 36 months (36) (100% in the 0–3 months 
age group) to 100% (37) at 24 months in children up to 2 years of age.
Adverse events during treatment are more frequent and more severe in 
adults than in children, and are particularly infrequent in children below 1 year. 
Fewer neurological events were noted among children, who present mainly with 
dermatological and gastrointestinal adverse events.
Treatment with benznidazole is of long duration and usually is given 
outside the hospital setting. Benznidazole is listed in the EMLc and WHO 
recommends it for the treatment of neonates, infants and children. The 
recommended dose is 5–10 mg/kg per day. The Expert Committee noted that 
the proposed formulations of benznidazole that are essential for the treatment 
of T. cruzi infections achieve paediatric doses more easily even in ambulatory 
care settings. The 12.5-mg tablet is registered in Brazil and the 50-mg tablet is 
registered in Argentina.
Taking into consideration the need for child-friendly formulations of 
benznidazole, the Expert Committee decided to add both the 12.5-mg and 50-mg 
scored tablets to the EMLc.
Section 8: Antineoplastics
8.4: Medicines used in palliative care
Palliative care (new section) – Children
An application was submitted by Dr Willem Scholten, team leader (until 31 
October 2012), Access to Controlled Medicines, WHO, for palliative care to be 
moved to a separate highest-level section of the EMLc. The Committee was also 
asked to consider a recommendation for a similar section in the EML.
Expert reviews were provided by Dr Lisa Bero, Mr Andrew Gray, 
Dr Gitanjali Batmanabane and Dr Abdol Majid Cheraghali.
This request was based on WHO’s Guidelines on pharmacological 
treatment of persisting pain in children with medical illnesses and the WHO policy 
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guidelines Ensuring balance in national policies on controlled substances: guidance 
for availability and accessibility of controlled medicines (8, 9). The World Health 
Assembly in its resolution WHA58.22 on “Cancer prevention and control” 
(2005) called on WHO to address access to opioid analgesics. Other international 
bodies, such as the International Narcotics Control Board and the United Nations 
Commission on Narcotic Drugs, have called for greater access for patients to 
these medicines.
It was noted that the opioids were listed under Section 8 since palliative 
care was initially addressed by the WHO Cancer Control Programme more than 
20 years ago. The Expert Committee recognized that medicines in palliative care 
are needed for conditions other than cancer – such as HIV/AIDS (38), MDR-TB 
(39) and severe congenital diseases (40). The present listing under Section 8.4 
(antineoplastic, immunosuppressive and medicines used in palliative care) may 
be interpreted by some countries as indicating that palliative care medicines 
are needed for use in cancer only. Listing palliative care medicines as a separate 
category would signify the importance of this group of medicines and promote 
their use in all conditions that require such care.
The Expert Committee consequently recommended changing the 
title of Section 2 of the EMLc to “Medicines for pain and palliative care”. The 
corresponding change would also be made in the EML. In addition, the Expert 
Committee recommended that the medicines for rheumatic conditions be moved 
from Section 2 to a new Section 30 (Medicines for diseases of joints).
Section 11: Blood products and plasma substitutes
11.1: Plasma substitutes
Colloids (review) – Children
At its 18th meeting the Expert Committee requested a review to determine 
whether adults and children with dengue fever should be treated with intravenous 
colloids rather than with crystalloids. The Committee also requested a review 
to determine whether plasma substitutes are essential medicines for children. It 
was not possible to address such a broad topic and therefore two reviews were 
commissioned by the Secretariat on two common causes of the need for volume 
replacement in children. The reviews considered by the Expert Committee were:
1. Colloids versus crystalloids for fluid resuscitation in dengue fever patients – a 
review, prepared by Dr Pablo Perel, London School of Hygiene & Tropical 
Medicine, London, United Kingdom.
2. Are colloid solutions essential for the treatment of paediatric trauma or burn 
patients? prepared by Christina Huwer, Department of Violence and Injury, 
Prevention and Disability, WHO, Geneva, Switzerland.
20
W
H
O
 T
ec
hn
ic
al
 R
ep
or
t S
er
ie
s, 
N
o.
 9
85
, 2
01
4
The Selection and Use of Essential Medicines   Report of the 19th WHO Expert Committee
Expert reviews were prepared by Dr Liliana de Lima and Dr Le Van Truyen. 
Comments were received from the Director of the Special Programme for 
Research and Training in Tropical Diseases (TDR).
Currently, the EMLc does not list plasma substitutes. The EML lists 6% 
dextran 70, with 3.5% polygeline noted as equivalent.
Colloids versus crystalloids in dengue fever
The purpose of the systematic review prepared for this meeting was to identify 
and synthesize the available evidence to assess the effect on mortality of using 
colloids compared with crystalloids for fluid resuscitation in patients with 
dengue fever. Current recommendations for the management of dengue patients 
with hypotensive shock include the administration of either crystalloids or 
colloids (41).
A recently published Cochrane systematic review found no evidence that 
colloids, in comparison to crystalloids, reduced the risk of death in critically ill 
patients (42). This review included 74 trials, 66 of which reported mortality data. 
Although trials involving patients with dengue fever were included, the review 
did not report the results in these patients separately.
The present review identified five trials evaluating colloids versus 
crystalloids in children with shock associated with dengue fever. Overall, the 
quality of the evidence for the effect of colloids versus crystalloids for fluid 
resuscitation was low. All of the included studies were underpowered, making 
any reliable assessment of the effect of colloids compared with crystalloids on 
mortality in dengue patients impossible. The review found no evidence that 
resuscitation with colloids reduced the risk of death compared with resuscitation 
with crystalloids (42–45).
However, the Expert Committee noted the comment from the Director 
of TDR that it is not possible to conclude from the studies (and probably from 
any study) whether colloids could be beneficial for the small subset of very severe 
dengue shock patients who do not respond to crystalloids or who present with no 
measurable blood pressure. Clinical experience suggested that such patients may 
benefit from treatment with colloids. Without colloids being available, clinicians 
may resort to using albumin, freeze-dried plasma or blood, which may pose 
different safety or cost challenges. The Expert Committee therefore decided that, 
for the same reason that colloids had been retained on the EML for the same 
indication, colloids would be added to the EMLc.
Colloids in paediatric trauma and burns
Fluid therapy plays an important role in the treatment of trauma patients with 
substantial blood loss, as well as in patients with burn injuries. The review 
Applications only for paediatric medicines
21
prepared for the 19th meeting of the Expert Committee focused on these 
indications for the use of colloids in children. No evidence from randomized 
controlled trials could be identified (41, 46, 47). All articles reviewed indicated 
that there was very little evidence available either for or against the use of 
colloids in children.
Volume replacement with colloids is considerably more expensive than 
with crystalloids. The International drug price indicator guide (48) shows that 
the supplier median price for dextran 70 is almost 12 times higher than that for 
normal saline.
In view of the low quality of evidence available on the clinical questions 
reviewed, the lack of evidence for the superiority of colloids compared with 
crystalloids in critically ill patients in general, and the higher cost of colloids, 
the Expert Committee decided that there is no justification for the inclusion of 
specific colloids for volume replacement in the EMLc. However, colloids would be 
added to EMLc for consistency with the EML and for use when safer alternatives 
are not available.
Section 12: Cardiovascular medicines
12.2: Antiarrhythmic medicines
Antiarrhythmics (review) – Children
In 2011 the Expert Committee requested a review to determine which 
antiarrhythmic medicines are essential for children. The topic was reviewed 
by Dr Pablo Perel, London School of Hygiene & Tropical Medicine, London, 
United Kingdom.
Expert reviews were prepared by Dr Shalini Sri Ranganathan and Dr Le 
Van Truyen.
Available data show that arrhythmias, and especially serious arrhythmias, 
are rare in children. Among the more common causes are congenital heart 
disease and rheumatic heart disease. For congenital heart disease, the appropriate 
treatment strategy is surgical correction. However, children sometimes do 
not receive the necessary surgical management, especially in developing 
countries. Arrhythmias associated with rheumatic heart disease usually present 
after childhood.
There is limited published evidence about the effectiveness of 
antiarrhythmic medicines in children (49).
Recognizing that arrhythmias in children are rare and that they are 
typically managed in specialized settings, it was noted that there does not appear 
to be a need to list antiarrhythmic medicines in the EMLc. Given that this 
section has limited public health relevance to children, the Expert Committee 
decided to delete it from the EMLc.
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12.6: Lipid-lowering agents
Statins (review) – Children
The 18th meeting of the Expert Committee had questioned the relevance of lipid-
lowering agents in children and requested a review of this section in the EMLc. 
Currently simvastatin is listed on the EML for use in high-risk patients.
The review on the need for statins in children was submitted by 
Dr Marcus M. Reidenberg, Weill Cornell Medical College, New York, NY, USA.
Expert reviews were prepared by Dr Shalini Sri Ranganathan and Dr Le 
Van Truyen.
Statins lower cholesterol in children just as they do in adults. The 
duration of reported randomized controlled trials in children showing change in 
blood lipids as the benefit ranged from 8 weeks to 3 years, with the median being 
6 months (50). No clinical trials showed that lowering cholesterol with statins 
was effective in preventing or delaying cardiovascular events in children with 
high plasma cholesterol and no initial clinical evidence of atherosclerosis. Statins 
are considered to be effective in secondary prevention of cardiovascular events 
in adults, but there is controversy about the effectiveness of statins for primary 
prevention in healthy adults (51–54).
Heterozygous familial hypercholesterolaemia (FH) occurs in about one in 
every 500 children. The estimated 10-year risk of a cardiovascular event in such 
patients is around 1%. However, available risk calculation tools do not include 
children and hence their predictive accuracy in children is unknown.
In general the safety profile of statins in children (including in relation 
to the hepatic and musculoskeletal systems) is similar to that observed in adults. 
However, long-term data in children are lacking.
The United States Food and Drug Administration (US FDA) has approved 
the use of pravastatin in children of 8 years or older with FH, and other statins 
in children of 10 years or older, where dietary measures have failed. The United 
States National Cholesterol Education Program (NCEP) recommends that drugs 
be used only in patients older than 10 years of age following failure of aggressive 
dieting. The American Heart Association (AHA) and the American Academy of 
Pediatrics (AAP) have recommended statin therapy for children with high-risk 
lipid abnormalities.
Considering that the indications for statin use in children were rare and 
that the long-term risks and benefits had not been well established (50), the 
Expert Committee decided not to add statins to the EMLc. However, given the 
global prevalence of obesity, including in children, the Committee recommended 
that a “watching brief ” be maintained on this topic. Not only will the public 
health relevance need to be considered, but emerging evidence on the choice 
of an appropriate approach to lowering very high lipids levels in children would 
need to be informed by sufficiently good evidence. As a result, it was agreed that 
the section heading would be retained although no medicines would be listed.
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Section 15: Disinfectants and antiseptics
15.1: Antiseptics
Chlorhexidine (new formulation) – Children
The application to include chlorhexidine digluconate 7.1% solution or gel 
delivering 4% chlorhexidine for cord care was submitted by the Program for 
Appropriate Technology in Health (PATH), Chlorhexidine Working Group.
Expert reviews were provided by Dr Lisa Bero and Dr Suzanne Hill.
In 2009, the Expert Committee reviewed an application to include this 
formulation of chlorhexidine. Although there was general consensus that, in 
unclean deliveries, topical antiseptics may help in reducing infections, there was 
no clear evidence regarding the superiority of any one product. In addition, no 
product was commercially available at that time. A 20% solution was added for 
dilution. In 2011 an updated application was submitted to replace the 20% listing 
with a ready-made 7.1% digluconate solution or gel. At that time, trials were 
continuing and the product was still not commercially available. The Committee 
then decided to list 4% chlorhexidine as one of the missing priority products in 
the “Priority medicines for mothers and children – 2011”.
An updated application was submitted to the 19th meeting of the 
Expert Committee for inclusion of the 7.1% concentration providing 4% free 
chlorhexidine formulation. It was felt that there is a need to specify concentrations 
correctly: 20.0% chlorhexidine digluconate provides 11.3% free chlorhexidine, 
while 7.1% provides 4.0%, and 5.0% provides 2.8%.
The evidence in the application consisted of three trials conducted in 
community settings in Bangladesh, Nepal and Pakistan where there were high 
rates of home deliveries and high neonatal mortality (55–57). Over 50 000 
newborns were enrolled, and the trial compared single or multiple applications 
of chlorhexidine with standard dry cord care practices. The results showed 
significant reductions in neonatal mortality (24%) and omphalitis (75%).
Systematically collected data on long- and short-term adverse events 
are scant. However, chlorhexidine was used widely in randomized trials and 
has been used elsewhere for neonates (58, 59). Transient contact dermatitis 
has been reported in preterm very‐low‐birth‐weight infants after long‐term 
(> 7 days) placement of chlorhexidine-impregnated dressings for central venous 
catheters (58).
Although a significant effect was seen for neonatal mortality and 
omphalitis, the studies were predominantly in high-mortality home birth settings 
in South Asia. The findings are therefore difficult to generalize to settings where 
the majority of births take place in health facilities and where neonatal mortality 
rates are lower.
Questions remain about the optimal treatment regimen with respect to 
timing of the application of chlorhexidine, as well as the number of applications. 
24
W
H
O
 T
ec
hn
ic
al
 R
ep
or
t S
er
ie
s, 
N
o.
 9
85
, 2
01
4
The Selection and Use of Essential Medicines   Report of the 19th WHO Expert Committee
Compared with dry and clean care (mean 4.78 days), separation time of the 
umbilical cord was longer in the single (mean 6.90 days, difference = 2.10, 95% 
CI: 1.85–2.35) and multiple (mean 7.49 days, difference = 2.69, 95% CI: 2.44–2.95) 
cleansing groups in a cluster randomized trial (60). This outcome may affect 
carer satisfaction, but the clinical importance is unclear.
The scalability and integration of the use of chlorhexidine into existing 
health systems have yet to be established. Two of the three studies that showed 
beneficial effects of chlorhexidine application to the cord included several visits 
by health-care workers, which may not be possible in all settings.
There is now a commercially available product in at least Bangladesh 
and India but there is as yet no global supply. Local production of the product 
may be an appropriate strategy to ensure adequate supply, although the precise 
concentration required in the formulation means that standards for the 
manufacturing process need to be ensured.
The Expert Committee recommended the listing of the new 4% gel 
formulation, the deletion of the 20% solution, and the retention of the 5% solution. 
The Committee hoped that inclusion in the list would increase the chances of 
making a commercial product available and noted that three manufacturers (two 
in India and one in Belgium) are already providing the gel product.
Section 24: Medicines for mental and behavioural disorders
24.1: Medicines used in psychotic disorders
Chlorpromazine and haloperidol (deletion) – Children only
The 18th meeting of the Expert Committee had noted the potential importance 
of chlorpromazine and haloperidol for a variety of disorders in children, but 
requested a review of the entire section. The Department of Mental Health 
and Substance Abuse, WHO, reviewed the section and submitted applications 
for (1) the deletion of chlorpromazine and haloperidol from the EMLc, (2) an 
increase in the minimum age for the use of fluoxetine, and (3) the inclusion of 
clozapine on the complementary list for the treatment of resistant schizophrenia 
in adults.
Expert reviews were prepared by Dr Kuruvilla Prasad Mathews and 
Mr Andrew Gray.
Psychosis is rare in childhood, with the prevalence estimated to be as low 
as 1.6 per 100 000 (61, 62). However, subclinical psychotic experiences (including 
delusions or hallucinations) are much more common. These more common 
conditions (which affect 6% of 11-year-olds) are usually benign and, in 75–90% 
of cases, spontaneously remit over time (63). Psychosocial interventions are the 
treatment of preference in the first instance.
Children on chlorpromazine and haloperidol are prone to sedation, 
extrapyramidal syndrome, withdrawal dyskinesia and tardive dyskinesia (64, 65).
Applications only for paediatric medicines
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Various guidance documents suggest that pharmacotherapy has a 
very limited role in the management of childhood mental disorders, and 
especially behavioural disorders, before puberty. Even for unresponsive cases, 
medication may be considered only after specialist consultation (66). WHO 
does not recommend using pharmacotherapy for behavioural problems except 
for attention deficit hyperactivity disorder (ADHD) after a first trial with 
psychological interventions (67).
The Expert Committee recognized that the indications for using 
chlorpromazine and haloperidol are very rare in children. Adverse events from 
these medicines may be more frequent in children than in adults. However, the 
Committee recognized the importance of ensuring that treatment is available for 
these severe psychiatric disorders in children and also noted that the application 
did not fully review all treatment options. The Expert Committee therefore 
requested a specific review of the evidence for the benefits and risks of each 
medicine in the paediatric population and decided to make no changes to the list 
until such reviews had been considered.
24.2: Medicines used in mood disorders
24.2.1: Medicines used in depressive disorders
Fluoxetine (change to age restriction/deletion from EMLc) – Adults and Children
See under Section 24: Medicines for mental and behavioural disorders.
Section 28: Ear, nose and throat medicines
Montelukast (addition) – Children
During the 18th meeting of the Expert Committee, a request was made to review 
the role of leukotriene receptor antagonists (LTRAs) in the management of 
childhood allergic rhinitis. The review was prepared by Dr Achal Gulati, Director/
Professor, Department of ENT and Head & Neck Surgery, Maulana Azad Medical 
College, New Delhi, India.
Expert reviews were prepared by Dr Shalini Sri Ranganathan and 
Dr Abdol Majid Cheraghali.
Therapeutic options for relief of allergic rhinitis include avoidance 
measures, oral antihistamines, intranasal corticosteroids (INCS), LTRAs, or allergen 
immunotherapy. The available LTRAs are montelukast, pranlukast and zafirlukast.
Randomized controlled trials and observational studies suggest that 
LTRAs as a class are effective in controlling symptoms related to allergic rhinitis. 
In a meta-analysis, the clinical efficacy of LTRAs, including montelukast, in the 
treatment of patients with allergic rhinosinusitis and nasal polyposis was compared 
with that of placebo, antihistamines, and nasal corticosteroids. The composite 
daily rhinitis symptom scores in each trial were standardized and pooled. Among 
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the trials included in the meta-analysis, eight compared LTRAs with a placebo 
(five montelukast trials, two zafirlukast trials, one L-649923 trial), two compared 
an LTRA and an antihistamine (both montelukast versus loratadine), and four 
compared an LTRA with a nasal corticosteroid (montelukast versus mometasone; 
montelukast versus budesonide; montelukast versus fluticasone and zafirlukast 
versus beclomethasone). In the composite daily rhinitis symptom score, LTRAs 
decreased the score by 5% when compared with placebo, antihistamine decreased 
the score by 2% compared with LTRAs, and intranasal corticosteroids were the 
most effective, decreasing the score by 12% compared with antihistamines (68). 
Two separate studies comparing montelukast, loratadine or cetirizine to placebo 
groups in children showed some benefits in various symptom assessments relative 
to placebo, but no consistent benefit of one treatment type over the other (69, 70).
Guidelines on allergic rhinitis and its impact on asthma (ARIA) propose 
antihistamines and intranasal corticosteroids as preferred first-line management. 
LTRAs are suggested either alone or in combination therapies after the 
antihistamines and intranasal steroids. However, individual management options 
can vary.
A post-marketing report suggests an association between neuropsychiatric 
events (mood and behavioural adverse effects) and montelukast, the most 
commonly prescribed of the agents in the group. The US FDA confirmed the 
association with neuropsychiatric adverse reactions and in June 2009 requested 
that manufacturers add a precaution to the prescribing information (71). Such 
reactions may also occur in children (71–73).
In view of the lack of evidence for the superiority of montelukast over 
other readily-available treatments for allergic rhinitis, the potential adverse events 
and the uncertainties regarding its cost and availability in most low- and middle-
income countries, the Expert Committee decided not to include montelukast in 
the EMLc.
Section 29: Specific medicines for neonatal care
Dexamethasone (new indication) – Children
An application was submitted by Dr Joy Lawn, Director of Global Evidence and 
Policy Saving Newborn Lives/Save the Children, London, United Kingdom 
and Fernando Althaea Instituto de Efectividad Clínica y Sanitaria, Buenos Aires, 
Argentina, for the addition of dexamethasone for the indication of accelerating 
lung maturation in preterm babies.
Expert reviews were provided by Dr Shalini Sri Ranganathan and 
Dr Liliana de Lima.
Preterm birth is the leading cause of neonatal deaths and the second 
most common cause of under-5 mortality, as well as a leading contributor to the 
global burden of disease because of a significant risk of disability. Each year an 
Applications only for paediatric medicines
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estimated 15 million babies are born preterm, three-quarters of them in South 
Asia and sub-Saharan Africa. Over 85% are moderate or late preterm, who are 
likely to survive without intensive care. However, if access to basic care is limited, 
antenatal corticosteroids could make a considerable difference to mortality and 
morbidity, primarily by reducing the risk of respiratory distress syndrome (RDS).
There is high-quality evidence showing that antenatal corticosteroids 
reduce all-cause neonatal mortality. A Cochrane review and meta-analysis 
of 18 trials (3956 infants) of antenatal corticosteroids found that the risk of 
neonatal mortality was reduced by approximately 30% (relative risk, RR: 0.69, 
95% CI: 0.58–0.81) (74). The same meta-analysis found that there was reduced 
incidence of RDS (RR: 0.66, 95% CI: 0.59–0.73, 21 studies, 4038 infants) and 
cerebroventricular haemorrhage (RR: 0.54, 95% CI: 0.43–0.69, 13 studies, 2872 
infants). A meta-analysis of four randomized controlled trials (672 infants) 
from middle-income countries found a decrease in neonatal mortality following 
preterm birth (RR: 0.47, 95% CI: 0.35–0.64). No studies were found from low-
income settings (75).
Two products – dexamethasone and betamethasone – were used in the 
majority of trials. No differences in effects were found between the two products. 
A large trial that is powered to detect a difference was continuing at the time of 
the 19th meeting of the Expert Committee but results were not expected until 
2015 (76).
The adverse effects of dexamethasone are well defined. A retrospective 
cohort study compared preterm babies exposed prenatally to dexamethasone 
to those not exposed and found no differences in verbal intelligence quotient, 
performance intelligence, body length, head circumference and body weight at 
one, three and six years (77).
Dexamethasone is recommended in WHO global clinical guidelines 
such as Managing complications in pregnancy and childbirth: a guide for midwives 
and doctors (78). The National Institutes of Health (79), the American College 
of Obstetricians and Gynecologists (80), and the Royal College of Obstetricians 
and Gynaecologists (81) have recommended antenatal corticosteroid treatment 
for women at risk for preterm delivery before 34 weeks of gestation to reduce the 
morbidity and mortality associated with preterm birth.
The most extensively studied regimens of corticosteroid treatment for the 
prevention of RDS are two doses of betamethasone 12 mg given intramuscularly 
24 hours apart, or four doses of dexamethasone 6 mg given intramuscularly 
12 hours apart. Evidence for other dosing regimens, such as the commonly used 
two doses of betamethasone 12 mg given 12 hours apart, is sparse, but it would 
seem reasonable to use a regimen that delivers 24 mg of either drug within a 
24–48-hour period (81).
Dexamethasone is generally inexpensive (< US$ 1 per four-injection 
course) and is widely available, making it the cheapest and most accessible means 
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of preventing RDS and deaths due to preterm birth. Dexamethasone treatment is 
likely to be cost-effective in most settings, at an estimated cost per case (including 
the cost of syringes, needles, swabs, personnel and clinic visits) of US$ 16.25, 
which is around one-third the cost of betamethasone treatment.
Dexamethasone was already listed on the EML in the same formulation 
(4 mg/ml) that is commonly used for this indication.
Given the compelling evidence of effectiveness, safety and cost–
effectiveness, the Expert Committee recommended the inclusion of 
dexamethasone in Section 29, under a new subheading of “Medicines for 
administered to the mother”.
29
5. Applications for the 18th Model List  
and the 4th EMLc
Section 2: NSAIMs and DMARDs
2.1: Non-opioids and non-steroidal anti-inflammatory medicines (NSAIMs)
Naproxen (addition) – Adults
An application was submitted by Dr Patricia McGettigan, William Harvey 
Research Institute at Barts and The London School of Medicine and Dentistry, 
London, United Kingdom and Dr David Henry, Institute for Clinical Evaluative 
Sciences, Toronto, Ontario, Canada, for the inclusion of naproxen as an individual 
medicine by virtue of its having the safest cardiovascular risk profile among non-
steroidal anti-inflammatory medicines (82).
Expert reviews were provided by Mr Andrew Gray and Dr Alar Irs.
Ibuprofen is specifically listed in the WHO Model List of Essential 
Medicines and not as a representative of the non-steroidal anti-inflammatory 
medicines (NSAIMs). This application requested the addition of naproxen 
because of its low cardiovascular risk. The application also highlighted the 
extensive listing of diclofenac in national essential medicines lists despite its 
high cardiovascular risk (83).
The data presented are from an update of the cardiovascular safety of 
various NSAIMs based on a meta-analysis of results from observational studies 
(case-control and controlled cohort studies). The pooled relative risk of a 
cardiovascular event in users of ibuprofen was 1.18 (95% CI: 1.11–1.25) and 1.09 
(95% CI: 1.02–1.16) with naproxen. In a pair-wise comparison of ibuprofen and 
naproxen, the ratio of relative risks (RRR) for naproxen was just significantly 
lower than for ibuprofen: RRR = 0.92 (99% CI: 0.87–0.99). However, when dose 
was taken into account, only high-dose ibuprofen (> 1200 mg/day) was associated 
with higher risk. Naproxen was risk-neutral at all doses.
No comparison of the analgesic effects of naproxen and ibuprofen was 
provided in the application. The pricing data showed ibuprofen and naproxen 
to be similarly priced. There was also no comparison of naproxen with other 
NSAIMs in terms of adverse effects and toxicities in other systems (e.g. 
gastrointestinal). A review in 1999 stated that ibuprofen was associated with the 
lowest risk of side-effects (84).
The increase in cardiovascular risk with ibuprofen applies to the higher 
doses only and the Expert Committee did not consider that there was adequate 
justification for including both ibuprofen and naproxen in the EML. However, the 
Committee noted that, in populations with high cardiovascular risk, it would be 
important to indicate that naproxen has the lowest cardiovascular risk. Since the 
application focused only on the cardiovascular outcomes for NSAIMs and not 
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the comparative gastrointestinal outcomes or comparative analgesia, the Expert 
Committee decided to keep only ibuprofen on the list.
However, the Expert Committee also drew attention to the evidence for 
not choosing diclofenac as a preferred NSAIM. Selection of an NSAIM needs to 
take gastrointestinal, renal and cardiovascular safety into account.
2.3: Medicines used to treat gout
Colchicine (reinstatement) – Adults
Gout
An application was submitted by Laboratoires Mayoly-Spindler, Chatou Cedex, 
France, for reinstatement of colchicine for gout, with an addition for familial 
Mediterranean fever.
Expert reviews were provided by Dr Youping Li and Dr Eva W. Njenga.
Colchicine was deleted from the EML in 2005 on the basis that “its 
usefulness for treating acute attacks is limited by its dose-dependent toxicity and 
the therapeutic margin is narrow”. That year the meeting of the Expert Committee 
also noted that colchicine was not cheaper than ibuprofen and that it had not 
been procured to any great extent by international suppliers over the previous five 
years. The Committee recommended that colchicine be deleted from the EML 
because of its unfavourable benefit–risk ratio when compared with NSAIMs for 
most people with gout (85).
The application to reinstate colchicine was based on a multicentre, 
randomized, double-blind, placebo-controlled, parallel-group study of a total 
of 185 patients, published in 2010, which compared self-administered low-dose 
colchicine (total 1.8 mg over 1 hour) and high-dose colchicine (total 4.8 mg over 
6 hours) with placebo. The end-point of > 50% reduction of pain was observed 
in 37.8% in the low-dose colchicine group, 32.7% in the high-dose group, and 
15.5% in the placebo group (P = 0.005 and P = 0034, respectively, versus placebo). 
Rescue therapy with NSAIMs was administered in the first 24 hours to 31.1% of 
patients in the low-dose group (P = 0.027 versus placebo), 34.6% in the high-dose 
group (P = 0.103 versus placebo), and 50.0% in the placebo group. With high-
dose colchicine, 40 patients (76.9%) had diarrhoea (OR: 21.3, 95% CI: 7.9–56.9), 
10 (19.2%) had severe diarrhoea, and nine (17.3%) had vomiting. With low-dose 
colchicine, 23.0% of the patients had diarrhoea (OR: 1.9, 95% CI: 0.8–4.8), none 
had severe diarrhoea, and none had vomiting (86).
No clinical trials comparing NSAIMs with colchicine were provided in 
the application. Colchicine appears as a first-line treatment in both the European 
and British Society of Rheumatology recommendations and is seen as an effective 
alternative to NSAIMs (87, 88).
The Expert Committee decided that, if commonly-available NSAIMs are 
as effective as colchicine in the treatment of gout, the necessity for a medicine 
Applications for the 18th Model List and the 4th EMLc
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useful only for gout is not clear. Additionally, the application was based on a 
single trial that showed the low dose to be as effective as the high dose. Reinstating 
colchicine would require a comprehensive assessment of the comparative benefits 
and harms of the proposed lower-dose regimen as well as information about the 
comparative costs.
The Expert Committee therefore did not recommend reinstatement of 
colchicine on the EML for the management of gout.
Familial Mediterranean fever
Familial Mediterranean fever is a common auto-inflammatory disease in the 
Eastern Mediterranean region. It has traditionally been regarded as inherited 
in an autosomal recessive manner, although some recent articles had reported a 
significant number of patients with only one mutation. Familial Mediterranean 
fever is divided into two main phenotypes. Type 1 is characterized by recurrent 
short episodes of inflammation and serositis including fever, peritonitis, synovitis, 
pleuritis and – rarely – pericarditis and meningitis. There is considerable 
variation in symptoms. Type 2 is characterized by amyloidosis as the first clinical 
manifestation of the disease in otherwise asymptomatic individuals (89). The 
mean age at the onset of clinical disease is 4 years (90% before 20 years). Renal 
failure as a result of amyloidosis is the most severe complication of Type 2 
familial Mediterranean fever (90).
Familial Mediterranean fever generally affects people in the Eastern 
Mediterranean – mainly non-Ashkenazi Jews, Arabs, Armenians and Turks – 
with a prevalence between 1 in 200 and 1 in 1000 population (91). However, 
possibly due to extensive population movements, familial Mediterranean fever 
has been reported throughout the world, including in Japan (92).
The clinical trials of colchicine in familial Mediterranean fever were 
carried out in the early 1970s (93–95). Subsequent work focused on defining 
the appropriate dose, although there is no clear recommendation as yet. 
Paediatricians treating children with familial Mediterranean fever appear to be 
aware of the necessity to treat with colchicine, as the national registry in Turkey 
showed that over 95% of the eligible patients were being prescribed colchicine, 
with 80% reporting regular use (91).
The Expert Committee decided that, while colchicine may be effective for 
this condition, the relatively limited population at risk does not justify inclusion 
in a global list. Additionally, physicians dealing with this condition appear to be 
aware of the necessity to use colchicine and including it in the EML therefore is 
unlikely to improve access.
The Expert Committee therefore recommended that colchicine for 
familial Mediterranean fever should not be included in the EML.
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Section 3: Antiallergics and medicines used in anaphylaxis
Histamine-1 receptor antagonists (review) – Adults and Children
The 18th meeting of the Expert Committee requested a comparative review of 
the safety and efficacy of chlorphenamine (which is listed in both the EML and 
the EMLc) and diphenhydramine, to provide information regarding the possible 
inclusion of diphenhydramine. Given the possible favourable clinical effects and 
side-effect profile of second-generation systemic antihistamines (SGAHs), three 
over-the-counter SGAHs (cetirizine, loratadine and fexofenadine) were also 
reviewed and compared with chlorphenamine and diphenhydramine (which 
are first-generation antihistamines, or FGAHs). The use in children and elderly 
people was specifically considered in the review, and the national essential 
medicines lists of 15 countries were checked for the availability of SGAHs. The 
review was prepared by Mr Harinder Chahal, Doctor of Pharmacy Candidate at 
the University of California, San Francisco, CA, USA.
Expert reviews were prepared by Dr Liliana de Lima and Dr Kuruvilla 
Prasad Mathews.
Evidence of the efficacy and safety of these five antihistamines in allergic 
rhinitis and urticaria was provided. Overall, there was a lack of high-quality 
data to compare the two FGAHs. The review found no randomized controlled 
trials that satisfactorily compared efficacy and safety of chlorphenamine and 
diphenhydramine for use in allergic rhinitis or urticarial conditions. The 
evidence from five randomized controlled trials comparing them with placebo 
or other medicines show similar effectiveness and side-effect profiles of the two 
medications for both allergic rhinitis and urticaria (96).
Fifteen randomized controlled trials showed similar efficacy of FGAHs 
and SGAHs in treating allergic rhinitis, with significantly fewer side-effects (in 
frequency and severity) with SGAHs. For treatment of urticaria, nine randomized 
controlled trials showed similar efficacy between FGAHs and SGAHs, with lower 
incidence of side-effects with SGAHs. Six randomized controlled trials, three 
retrospective studies and one systematic review provided evidence establishing 
the safety profile of SGAHs as superior to that of FGAHs (97). Significant 
sedation and psychomotor impairment were observed with FGAHs compared 
with SGAHs.
Due to the anticholinergic side-effects and the reduced drug clearance 
in elderly people, the use of FGAHs in this population is strongly discouraged. 
Evidence from five randomized controlled trials, two pharmacokinetic studies, 
a systematic review and from guidelines, recommends against the use of FGAHs 
in infants and children, due to risk of sedation and death (96, 98).
The review provided a detailed discussion on the use of antihistamines 
in anaphylaxis and concluded that there was no strong evidence to recommend 
the use of antihistamines for this indication.
Applications for the 18th Model List and the 4th EMLc
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The review also found that the monthly treatment cost of loratadine was 
lower than that of chlorphenamine and that 53% of the 15 low- and middle-
income countries surveyed already had an SGAH on their respective national 
essential medicines lists.
The Expert Committee further considered the evidence on safety. The 
FGAHs are referred to as “sedating” and the SGAHs as “non-sedating”. This 
broad distinction is based on two primary differences between these medicine 
classes: (1) SGAHs are more specific to H-1 receptors than are FGAHs and 
(2) FGAHs are able to cross the blood–brain barrier while the SGAHs are not. 
These differences in receptor specificity and liphophilicity cause FGAHs to display 
significant central nervous system, cardiovascular system and gastrointestinal 
system side-effects. These effects were seen during clinical trials.
Based on considerations of inferior safety, especially in children 
and elderly people, and the equal efficacy of SGAHs and FGAHs, the Expert 
Committee decided to delete chlorphenamine from the EML and EMLc, and to 
recommend the addition of loratadine tablets (10 mg) and oral liquid (1 mg/ml) 
to  the EML and EMLc with a square box. A lower age limit of 2  years for 
loratadine may be applied, although use below this age has occurred in some 
settings (99–104).
Section 4: Antidotes and other substances used in poisonings
Fomepizole (addition) – Adults and Children
An application to include fomepizole on both the EML and the EMLc was 
submitted by Guangduo Zhang, Kasumi Crews, Heather Wiseman and Nicola 
Bates of Medical Toxicology Information Services Ltd, London, United Kingdom; 
Dr Knut Erik Hovda of The National NBC Center, Department of Acute 
Medicine, Oslo University Hospital Ullevaal, Oslo, Norway; and Dr John Archer 
and Dr Paul Dargan of Clinical Toxicology, Guy’s and St Thomas’ NHS Foundation 
Trust and King’s Health Partners, London, United Kingdom.
Expert reviews were prepared by Dr Le Van Truyen and Dr Gilles Sama 
Kwende. Comments were received from the Department of Evidence and Policy 
on Environmental Health Issues, WHO; the Department of Pharmacology, 
Toxicology and Neuroscience, Louisiana State University Health Sciences Center, 
Shreveport, LA, USA; and Dr Hans Perrson, former Director of the Swedish 
Poisons Information Centre.
Fomepizole is used for the treatment of toxic alcohol and glycol 
poisoning – principally methanol and ethylene glycol – in adults and children. 
Ethylene glycol poisoning occurs worldwide and in the majority of cases is due 
to the ingestion of substances such as antifreeze, vehicle screen wash and fuel 
additives. Methanol poisoning is usually associated with illicit alcohol. Epidemics 
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of methanol poisoning (caused by ingestion of contaminated beverages) and of 
diethylene glycol poisoning (caused by adulterated medications) continue to occur 
worldwide, predominantly in developing countries and among economically 
disadvantaged communities. Poisoning with these agents is associated with 
severe morbidity and mortality.
The toxicity associated with the toxic alcohols and glycols is due to 
their metabolism by the enzyme alcohol dehydrogenase to toxic intermediates. 
Fomepizole prevents formation of the toxic metabolites by competitively 
inhibiting alcohol dehydrogenase. Ethanol can also be used as an antidote and 
acts through the same mechanism. Experimental studies have demonstrated 
the ability of fomepizole to inhibit alcohol dehydrogenase, and animal studies 
have shown that fomepizole reverses the toxic effects of methanol and ethylene 
glycol poisoning.
Prospective observational studies, clinical trials and retrospective case 
reviews have demonstrated that fomepizole improves outcomes by improving 
renal function, preventing visual impairment associated with methanol 
poisoning, and preventing metabolic acidosis (105, 106). In a retrospective case 
series, ethanol and fomepizole were equally effective but fomepizole provided 
practical advantages, such as ease of administration and monitoring, and a better 
adverse events profile (106–111). However, no high-quality studies have directly 
compared fomepizole with ethanol.
Fomepizole is approved by the US FDA for these indications and is 
recommended by American and European associations of clinical toxicologists. 
Ethanol is not US FDA-approved for this indication.
The relative ease of use of fomepizole may confer some benefits through 
the potential avoidance of intensive therapy, although this would not apply to 
severely ill patients who would require intensive support. The limited data made 
it difficult to determine whether the greater cost of fomepizole was offset by any 
potential savings. The laboratory tests that are needed to initiate treatment and 
monitor therapy may not be available in all situations where poisonings occur. 
There are insufficient data from children and elderly people. However, most 
available information suggests that fomepizole is a safe medicine. It is classified 
as US FDA pregnancy category C.
It was also noted that access to parenteral ethanol was problematic as this 
product was difficult to manufacture and pack in ampoule form.
Though rare in some settings, toxic alcohol and glycol poisoning can lead 
to serious harm. Considering this need, the Expert Committee recommended 
the addition of fomepizole to the complementary list of the EML. The need for 
specialist care was a consideration for inclusion on the complementary list rather 
than on the core list.
Applications for the 18th Model List and the 4th EMLc
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Section 6: Anti-infective medicines
6.2: Antibacterials
6.2.2: Other antibacterials
Isoniazid + pyridoxine + sulfamethoxazole + trimethoprim (addition) –  
Adults and Children
An updated application to include the fixed-dose combination of isoniazid + 
pyridoxine + sulfamethoxazole + trimethoprim was submitted by the Department 
of HIV/AIDS, WHO.
An application for addition of this product had been submitted to the 
18th meeting of the Expert Committee but the addition was not made at that 
time since the product was not then commercially available.
An expert review was prepared by Mr Andrew Gray.
On the basis of known activities of the component medicines, the fixed-
dose combination was expected to be of use in preventing tuberculosis, bacterial 
pneumonia, malaria, isosporiasis and other infections and to reduce mortality 
and hospitalizations among adults and children living with HIV/AIDS (PLHIV).
WHO had listed this fixed-dose combination in the 10th Invitation for 
Expression of Interest for HIV medicinal products. A product – once available 
and prequalified by WHO – would provide a reliable and safe source for this 
fixed-dose combination.
Current WHO guidelines recommend both co-trimoxazole preventive 
therapy (CPT) and isoniazid preventive therapy (IPT) as part of the standard 
package of care for PLHIV (112). In most settings CPT is recommended 
indefinitely while IPT is recommended for at least 6 months. CPT prevents 
Pneumocystis jiroveci pneumonia, cerebral toxoplasmosis, bacterial pneumonia, 
diarrhoea, Isospora belli infections, malaria and other infections, and its use 
has led to significant reduction in mortality in clinical trials in low- and high-
income countries. IPT prevents active tuberculosis in HIV-infected persons. 
Pyridoxine is recommended in all HIV-infected persons receiving isoniazid, 
though it may be difficult for countries to procure and distribute pyridoxine 
with isoniazid. Including pyridoxine in the fixed-dose combination ensures 
that all patients on IPT are on concomitant pyridoxine, thereby preventing 
isoniazid-induced neuropathy.
The efficacy of CPT and IPT are compromised by lapses in adherence. 
Fixed-dose combinations have the potential to improve adherence and reduce 
the pill burden. Access to the fixed-dose combination was also proposed as a 
means to address the lower uptake of IPT compared with CPT.
The data on efficacy and safety presented to the meeting were mainly 
from studies of the individual components or prophylactic IPT and CPT 
regimens. These regimens are clearly effective for improving outcomes in PLHIV. 
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The safety profiles of the components are also well characterized. Though rare, 
the risk of Stevens–Johnson syndrome with CPT must be taken into account. All 
the constituent elements of this proposed fixed-dose combination were already 
included in the EML.
The application presented to the 19th meeting of the Expert Committee 
contained no new evidence compared with the application presented to the 
previous meeting.
The Expert Committee noted that, although the public health arguments 
for increased use of fixed-dose combinations to enhance compliance with 
recommended standard regimens and to avoid prescriber error are compelling, 
much depends on the availability of a quality-assured and affordable commercial 
product for procurement by country programmes and donors. In this case, no 
such product was yet commercially available. The Expert Committee noted that 
Cipla, India, manufactures the fixed-dose combination for clinical trials and 
was reported to be scaling up production. It appeared from the application that 
bioequivalence studies of the proposed fixed-dose combination formulation had 
not yet been conducted.
This application provided no additional information that could justify a 
different conclusion from that reached by the previous meeting, and therefore 
the Expert Committee recommended that the proposed fixed-dose combination 
should not be included in the EML.
6.2.4: Antituberculosis medicines
An application to include bedaquiline in the EML was submitted by Janssen 
Research & Development LLC, Beerse, Belgium.
Expert reviews were provided by Dr Lisa Bero and Dr Gitanjali 
Batmanabane.
There are an estimated 630 000 prevalent cases of MDR-TB globally 
(113), but appropriate treatment remains a problem. Bedaquiline is the first 
new drug with a novel mechanism of action (adenosine triphosphate, or ATP, 
synthase inhibition) for tuberculosis in more than 40 years. The proposed use of 
this medicine is as part of combination therapy, preferably as directly-observed 
therapy (DOT), for persons over 18 years of age newly diagnosed with MDR 
pulmonary tuberculosis. The total duration of treatment is 24 weeks.
On the basis of the available phase IIb data, the US FDA approved 
bedaquiline in late 2012 under its accelerated approval programme, as part of 
combination therapy to treat adults with MDR-TB when other alternatives are 
not available.
WHO’s Stop TB Department noted the accelerated approval by the 
US FDA, and in December 2012 a rapid interim guidance on the potential use 
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of bedaquiline for the treatment of MDR-TB was being developed. However, 
this was not available to the Expert Committee.
The Expert Committee noted that available trial data (consisting of 
two phase IIb trials) suggested that bedaquiline is effective in MDR pulmonary 
tuberculosis in adults. Primary efficacy analysis was based on a modified 
intention to treat (mITT) the population, which excluded subjects who had 
drug-susceptible tuberculosis, XDR-TB or unconfirmed MDR-TB (based on 
susceptibility tests taken before randomization), or had missing or negative 
baseline cultures, or were positive at baseline but had no post-baseline culture 
results. The mITT population comprised 132 subjects (66 in each of the 
bedaquiline and placebo groups). The median time to culture conversion was 
83 days (95% CI: 56–97) in the bedaquiline group compared with 125 days (95% 
CI: 98–168) in the placebo group.
Twelve deaths were reported in total; of these, 10 (12.7% of 79) came 
from the bedaquiline group and two (2.5% of 81) from the placebo group 
(P = 0.017). In the bedaquiline group, eight of the 10 deaths occurred in culture 
converters. Tuberculosis was the cause of death in the two placebo-arm deaths 
and in five of the 10 bedaquiline-arm deaths (all occurred when off bedaquiline 
treatment). Counting deaths strictly at the 120 weeks cut-off point revealed 
nine deaths in the bedaquiline group and one death in the placebo group. 
There was no discernible relationship between death and culture conversion, 
relapse, microbiological response, susceptibility to drugs used in the MDR-TB 
background medication regimen, HIV status, or severity of disease. The reasons 
for the imbalance were not clear.
The Expert Committee considered that further efficacy and safety data 
from clinical trials conducted in different backgrounds were needed and noted 
that bedaquiline was registered only in the USA (114). Bedaquiline was also 
not currently available commercially outside the USA and was expected to be 
available in some countries only by the end of 2013. The cost in high-burden 
countries was unknown.
On the basis of these considerations, the Expert Committee recommended 
that bedaquiline should not be included in the EML. However, the Committee 
also recommended that there should be efficient and timely alignment of the 
EML with WHO guidelines on the use of new medicines for MDR-TB.
6.3: Antifungal medicines
Amphotericin B (to be moved to the core list);  
Flucytosine (to be moved to the core list) – Adults and Children
The Department of HIV/AIDS, WHO, submitted applications to move 
amphotericin B and flucytosine to the core list of the EML and the EMLc.
Dr Suzanne Hill reviewed both amphotericin B and flucytosine, and 
Dr  Gilles Sama Kwende and Dr Hany Abdel-Aleem reviewed flucytosine. 
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Comments were received from Dr Myriam Henkens, International Medical 
Coordinator, MSF.
Cryptococcal meningitis accounts for 20–25% of AIDS-related mortality 
and is the most common cause of adult meningitis in sub‐Saharan Africa, 
constituting a major public health burden. The mortality from this infection 
remains high at 35–65%. Poor or delayed access to effective drug treatments is 
an important contributing factor to mortality.
WHO rapid advice guidelines on Diagnosis, prevention and management 
of cryptococcal disease in HIV‐infected adults, adolescents and children were 
published in December 2011 (115). Amphotericin‐based regimens were 
recommended as preferred in three of the five regimens. A two‐week regimen 
of amphotericin B plus flucytosine was recommended as the preferred option. 
Where amphotericin is unavailable, or cannot be monitored safely, the treatment 
guidelines recommend flucytosine in conjunction with high-dose fluconazole. 
However, the guidelines with flucytosine could not be followed in many parts of 
Africa because flucytosine was not available.
A cost–effectiveness analysis that also analysed mortality from pooled 
clinical trial data showed that regimens containing amphotericin were consistently 
superior (116). The addition of flucytosine to amphotericin B during induction 
therapy, compared with amphotericin B alone, was found to be associated with 
increased rates of cerebrospinal fluid (CSF) sterilization, a reduced risk of relapse, 
and a nonsignificant reduction in mortality at 2 weeks and a significant reduction 
at 10 weeks (116).
The 2011 WHO rapid advice guidelines also recommended appropriate 
strategies to ensure the safe administration of amphotericin, including 
intravenous hydration coupled with electrolyte monitoring. In a review of seven 
trials, using the recommended dose of 100 mg/kg per day of flucytosine for 
14 days with either amphotericin B or fluconazole, the incidence of grade IV 
neutropenia was 8 out of 183 (4.4%). A dose adjustment for renal function is 
needed for flucytosine.
Amphotericin B is produced by multiple generic manufacturers; generic 
flucytosine is not available in many countries although it has been off-patent for 
many years. The combination of flucytosine + fluconazole can be managed in 
resource-limited settings and an effective oral option is important.
The evidence provided to the Expert Committee included a published 
cost-utility analysis cited in the WHO guidelines (116). The Expert Committee 
noted that there were several problems with the analysis that led to difficulty 
in interpreting the results. The estimates of survival from different treatment 
regimens were extrapolated from 10 weeks to 1–3 years on the basis of several 
different cohorts that may or may not provide valid data for deriving incremental 
survival benefit. Quality-adjusted life years (QALYs) were calculated on the 
basis of Karnofsky performance scores from patients treated with antiretroviral 
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treatment (a completely different intervention), and these scores were then 
used to calculate incremental changes in estimated life years. This is not a valid 
approach to calculating QALYs, which should be calculated on the basis of an 
implied trade-off between survival and quality of life. As it was difficult to rely 
on the results of the analysis as presented, the Expert Committee decided that its 
decision should be weighted by other factors.
Given the obvious public health need, the potential to promote the 
availability of effective combinations in countries with heavy disease burdens, 
and the evidence of safety in the context where the products will be used, 
the Expert Committee decided to move these products to the core list. The 
Committee considered that transferring these medicines to the core list could 
improve availability. The Committee also strongly recommended that WHO 
should monitor the change in availability over the next five years.
6.4: Antiviral medicines
6.4.2: Antiretrovirals
Abacavir + Lamivudine (addition); Atazanavir + Ritonavir (addition);  
Tenofovir disoproxil fumarate + Lamivudine (addition);  
Tenofovir disoproxil fumarate + Lamivudine + Efavirenz (addition) – Adults
As described above, decisions on these applications were deferred.
Antiretrovirals (formulations to be considered for possible deletion) – Adults and Children
As described above, decisions on these applications were deferred.
6.4.3: Other antivirals
Oseltamivir (deletion) – Adults and Children
An application to delete oseltamivir from the EML was submitted by the Acute 
Respiratory Infections Cochrane Review group.
Expert reviews were provided by Dr Nicola Magrini and Dr Alar Irs. 
Comments were received from the WHO Department of Pandemic and 
Epidemic Diseases.
Oseltamivir was added to the EML and EMLc in 2010, with notes to 
indicate the conditions of use in compliance with WHO treatment guidelines. 
These notes specified that oseltamivir should be used only in patients with 
severe or progressive clinical illness with confirmed or suspected influenza 
A(H1N1)pdm09 and in patients with confirmed or suspected but uncomplicated 
illness due to pandemic influenza virus infections who were in higher-risk groups 
– most notably pregnant women and children under 2 years of age.
The effect of oseltamivir in reducing the complications of influenza 
was originally reported in a pooled analysis of 10 manufacturer-sponsored 
randomized trials of oseltamivir for the treatment of seasonal influenza (117). 
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This  analysis and an independent re-analysis of 11 randomized controlled 
trials (118) found that oseltamivir treatment reduced the risk of lower 
respiratory tract complications requiring antibiotic treatment by 28% overall 
(95%  CI:  11–42%) and by 37% among patients with confirmed influenza 
infections (95% CI: 18–52%).
The application proposed deletion of oseltamivir from the EML, citing a 
systematic review done by the applicants (119) which re-examined the evidence 
base for neuraminidase inhibitors and found that the only benefit was reduction 
in time to first alleviation of symptoms. The application also argued that – 
because of limitations in the design, conduct and reporting of the trials – there 
was insufficient detail to assess the credibility of the possible effect of oseltamivir 
on complications and viral transmission. The applicants also noted the significant 
publication and reporting bias in trials of oseltamivir.
The Expert Committee recalled that the addition of oseltamivir to the 
EML in 2011 was based on consideration of not only the randomized trials but 
also systematic reviews of observational studies (120). The Expert Committee 
had also been provided with some unpublished data in relation to the use and 
dose of oseltamivir in children. The observational studies reported outcomes 
that were relevant to the assessment of effectiveness and safety in the context of 
pandemic influenza, and also in populations that were not included in the trials 
(e.g. pregnant women).
The meta-analysis of observational data examined by the supplementary 
meeting of the Expert Committee in 2010 was published as an independent 
systematic review and meta-analyses of 74 studies (120). The few studies providing 
effects with adjustment for confounders suggest that, in high-risk populations, 
oral oseltamivir may reduce mortality (OR: 0.23, 95% CI: 0.13–0.43; low-quality 
evidence), hospitalization (OR: 0.75, 95% CI: 0.66–0.89; low-quality evidence), 
and duration of symptoms (33 hours, 95% CI: 21–45; very low-quality evidence) 
compared with no treatment. This very large effect on mortality was taken into 
account when deciding whether to include oseltamivir for treatment.
The 19th Expert Committee also acknowledged an additional recent 
systematic review and meta‐analysis (121) of observational data from 90 studies 
(80  reported exclusively laboratory-confirmed diagnoses) that assessed the 
impact of neuraminidase inhibitor treatment on severe outcomes in hospitalized 
patients during the 2009–2010 influenza A(H1N1) pandemic. There was a 
nonsignificant reduction in mortality associated with neuraminidase inhibitor 
treatment (at any time) versus none (OR: 0.72, 95% CI: 0.51–1.01), a significant 
reduction for early treatment (≤ 48 hours after symptom onset) versus late 
(OR: 0.38, 95% CI: 0.27–0.53) and for early treatment versus none (OR: 0.35, 
95% CI: 0.18–0.71). This study and the previously reviewed studies did not 
provide sufficiently compelling evidence to alter the current assessment of safety 
and benefit.
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The Expert Committee acknowledged that, although observational 
studies have inherent biases and estimates of effect from such studies may 
be subject to confounding, when there is a large effect on the most relevant 
outcomes (such as mortality) these studies should be part of the evidence base 
and can be taken into account in policy decision-making and in formulating 
a recommendation.
The Expert Committee noted that the WHO guidelines assessed the 
quality of the clinical evidence in relation to oseltamivir as low. While noting the 
limitations of the evidence, the previous decision to include oseltamivir in the 
EML took account of the magnitude of the effect on mortality and hospitalization, 
principles of equity, lack of alternative and the severity of infection, and strongly 
recommended it for restricted use (122).
In August 2010 WHO declared the H1N1 pandemic over. However, the 
responsible influenza strain continues to circulate and neuraminidase inhibitors 
are the only antiviral medicines that are effective against currently circulating 
strains. The recently identified H7N9 virus seen in China also appeared to be 
sensitive to oseltamivir.
Oseltamivir is widely available and is the only neuraminidase inhibitor 
suitable for children (noting that zanamivir cannot be used in children under 
5 years of age).
The Expert Committee decided, on the balance of the updated 
evidence and the strain susceptibility, to retain oseltamivir in the EML for 
the restricted indication of potentially severe or complicated illness due to 
confirmed or suspected influenza virus infection, in accordance with WHO 
treatment guidelines.
The Expert Committee strongly supported the need for access to all 
randomized trial data but also expressed reservations about whether additional 
data from such trials would be applicable as the trials are generally conducted 
in healthy individuals with influenza-like illness. The Expert Committee also 
noted that influenza vaccines should remain the first-line intervention against 
such infections.
Pegylated interferon (addition) – Adults
An application for addition of pegylated interferon was submitted by Médecins 
Sans Frontières – Access Campaign, Geneva, Switzerland.
Expert reviews were prepared by Dr Nicola Magrini and Dr Kuruvilla 
Prasad Mathews. Comments were received from the Global Hepatitis Programme 
of WHO, AIDS treatment organizations, multiple civil society organizations and 
patients’ groups.
Peginterferon is a covalent conjugate of recombinant interferon alfa-2 
with polyethylene glycol (PEG). The 2a and 2b formulations differ in the size and 
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nature of the covalently attached PEG, resulting in differences in pharmacokinetics 
and doses.
Globally, approximately 150 million people are infected with hepatitis C 
and it is estimated that 350 000 people die each year from hepatitis C-related liver 
disease (123). The goal of therapy is to produce a sustainable virological response 
(SVR) which can potentially result in the reversal of liver injury and can prevent 
serious consequences such as cirrhosis, end-stage liver disease, hepatocellular 
carcinoma and death.
When compared with standard interferon-alfa alone, interferon-alfa in 
combination with ribavirin increased the SVR from 10–20% to 40–60% (124, 
125). The long-acting pegylated formulation in combination with ribavirin has 
further increased SVR rates to 50–60% for genotype 1 and to 80% for genotypes 2 
and 3 (126, 127). A recent meta-analysis showed that treatment success rates 
in low- and middle-income countries were similar to those obtained in high-
income countries (128). Head-to-head randomized controlled trials – including 
the large randomized IDEAL trial (n = 3070) – demonstrated similar SVR rates 
for peginterferon alfa-2a and alfa-2b (41% versus 39% in IDEAL) in combination 
with ribavirin (129). While peginterferon alfa-2a or alfa-2b in combination with 
ribavirin has been the standard of care for chronic hepatitis C, the new direct-
acting oral antiviral agents (bocepravir and telapravir) are more effective but 
more expensive (130, 131). The Expert Committee noted that there are several 
more direct-acting antivirals in development.
Pegylated interferons + ribavirine are associated with a range of adverse 
events that often require dose reduction and discontinuation. Adverse events that 
resulted in treatment termination were reported in 39 studies and were present in 
4% (95% CI: 3–5) (128). Peginterferon alfa-2a and alfa-2b appear to be similarly 
tolerated (125).
Before treatment patients must be screened, RNA measurements and 
genotyping (which require high-level laboratory support) must take place, 
and facilities are required for liver biopsy and for detecting and managing 
complications.
WHO is developing guidelines for the screening, care and treatment of 
hepatitis C. Other expert bodies such as NICE (132), the European Association 
for the Study of the Liver (133) and the American Association for the Study of 
Liver Diseases (134) recommend peginterferon alfa-2a or alfa-2b with ribavirin 
for treatment of hepatitis C. Ribavirin was already listed in the EML and EMLc 
for viral haemorrhagic fevers.
The Expert Committee agreed on the public health need for this medicine 
and, because of the high level of expertise and facilities needed and the high cost, 
decided to list pegylated interferon alfa-2a and alfa-2b in the complementary 
list, to be used with ribavirin for treatment of hepatitis C when these products 
are available.
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The Expert Committee stressed the need to follow the development of 
direct oral hepatitis C protease inhibitors and to consider applications for triple 
therapy or all-oral options for the treatment of hepatitis C.
6.5: Antiprotozoal medicines
6.5.3: Antimalarial medicines
6.5.3.1: For curative treatment
Artesunate + mefloquine (addition) – Adults and Children
An application for the addition of the fixed-dose combination of artesunate + 
mefloquine was submitted by the Drugs for Neglected Diseases initiative (DNDi), 
Geneva, Switzerland.
Expert reviews were prepared by Dr Shalini Sri Ranganathan and 
Dr Eva Njenga.
Artesunate (AS) and mefloquine (MQ) are well established for the 
treatment of malaria and are listed in the EML and EMLc, with notes advocating 
their use in combination therapy. The combination artesunate + mefloquine 
(ASMQ) is recommended by WHO as one of five fixed-dose combinations for 
the treatment of uncomplicated falciparum malaria. The ASMQ combination is 
first-line therapy for Plasmodium falciparum malaria in the national policies of 
some Asian and South American countries.
Fixed-dose combinations of the drugs reduce the pill burden and, more 
importantly, eliminate the possibility of patients taking only one component of 
the combination or providers selling only one drug to reduce costs. The age-
based unit dose packaging provided is appropriate for all age groups, which 
should make the dosing easier at all levels of the health care system, including in 
the community.
Evaluations of the fixed-dose combination in clinical studies have 
shown similar comparative efficacy to that demonstrated with separate tablets 
of artesunate and mefloquine (135, 136). Reported adverse events were also 
comparable between the fixed-dose combination and separate tablets. There 
is some evidence to suggest that transmission is decreased in places where the 
fixed-dose combination is used (137).
The current price per child and adult treatment with the ASMQ fixed-
dose combination compares well with co-blister presentations or separate tablets 
of artesunate and mefloquine. DNDi and its partners are working towards 
lowering the price of the ASMQ combination in the future. ASMQ fixed-dose 
combination products are prequalified by WHO and the fixed-dose combination 
is currently registered in Brazil, India, Malaysia and Myanmar.
WHO does not recommend the use of separate tablets of artesunate and 
mefloquine in African children because of concerns about toxicity, including 
vomiting. To address these concerns DNDi is sponsoring a multicentre, open-
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label, prospective, randomized and controlled phase IV study in Burkina Faso, 
Kenya and the United Republic of Tanzania to assess the efficacy, safety and 
pharmacokinetics of the ASMQ fixed-dose combination versus artemether–
lumefantrine in approximately 1000 children with uncomplicated P. falciparum 
malaria (138).
The Expert Committee recommended the addition of both ASMQ 
25+55 mg and ASMQ 100+220 mg to the EMLc and EML. The Committee 
further emphasized the need for access to the data from the planned clinical trial 
in children, as well as to evidence on the use in P. vivax malaria.
6.5.5: Antitrypanosomal medicines
6.5.5.1: African trypanosomiasis
Nifurtimox + eflornithine (review) – Adults and Children
Please refer to Nifurtimox tablets (addition) – Children.
Section 8: Antineoplastics, immunosuppressives 
and medicines used in palliative care
8.2: Cytotoxic and adjuvant medicines
During discussion on the addition of two new medicines to this section, the 
Expert Committee acknowledged the growing public health importance of 
cancer as a global health issue. The Expert Committee recognized the need for 
countries to consider the addition of highly effective but high-cost medicines for 
cancer treatment in the context of evidence-based treatment regimens, but also 
in the context of ensuring comprehensive systems and interventions for cancer 
care. The Committee also recognized the urgent need to review the section on 
cytotoxic medicines, using a process and structure similar to those used for 
the EMLc. The process would require the systematic identification of the most 
treatable tumours in adults and the medicines required to treat those tumours, 
within the context of a stepwise development of cancer care systems in the overall 
context of health system development.
It was proposed that the outcome of this review could be considered by an 
extraordinary meeting of the Expert Committee or through an ad hoc subgroup 
(possibly electronically). The review would also need to be accompanied by 
the development of a systematic approach to the consideration of expensive 
medicines and the pricing of such products.
The Expert Committee therefore decided to consider the applications 
in detail, and the results of its discussion are set out below. However, given the 
need to restructure the published EML, the decision was taken not to amend 
Section 8.2 of the list by adding or deleting medicines at this time. The Expert 
Committee noted that a comprehensive review of Section 8.2 would identify 
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other effective but high-cost medicines that should be considered in the overall 
allocation of resources for pharmaceuticals used for management of cancer.
Imatinib (addition) – Adults
Imatinib (addition) – Adults and Children
Two applications were submitted for the inclusion of imatinib for the treatment 
of chronic myeloid leukaemia.
The first application was from Dr Sandeep P. Kishore, Malini Aisola, 
Ruth Lopert and Nii Koney from the Weill Cornell Medical College, New York, 
NY, USA, for adult patients. The second application was from Dr  Lawrence 
N. Shulman of the Center for Global Cancer Medicine, Dana-Farber Cancer 
Institute, Boston, MA, USA and Julie Torode, Deputy CEO, Union for 
International Cancer Control, Geneva, Switzerland; this application was for both 
adult and paediatric patients.
Expert reviews were provided by Dr Suzanne Hill and Dr Nicola Magrini.
The Expert Committee noted that chronic myelogenous leukaemia 
constitutes 15% of all adult leukaemia cases and 5% of all childhood leukaemias, 
with an estimated incidence of 1–1.5 per 100 000 people globally. In high-income 
countries, the estimated five-year survival rate of patients diagnosed between 
2001 and 2007 (i.e. before wide use of imatinib) was 57%.
Imatinib has been in use since 2001 and has become the first-line 
treatment for Philadelphia chromosome positive-chronic myeloid leukaemia 
(139–141). It is now generally considered as the treatment of choice for disease 
control of chronic myeloid leukaemia in the chronic phase. The large randomized 
controlled trial that compared imatinib to interferon plus cytarabine (142) 
showed that, at 19 months, major cytogenetic remissions were seen in 87.1% of 
the imatinib-treated group compared with 34.7% of the comparator group. At six 
years, the overall survival in the imatinib-treated group was 88% (comparative 
data not available due to crossover of subjects) and the remission rate in the 
imatinib-treated group was also much higher (143). Data comparing survival 
before and after the introduction of imatinib show a large absolute improvement 
in survival rates at eight years from 45% (in the years 1991–2000) to 75% in the 
imatinib-treated cohorts (144).
The Expert Committee noted that the first application described the use 
of imatinib in low- and middle-income countries with results that were varied but 
were generally in line with the results from treatment in high-income countries 
(145–149). Access to imatinib in low- and middle-income settings has been 
highly variable and to some extent has depended on the original manufacturer 
supplying the product through compassionate access programmes.
The cost of imatinib has been very high. Generic preparations may 
become available: Europe has already granted approval for one generic imatinib 
46
W
H
O
 T
ec
hn
ic
al
 R
ep
or
t S
er
ie
s, 
N
o.
 9
85
, 2
01
4
The Selection and Use of Essential Medicines   Report of the 19th WHO Expert Committee
preparation and multiple applications for generic preparations in the USA are 
awaiting expiry of the patent period (150). The price of imatinib is therefore 
expected to decrease.
The Expert Committee considered that the evidence showed that imatinib 
is a highly effective treatment for Philadelphia chromosome-positive chronic 
myeloid leukaemia, which is a relatively uncommon form of leukaemia. While 
noting the limited population for which the drug might be useful, the Expert 
Committee agreed that imatinib meets the criteria for inclusion as an essential 
medicine. The Committee considered that the cost–effectiveness of imatinib 
would depend mainly on the price that countries could negotiate with suppliers, 
but also noted that long-term supply and use of the product are necessary to 
maintain the therapeutic effect. Thus it would be important for countries 
to  consider total cost in making a decision on whether to include imatinib in 
national EMLs or reimbursement programmes.
Given the need for the list of medicines in Section 8.2 of the EML to be 
reviewed, the Expert Committee decided that the final specification of imatinib 
in the EML should be done by the Committee once the review is completed.
Trastuzumab (addition) – Adults
There were two applications for the addition of trastuzumab for breast cancer. 
The first was from Dr Lawrence N. Shulman of the Center for Global Cancer 
Medicine, Dana-Farber Cancer Institute, Boston, MA, USA and Julie Torode, 
Deputy CEO, Union for International Cancer Control, Geneva, Switzerland. The 
second application was from Knowledge Ecology International, Washington, 
DC, USA, University of California, San Francisco, Department of Medicine, 
San  Francisco, CA, USA, and Universities Allied for Essential Medicines and 
Young Professionals Chronic Disease Network, Weill Cornell Medical College, 
New York, NY, USA.
Expert reviews were provided by Dr Suzanne Hill, Dr Nicola Magrini and 
Dr Johannes Löwer.
The importance of breast cancer as a public health priority is recognized 
in the fact that many of the antineoplastics necessary for its treatment are 
available in Section 8 of the EML. Human epidermal growth factor receptor 2 
(HER2) positive breast cancer is estimated to account for around 20% of patients 
with the disease.
The Expert Committee noted that, for adjuvant therapy, the systematic 
review (based on eight trials) cited in the applications showed that in early 
HER2-positive breast cancer the use of trastuzumab in combination with 
standard treatment (surgery, radiotherapy and chemotherapy) has been found 
to increase the likelihood of survival. The estimated relative effect (hazard ratio) 
from the review for overall survival and disease-free survival were 0.66 (95% 
CI: 0.57–0.77) and 0.60 (95% CI: 0.50–0.71) respectively (151–153). Viani et al. 
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(2007) found that the absolute effect on survival was a mortality of 6.0% (217 of 
4555) in the group treated with trastuzumab compared with 8.5% (392 of 4562) 
in the group not treated with trastuzumab (154). The review noted that there 
was some risk of bias in the trials due to inadequate allocation concealment, and 
also noted that some of the trials were stopped early for benefit. The sensitivity 
analyses conducted in the review to examine these factors did not find changes 
in the size of relative effect. The review also noted that two trials, including 
approximately 2800 patients, had not been published. A Cochrane review in 2012 
found a survival benefit of 3.3%, 9.0% and 13.3% in women with low, moderate 
and high risk of death at 36 months (151).
In metastatic breast cancer the addition of trastuzumab to standard 
chemotherapy may be associated with prolonged survival. The Expert Committee 
noted that the main evidence of benefit in this population is based on the trial 
published in 2001 (155) which found an increase of five months in overall survival. 
However, other studies have shown that the effect on advanced/metastatic breast 
cancer has been less.
The toxicity – including cardiac toxicity – of trastuzumab is well defined. 
The ongoing costs of managing congestive cardiac failure in patients on extended 
treatment could be significant and, if so, would have an effect on estimates of 
cost–effectiveness.
The Expert Committee noted that, to provide optimal use of trastuzumab 
for breast cancer, a health care system should ensure that there are appropriate 
screening programmes, surgery, radiotherapy and chemotherapy in place. In 
addition, specialized diagnostic facilities are needed for cytogenetic testing and 
the identification of different types of tumour receptors. The second application 
argued that simplified testing techniques were being developed but the 
Committee noted that these were not yet available or validated.
The cost of trastuzumab is very high. Biosimilar preparations are not yet 
available, and the costs differential between originator and biosimilar versions is 
not yet known.
The Expert Committee considered that the evidence showed that 
trastuzumab is an effective adjuvant treatment in early-stage breast cancer. The 
Committee agreed that trastuzumab meets the criteria for inclusion as an essential 
medicine in health systems that have the capacity for specialized diagnostic 
facilities and for delivering the other treatment modalities for the management 
of breast cancer. The Expert Committee considered that the cost–effectiveness is 
likely to be unfavourable and recommended that WHO should develop strategies 
to assist countries to determine how to manage purchasing decisions in relation 
to high-cost medicines in general, including those for cancer.
Given the need for the list of medicines in Section 8.2 of the EML to be 
reviewed, the Expert Committee decided that final specification of trastuzumab 
in the EML should be done by the Committee once the review is completed.
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8.4: Medicines used in palliative care
An application for medicines for palliative care in adults was submitted by the 
International Association for Hospice and Palliative Care (IAHPC), Houston, 
TX, USA.
An expert review was provided by Dr Gitanjali Batmanabane. Comments 
were received from Dr Myriam Henkens, International Medical Coordinator, 
Médecins Sans Frontières.
In response to a request from the Expert Committee in 2005, the IAHPC 
developed a list of essential medicines for palliative care based on the consensus 
of palliative care workers from around the world (156). As this list was based on 
expert opinion, the Expert Committee requested that a list be developed on the 
basis of scientific evidence.
The 17th EML stated: “The WHO Expert Committee recognizes the 
importance of listing specific medicines in the palliative care section. Some 
medicines currently used in palliative care are included in the relevant sections of 
the Model List, according to their therapeutic use, e.g. analgesics. The Guidelines 
for Palliative Care that were referenced in the previous list are in need of update. 
The Committee expects applications for medicines needed for palliative care to 
be submitted for the next meeting” (157).
The second EMLc included 17 medicines for paediatric palliative care 
based on an application made by paediatric palliative care specialists.
The application submitted by the IAHPC describes the principles of 
palliative care which (158):
 ■ provides relief from pain and other distressing symptoms;
 ■ affirms life and regards dying as a normal process;
 ■ intends neither to hasten nor postpone death;
 ■ integrates the psychological and spiritual aspects of patient care;
 ■ offers a support system to help patients live as actively as possible 
until death;
 ■ offers a support system to help the family cope during the patient’s 
illness and in their own bereavement;
 ■ uses a team approach to address the needs of patients and their 
families, including bereavement counselling, if indicated;
 ■ will enhance quality of life, and may also positively influence the 
course of illness;
 ■ is applicable early in the course of illness, in conjunction with other 
therapies that are intended to prolong life, such as chemotherapy or 
radiation therapy, and includes those investigations needed to better 
understand and manage distressing clinical complications.
Applications for the 18th Model List and the 4th EMLc
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It was noted that there was a difficulty in implementing high-quality 
prospective studies of symptoms and associated distress in patients receiving 
palliative care. The data identified were mainly from retrospective case reviews, 
expert opinion and case reports (156, 159–162). However, there is an interest in 
systematically gathering evidence in the area of palliative care in adults (163, 164).
To develop the list of proposed medicines, a working group was 
constituted by IAHPC. Using WHO global mortality data this group identified 
the  most common causes of death, and the most common and distressing 
symptoms in palliative care by means of a literature search. The final step was 
identification of the medicines to be recommended for the treatment of symptoms. 
Table 1 lists the most common and distressing symptoms occurring in people 
receiving palliative care, and the medications included in the application:
Table 1
Symptoms in palliative care, and proposed medicines
Symptom Proposed medicine
Anorexia (appetite loss) Dexamethasone
Injection: 4 mg/ml in 1‐ml ampoule (as disodium 
phosphate salt)
Oral liquid: 2 mg/5 ml
Tablet: 4 mg (not listed in the EML)
Anxiety Diazepam
Injection: 5 mg/ml
Oral liquid: 2 mg/5 ml
Rectal solution: 2.5 mg; 5 mg; 10 mg
Tablet: 5 mg; 10 mg
Lorazepam
Injection: 2 mg/ml in 1-ml ampoule
Tablet: 1 mg; 2.5 mg (not listed in the EML)
Constipation Docusate sodium
Capsule: 100 mg
Oral liquid: 50 mg/5 ml
Senna
Oral liquid: 7.5 mg/5 ml
Sodium picosulfate
Oral liquid 7.5 mg/ml (not listed in the EML)
Delirium (confusion) Haloperidol
Injection: 5 mg in 1‐ml ampoule
Oral liquid: 2 mg/ml
Solid oral dosage form: 0.5 mg; 2 mg; 5 mg
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Table 1 continued
Symptom Proposed medicine
Depression Amitriptyline
Tablet: 10 mg; 25 mg
Fluoxetine
Tablet or capsule: 20 mg (as hydrochloride)
Diarrhoea Loperamide
Tablet or capsule: 2 mg
Dyspnoea (breathlessness) Morphine
Recommended formulations for inclusion:
Granules (modified release) (to mix with water): 
20 mg; 30 mg; 60 mg; 100 mg; 200 mg
Injection: 10 mg/ml
Oral liquid: 10 mg/5 ml
Tablet (immediate release): 10 mg.
Tablet (controlled release): 10 mg; 30 mg; 60 mg
Fatigue Dexamethasone
Injection: 4 mg/ml in 1‐ml ampoule (as disodium 
phosphate salt)
Oral liquid: 2 mg/5 ml
Tablet: 4 mg (not listed in the EML)
Nausea and vomiting Metoclopramide
Injection: 5 mg (hydrochloride)/ml in 2‐ml ampoule
Oral liquid: 5 mg/5 ml
Tablet: 10 mg (hydrochloride)
Pain Ibuprofen
Oral liquid: 200 mg/5 ml
Tablet: 200 mg; 400 mg; 600 mg
Morphine
Granules (modified release) (to mix with water): 
20 mg; 30 mg; 60 mg; 100 mg; 200 mg
Injection: 10 mg/ml
Oral liquid: 10 mg/5 ml
Tablet (controlled release): 10 mg; 30 mg; 60 mg
Tablet (immediate release): 10 mg
Respiratory tract secretions Hyoscine butylbromide
Injection: 10 mg/ml (not listed in the EML)
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The Expert Committee noted that good-quality evidence for rational 
pharmacotherapy for many of the symptoms was lacking. The systematic reviews 
in the literature of symptom management related to patients with cancer. 
These reviews concluded that there was insufficient evidence to draw any firm 
conclusions on medicines for the treatment of symptoms such as fatigue, anxiety 
or anorexia in cancer. However, there is extensive experience in the use of these 
medicines for the treatment of most of the common symptoms experienced 
in terminally ill patients. The medicines that have been recommended in 
the application are already listed in the EML, under either palliative care or 
another indication. The unique position of the terminally ill patient and the 
objectives of providing palliative care means that experience needs to be taken 
into account.
Given the above, much of the evidence for the efficacy of these drugs 
was based on studies that were not of patients receiving palliative care. The 
Expert Committee also noted the medicines that were included for palliative 
care in children.
Lorazepam was not considered necessary as diazepam and midazolam 
were already available. The evidence for sodium picosulfate was insufficient 
to justify inclusion and there were already two other laxatives (docusate and 
senna) on the list. Although the evidence for the benefit to the patient of the 
use of antimuscarinic agents in prevention of accumulation of respiratory tract 
secretions during the dying phase was acknowledged as weak, the inclusion of 
hyoscine butylbromide (which, in contrast to the hydrobromide included for 
children, does not cross the blood–brain barrier) was supported. The inclusion of 
loperamide, in accordance with the existing WHO guidelines for the treatment 
of HIV, was supported.
The Expert Committee therefore recommended the listing of medicines 
for adults for common symptoms in palliative care, other than for pain, as shown 
in Table 2.
Table 2
Medicines for common symptoms other than pain in palliative care
Medicine Dosages
amitriptyline Tablet: 10 mg; 25 mg; 75 mg
dexamethasone Injection: 4 mg/ml in 1-ml ampoule (as disodium 
phosphate salt)
Oral liquid: 2 mg/5 ml
Tablet: 4 mg
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Table 2 continued
Medicine Dosages
diazepam Injection: 5 mg/ml
Oral liquid: 2 mg/5 ml
Rectal solution: 2.5 mg; 5 mg; 10 mg
Tablet: 5 mg; 10 mg
docusate sodium Capsule: 100 mg
Oral liquid: 50 mg/5 ml
fluoxetine Solid oral dosage form: 20 mg (as hydrochloride)
haloperidol Injection: 5 mg in 1‐ml ampoule
Oral liquid: 2 mg/ml
Solid oral dosage form: 0.5 mg; 2 mg; 5 mg
hyoscine butylbromide Injection: 20 mg/ml
loperamide Solid oral dosage form: 2 mg
metoclopramide Injection: 5 mg (hydrochloride)/ml in 2‐ml ampoule
Oral liquid: 5 mg/5 ml
Solid oral dosage form: 10 mg (hydrochloride)
midazolam Injection: 1 mg/ml; 5 mg/ml
Solid oral dosage form: 7.5 mg; 15 mg
senna Oral liquid: 7.5 mg/5 ml
Section 9: Antiparkinsonism medicines
Antiparkinsonism medicines (review) – Adults
A review of this section was submitted by Professor Richard Walker (United 
Republic of Tanzania/United Kingdom) on behalf of the Africa Task Force of the 
Movement Disorders Society.
Expert reviews were prepared by Dr Alar Irs and Dr Youping Li. 
Comments were received from Dr Shekhar Saxena, Director, Mental Health and 
Substance Abuse, WHO.
Parkinson disease is prevalent the world over. Life expectancy for 
patients with Parkinson disease in Europe was shown to be severely limited 
before the introduction of levodopa. That is essentially the situation that still 
exists in resource-constrained settings such as sub-Saharan Africa.
The current EML lists levodopa + carbidopa as 100 mg + 10 mg and 
250 mg + 25 mg. Also listed is biperiden, an anticholinergic. Evidence shows that 
Applications for the 18th Model List and the 4th EMLc
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the risk of death was significantly reduced following the initiation of levodopa, 
regardless of pre-levodopa duration of Parkinson disease, and this reduction 
persisted over 17 years (165). Levodopa + carbidopa is the mainstay of therapy. 
The 10:1 ratio of levodopa:carbidopa that is listed is too high to prevent levodopa-
induced nausea for many patients. The 100 mg + 25 mg tablet with its 4:1 ratio 
is preferable for use for titration to the effective dose. Many guidelines and use 
data from the United Kingdom, for instance, support this statement. Patients are 
usually started on a 50 mg + 12.5 mg dose twice daily and gradually increased 
to 100 mg + 25 mg three times daily. The application reported that the current 
WHO listing was affecting availability of the correct formulation, especially in 
some African countries.
The application reported that biperiden was not widely available. 
Anticholinergics as a class are now rarely used, except in younger patients with 
predominant tremor problems. Anticholinergic use in elderly patients and in 
patients with cognitive impairment is limited because of well-known side-effects, 
including confusion, dizziness, memory loss and psychosis (hallucinations and 
agitation). Hence, the application argued that retaining this medicine in the 
EML was not justified. Trihexphenidyl was reported to be more widely available 
and was therefore recommended for addition, with clear notes to indicate that it 
should be used only in younger patients.
The review mentioned other newer medicines for Parkinson disease, 
for use by clinicians with experience in treating this disease. Pramipexole and 
ropinirole are available in low- and middle-income countries but are expensive 
compared with levodopa/carbidopa. Selegiline, a monamine oxidase type B 
inhibitor, can be used both as initial and as add-on therapy. Amantadine has 
moderate antiparkinsonian effects but has been found to be potentially helpful 
for dyskinesia.
On the basis of the data presented, the Expert Committee decided to add 
the levodopa/carbidopa 100 mg + 25 mg dosage form, but decided to retain the 
100 mg + 10 mg and 250 mg + 25 mg dosage forms as they were commonly used. 
The Committee agreed to add a square box symbol to biperiden to allow for the 
option of procuring trihexphenidyl. The Expert Committee called for a detailed 
application for the addition of a dopamine agonist.
Section 10: Medicines affecting the blood
10.1: Antianaemia medicines
Ferrous salt + folic acid (new formulation) – Adults
An application was submitted by the Department of Nutrition for Health and 
Development, WHO, for inclusion of a new formulation of ferrous salt and folic 
acid (60 mg elemental iron in a ferrous form plus folic acid 2.8 mg tablet/capsule) 
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for the prevention of anaemia in menstruating women and adolescent girls 
through an intermittent treatment regimen.
Expert reviews were provided by Dr Eva Njenga and Dr Shalini Sri 
Ranganathan.
There is a high prevalence of anaemia in non-pregnant women, especially 
in low- and middle-income countries, leading to low resistance to infections 
and reduced work performance. Anaemic women who become pregnant have 
poor maternal and neonatal outcomes. The evidence in a Cochrane review shows 
that intermittent supplementation with iron (either alone or in combination 
with other nutrients) is significantly more effective in reducing anaemia among 
menstruating women compared with no supplementation or placebo (RR: 0.73, 
95% CI: 0.56–0.95). The positive effect of the intermittent supplement was seen 
in patients receiving iron once or twice a week. Overall, the finding appears to 
remain constant whether the supplements were given once or twice weekly, for 
less or more than three months, contained less or more than 60 mg of elemental 
iron per week, or the populations had different degrees of anaemia at baseline. 
Intermittent iron and folic acid supplements could, therefore, reduce the risk of 
anaemia in menstruating women and adolescent girls.
The most common side-effects of iron supplementation include nausea, 
constipation, dark stools and metallic taste. There is no significant difference in 
adverse side-effects of once-weekly intermittent iron supplementation versus 
no intervention or placebo (RR: 1.98, 95% CI: 0.31–12.72) and of once-weekly 
intermittent iron supplementation versus daily iron supplementation (RR: 0.36, 
95% CI: 0.10–1.31) (166).
The EML currently lists the fixed-dose combination “ferrous salt + folic 
acid tablet equivalent to 60 mg iron + 400 µg folic acid”. Ferrous salt and folic 
acid are also listed separately. There are no data on efficacy comparing the 
“ferrous 60 mg + folic acid 400 micrograms” to “ferrous 60 mg plus folic acid 
2.8 mg” in preventing anaemia. The difference in folic acid dose (400 µg to be 
replaced with 2.8 mg) was based on minimal evidence. The Cochrane review 
(166) and WHO guidelines (167) state that the recommendation of 2.8 mg is 
based only on the rationale of providing seven times the recommended daily 
dose to prevent neural tube defects and experimental evidence that high weekly 
doses can improve red blood cell folate concentrations to levels that have been 
associated with a reduced risk of neural tube defects.
While recognizing the programmatic needs for appropriate 
supplementation in pregnancy, the Expert Committee decided after careful 
consideration not to include this combination in the EML. Data to show the 
intermittent regimen to be at least equivalent to existing options (and not 
placebo) for the prevention of anaemia and/or neural tube defects would be 
needed. It was also noted that no commercial preparation of this fixed-dose 
combination yet exists.
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Section 11: Blood products and plasma substitutes
11.2: Plasma fractions for specific use
Human normal immunoglobulin (additional dosage) – Adults and Children
An application was submitted by CSL Behring AG, Bern, Switzerland, for 
inclusion of subcutaneous immunoglobulin (SCIg) 20% in the complementary 
list of the EML.
Expert reviews were provided by Dr Abdol Majid Cheraghali, Dr Youping 
Li and Dr Johannes Löwer. Comments were received from International 
Patient Organisation for Primary Immunodeficiencies, the African Society 
for  Immunodeficiencies, the Latin American Society for Immunodeficiencies 
and Dr Ana Padilla of the Department of Essential Medicines and Health 
Products, WHO.
Human normal immunoglobulin is included in the EML (Section 11.2 – 
Plasma fractions for specific use) in concentrations of 5–16%, for intramuscular, 
intravenous and subcutaneous administration. The application was for a 
20% concentration to be used subcutaneously with no change in indications. 
The schedules and doses of SCIg 20% would be the same as with the 15–16% 
concentrations but the infusion volumes would be smaller (168).
The major advantage cited for this formulation was patient convenience, 
with a lesser volume being required for the repeated administration that is 
required for the chronic conditions. The applications stated that the new 
preparation would decrease the cost of home-based therapy but no formal cost 
analysis was provided.
The Expert Committee decided not to change the list at this stage, 
pending amendments to the pharmacopoeial monographs applicable to such 
products. Once the monographs are updated, a more general listing that is 
compliant with the pharmacopoeial standards will be possible.
Whole blood and red blood cells (addition) – Adults and Children
An application was submitted by AABB (formerly the American Association 
of Blood Banks), the American Red Cross and Canadian Blood Services for the 
inclusion of whole blood and red blood cells in the EML.
Extensive comments were received from ministries of health, medicines 
and blood regulatory authorities, multilateral agencies, experts in transfusion 
medicine and their professional associations, Red Cross national societies, patient 
organizations and associations of voluntary blood donors. All comments remain 
available on the WHO EML website at: http://www.who.int/selection_medicines/
committees/expert/19/applications/blood.
Expert reviews were provided by Dr Suzanne Hill, Dr Liliana de Lima 
and Dr Johannes Löwer.
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The application stated that the inclusion of whole blood and red blood 
cells in the EML would accomplish several critical objectives in furtherance of 
World Health Assembly resolution WHA63.12 on the availability, safety and 
quality of blood products. These would include:
 ■ heightened awareness of the need for blood in every country and of 
the role of blood in protecting public health;
 ■ government responsibility for ensuring sustainable funding and 
support for a safe and adequate supply of blood that is accessible to 
patients in need;
 ■ creation of a favourable environment for governments for national 
regulation dealing with blood and blood products;
 ■ investment in infrastructure, systems and governance for blood 
establishments;
 ■ additional emphasis on the need for effective and efficient 
procurement systems to provide equipment, supplies and reagents 
to collect, process, test, store and transport blood;
 ■ additional emphasis on the need to ensure that blood is cost-effective, 
affordable and available; and
 ■ enabling, and putting additional emphasis on the importance of, 
appropriate regulatory oversight of blood collection, processing, 
testing, storage and distribution to ensure the safety and quality of 
blood and the safety of blood transfusion.
The Expert Committee noted the discussion in the Open Session which 
reflected the many comments received and made available on the WHO EML 
website, both supporting and opposing the inclusion of whole blood and red 
blood cells in the EML. The Committee considered the fact that the application 
raised many issues that span technical, clinical, ethical and regulatory issues.
The Expert Committee discussed whether blood could be considered as 
a “medicine”, since this was a key issue highlighted in many of the comments 
both for and against inclusion. While noting that blood may be different from 
conventional medicines in that it is a “human-derived biological material”, it 
was acknowledged that many countries already regulate blood as a “biological 
medicine”. The heading of Section 11 in the first EML of 1977 was “Blood and 
haematopoietic system drugs”. It was also noted that the WHO Expert Committee 
on Biological Standardization defines blood products as “any therapeutic 
substances derived from human blood, including whole blood, labile blood 
components and plasma-derived medicinal products”.
The Committee agreed that there was no need to debate whether blood 
and red blood cells were essential as they were necessary for the treatment and 
management of many clinical conditions – such as anaemia and diseases of the 
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blood (where the haemoglobin levels requiring transfusion are well defined), 
gastrointestinal bleeding and injuries – as well as during surgery, and for obstetric 
conditions such as postpartum haemorrhage and neonatal conditions requiring 
exchange transfusions (169–174).
The Expert Committee also considered the issue of safety of blood. 
On the basis of the application and the comments, the safety issues relating to 
the use of blood were well defined and the importance of appropriate quality 
standards for its production were clear. Global application of these standards 
would improve the safety of blood for use in transfusion. It was noted that the 
risk of transfusion-mediated viral infections remains a constant concern.
The Expert Committee discussed the cost of delivering appropriate 
quality blood products. The cost of production is recognized as significant but 
WHO has taken many steps over the years to support countries in developing 
affordable and high-quality transfusion services. The Committee recognized 
the need to promote the appropriate use of transfusion to ensure that its cost–
effectiveness would be maintained.
The Expert Committee further considered the concerns raised by 
some Member States and organizations regarding payment for donors, 
commercialization and commodification, including arguments relating to factor 
VIII and factor IX complex that are currently in the EML. Factors VIII and IX 
are supplied as commercial products, are used for a very limited number of 
conditions affecting a small population, and require sophisticated manufacturing 
technology; therefore they cannot be seen as examples of commodification for 
whole blood or red blood cells which have a limited lifespan/shelf-life and are 
used in very different clinical situations that affect a much larger population. 
The Committee noted that neither the applicant nor any of the comments 
provided data to support the claims that listing blood and red blood cells in the 
EML would lead to their commodification.
It was noted that medicines regulatory authorities, through the ICDRA 
resolution,5 had expressed a strong preference for listing blood and red blood 
cells as an essential medicine to advance access to safe blood products that 
are appropriately regulated and traceable. Listing as an essential medicine 
would not be a sufficient solution in itself but would enable the beginning of 
a systematic approach to improving access to safe blood products. The Expert 
Committee noted that World Health Assembly resolution WHA63.12 called on 
Member States “to enhance the quality of evaluation and regulatory actions in 
the area of blood products and associated medical devices, including in vitro 
diagnostic devices”.
5  See: http://www.who.int/medicines/areas/quality_safety/regulation_legislation/icdra/14-ICDRA_
recommendations.pdf.
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The Committee fully concurred that listing whole blood and red blood 
cells in the EML would not be contradictory to the principles of voluntary, non-
remunerated blood donation, as noted in World Health Assembly resolution 
WHA63.12. Such a listing would strongly support these principles.
Having considered all the above arguments, the Expert Committee 
decided to change the heading of Section 11 to “Blood products of human origin 
and plasma substitutes” and to restructure the section to specify blood products 
clearly. The note under Subsection 11.2 would be moved to Subsection 11.1 and 
would be updated to reflect World Health Assembly resolution WHA63.12. 
Subsection 11.1 would be relabelled “Blood and blood components” and 
would list fresh–frozen plasma, red blood cells, platelets and whole blood. The 
balance of the section would be renumbered. Subsection 11.2 would be labelled 
“Plasma-derived medicinal products”, with a Subsection 11.2.1 labelled “Human 
immunoglobulins”. Subsection 11.2.2 would be labelled “Blood coagulation 
factors” and would list factor VIII and factor IX. Subsection 11.3 would be 
labelled “Plasma substitutes”. A note would also be inserted to indicate that a 
review of this last subsection would be needed at the next meeting of the Expert 
Committee as the subsection contains dextran, and that the Committee should 
also consider a possible move of the three immunoglobulins (anti-D, anti-tetanus 
and anti-rabies) from Section 19.2 to the new Subsection 11.2.1.
Section 12: Cardiovascular medicines
Fixed-dose combination for secondary prevention of 
cardiovascular disease (addition) – Adults
An application was submitted by Dr Mark D. Huffman, Northwestern University 
Feinberg School of Medicine, Chicago, IL, USA, Dr Shanthi Mendis, Director, 
Management of Noncommunicable Diseases, WHO, Dr Valentin Fuster, Mount 
Sinai School of Medicine, New York, NY, USA, Dr Anthony Rodgers, The 
George Institute, Sydney, Australia, Dr Sidney C. Smith Jr, University of North 
Carolina, Chapel Hill, NC, USA and Dr Salim Yusuf, Population Health Research 
Institute, McMaster University, Hamilton, Canada, for the inclusion of fixed-
dose combination therapy for secondary prevention of cardiovascular disease 
(ischaemic heart disease and thrombotic stroke).
Expert reviews were provided by Mr Andrew Gray and Dr Lisa Bero.
The three preparations mentioned in the application were:
 ■ Indian Polycap in two strengths:
 – (low dose) aspirin 100 mg, simvastatin 20 mg, ramipril 5 mg, 
atenolol 50 mg, hydrochlorothiazide 12.5 mg;
 – (high dose) aspirin 200 mg, simvastatin 40 mg, ramipril 10 mg, 
atenolol 100 mg, hydrochlorothiazide 25 mg;
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 ■ Trinomia/Sincronium:
 – aspirin 100 mg, simvastatin 40 mg, ramipril (2.5 mg, 5 mg 
or 10 mg);
 ■ Red Heart Pill in two strengths and combinations (not yet 
commercially available):
 – aspirin 75 mg, simvastatin (20 mg or 40 mg), lisinopril 10 mg, 
atenolol 50 mg;
 – aspirin 75 mg, simvastatin (20 mg or 40 mg), lisinopril 10 mg, 
hydrochlorothiazide 12.5 mg.
The Polycap brand is registered in India, while the Trinomia/Sincronium 
brand is available in Guatemala and Mexico. It was not clear to the Expert 
Committee which of these combinations was being proposed for inclusion in the 
EML and specifically in which strengths.
The Expert Committee noted that there is a need for access to effective 
and appropriate secondary prophylaxis for cardiovascular diseases. Although 
there is wide acceptance of the concept of using a fixed-dose combination 
for the prevention of cardiovascular disease, the proposal did not present a 
comprehensive review of the projected health gains from use of any of the fixed-
dose combinations in either primary or secondary prophylaxis.
The clinical trials cited in the proposal were chiefly in primary prevention, 
were of short duration, and relied on surrogate end-points (175, 176). There is 
as yet no trial with any of the fixed-dose combinations that is powered to show a 
difference in morbidity and mortality. While the medicines in the proposed fixed-
dose combinations have been individually tested, there have been no adequate 
trials of these combinations in secondary prophylaxis.
The Expert Committee considered that there might be improved adherence 
to treatment regimens using a fixed-dose combination as opposed to multiple 
separate agents. However, the Committee also noted that previous reviews of 
the effect of fixed-dose combinations on adherence in other therapeutic areas 
such as HIV and malaria may not be directly relevant to the potential adherence 
outcomes in patients with cardiovascular disease. In addition, there was no 
evidence to substantiate the claim that widespread use of the proposed fixed-dose 
combinations would translate into significant clinical benefits or whether such 
use would also be associated with increased adverse effects.
The Expert Committee noted that there are serious gaps in the data on 
the proposed fixed-dose combination formulations. Only one of the three dosage 
forms listed has undergone a bioavailability study comparing the individual 
components with the fixed-dose combination (177). The application stated 
that “other fixed-dose combination therapies demonstrate similar degrees of 
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bioequivalence with the individual components” but did not provide data to 
support this claim.
The Expert Committee therefore recommended that these products 
should not be included in the EML. However, it noted that the use of fixed-dose 
combinations for the prevention of cardiovascular disease is a promising concept 
and that a further submission should be made once adequate clinical trials are 
available and the choice of formulation is clear.
12.4: Medicines used in heart failure
Spironolactone (new indication) – Adults
An application was submitted by Evan Blank, Claire Hutchinson, Alexander 
Peters and Rajesh Vedanthan, Mount Sinai School of Medicine, New York, NY, 
USA, Mark Huffman, Amisha Patel, Northwestern Feinberg School of Medicine, 
Chicago, IL, USA and Sandeep Kishore, Weill Cornell Medical College, New 
York, NY, USA, for aldosterone antagonists to be added as a therapeutic class 
(with spironolactone as the representative) to Section 12.4 of the EML.
Expert reviews were provided by Dr Kuruvilla Prasad Mathews and 
Dr Suzanne Hill. Comments were received from Dr Shanthi Mendis, Director, 
Management of Noncommunicable Diseases, WHO, Dr Valentin Fuster, 
Director, Sinai Heart, New York, Dr Prabhakaran, Public Health Foundation of 
India and Dr Myriam Henkens, International Medical Coordinator, Médecins 
Sans Frontières.
Spironolactone has been in the EML since 1983 as a potassium-sparing 
diuretic.
Three clinical trials were presented as evidence for efficacy in the 
application. The first was the Randomized Aldactone Evaluation Study (RALES, 
1999), which demonstrated a significant benefit with the addition of spironolactone 
to the standard therapy of an angiotensin-converting-enzyme (ACE) inhibitor 
and a loop diuretic in patients with severe heart failure. This randomized, double-
blinded, placebo-controlled trial assessed the efficacy of spironolactone (25 mg) 
in 1663 patients in 195 centres in 15 countries. Patients included in the trial had 
New York Heart Association (NYHA) class IV heart failure within the previous 
six months, NYHA class III or IV heart failure at the time of enrolment, and a left 
ventricular ejection fraction (LVEF) of no more than 35%.
The trial was stopped early after a mean follow-up period of 24 months 
due to an interim analysis showing that spironolactone was superior to placebo. 
The trial found a 30% reduction in overall mortality (hazard ratio, HR = 0.70, 
95% CI: 0.60–0.82), a 35% reduction in hospitalization (HR = 0.65, 95% 
CI:  0.54–0.77), and significant improvement in heart failure symptoms based 
on the NYHA functional class (P < 0.001) in the treatment group. The number 
needed to treat (NNT) to prevent one death over 24 months was 8.8 (178).
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The second clinical trial was the Eplerenone Post-Acute Myocardial 
Infarction Heart Failure Efficacy and Survival Study (EPHESUS), which evaluated 
the effectiveness of eplerenone (25 mg initial dose, titrated to a maximum of 
50 mg) in patients with post-myocardial infarction left ventricular systolic 
dysfunction (left ventricular ejection fraction (LVEF) ≤  40%) in a randomized, 
double-blinded, placebo-controlled trial. Eplerenone reduced overall mortality 
by 15% (HR = 0.85, 95% CI: 0.75–0.96) and cardiovascular disease-specific 
mortality by 17% (HR = 0.83, 95% CI: 0.72–0.94) when compared with placebo 
over a mean follow-up of 16 months (179).
The third trial was the Eplerenone in Mild Patients Hospitalization and 
Survival Study in Heart Failure (EMPHASIS-HF), a randomized, double-blinded, 
placebo-controlled study that also showed that eplerenone was effective in 
patients with left ventricular systolic dysfunction (EF < 35%) and mild symptoms 
(NYHA class II). The trial was also stopped early because of a significant decrease 
in deaths from cardiovascular causes (HR = 0.76, 95% CI: 0.61–0.94) and a 
decrease in hospitalization from heart failure (HR = 0.58, 95% CI: 0.47–0.70) in 
the eplerenone treatment group (180).
Spironolactone is associated with an increased risk of gynaecomastia, 
which may not be as frequent with eplerenone. However, both are associated with 
an increased risk of hyperkalaemia, which may be worse with eplerenone. Both 
products would require potassium concentrations to be monitored to ensure 
safe use.
The most recent systematic review concluded that eplerenone was similar 
to older, less expensive aldosterone antagonists, but hyperkalaemia may be more 
frequent with epleronone whereas gynaecomastia was more frequent with the 
older aldosterone antagonists (181). Other systematic reviews have confirmed 
the decrease in mortality with aldosterone antagonists (182).
There are no direct comparative studies of spironolactone and eplerenone.
Spironolactone is widely available and inexpensive. Eplerenone is 
substantially more expensive. Several cost–effectiveness studies from high-income 
countries show that spironolactone, compared with placebo as an add‐on therapy 
in heart failure patients already treated with ACE‐inhibitors and beta‐blockers, 
is cost effective under most assumptions.
The Heart Failure Society of America Guidelines Committee 
recommends: “Until such time as the effectiveness of these two drugs 
(spironolactone and epleronone) in several different patient groups is compared 
in a well-designed clinical trial, it seems most reasonable for the clinical use of 
these agents to be consistent with their use in clinical trials. If cost or insurance 
reimbursement is an issue, as it will be for many, a reasonable choice is to 
substitute spironolactone” (183).
The Expert Committee recommended the expansion of the indication 
for spironolactone for heart failure (by listing in Section 12.4, as part of the 
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core list), without a square box because of the current price differential between 
spironolactone and eplerenone as the other main aldosterone antagonist and 
possible significant differences in safety profile with respect to hyperkalaemia. 
No change was made to the EMLc since additional data would be needed to 
justify inclusion for this patient group, in which the etiology of heart failure is 
very different.
Section 13: Dermatological medicines (topical)
13.4: Medicines affecting skin differentiation and proliferation
Benzoyl peroxide (review) – Adults and Children
The 18th meeting of the Expert Committee requested a review of whether 
adults and children with mild-to-moderate acne should be treated with benzoyl 
peroxide compared with other topical preparations. The review was prepared by 
the International League of Dermatology Societies (ILDS).
Expert reviews were prepared by Dr Youping Li and Dr Alar Irs.
Acne is one of the common skin conditions mostly affecting the younger 
age group. Benzoyl peroxide has been in used in different formulations for over 
50 years and is available worldwide. It remains the first-line choice of treatment 
for mild-to-moderate acne; it is effective and inexpensive and is mentioned in 
a large number of national treatment guidelines, such as those of the United 
Kingdom and the USA (184–186).
Systematic reviews have evaluated the efficacy and safety of benzoyl 
peroxide across a range of age groups and presentations and two reviews in 
2001 (187) and 2004 (188) rated the treatment effect of benzoyl peroxide as 
favourable compared to placebo. Side-effects were erythema, peeling and 
occasionally burning. A recent systematic review using GRADE methodology 
on the management of acne compared benzoyl peroxide to other contemporary 
treatments and concluded that it should be considered as the first-line choice for 
mild acne (189). The adverse events mentioned, which were seldom severe, may 
be linked to the higher concentrations available, including the 10% formulation.
The Expert Committee recommended that benzoyl peroxide should be 
retained on the EML for both adults and children.
Coal tar (review) – Adults
At its 18th meeting, the Expert Committee requested a review of whether adults 
and children with psoriasis should be treated with coal tar solution rather than 
other topical preparations for psoriasis. The review was prepared by ILDS.
Expert reviews were prepared by Dr Youping Li and Dr Alar Irs.
Although coal tar preparations have been used for over 100 years in 
psoriasis, their mechanism of action is still unclear. Preparations are available 
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for the treatment of psoriasis in a variety of different formulations for lesions on 
the trunk and limbs, and as shampoos for scalp lesions.
A Cochrane systematic review of topical treatments for psoriasis 
included 131 randomized controlled trials some of which investigated coal  tar 
versus placebo or alternative medicines, notably vitamin D analogues and 
topical corticosteroids (190). Both vitamin D analogues (e.g. calcipotriol) and 
corticosteroids performed better than placebo but no better than each other. 
Combined vitamin D and corticosteroids performed significantly better than 
either treatment alone.
Concerns have been expressed about the potential carcinogenicity of 
coal  tar preparations. Reviews of the literature have, however, been unable to 
uncover evidence of increased risk of cancer in those treated with medical 
formulations of coal tar (191, 192).
One study has estimated the relative costs of coal tar and calcipotriol 
using contemporary measures of psoriasis area and severity. The coal tar 
treatment produced greater improvement in severity and at less cost (US$ 0.92 
per 1% improvement in scoring) than calcipotriol treatment (US$ 35.42 per 
1% improvement) after 12 weeks of treatment. After treatment and six weeks 
of follow-up (at week 18), the relative costs were US$ 1.01 in the coal tar group 
and US$ 58.11 in the calcipotriol group because the coal tar group maintained 
the improvement while the calcipotriol group significantly worsened (193). 
Although there are other medications available, coal tar is an effective and safe 
treatment for psoriasis, is affordable and is widely available.
The Expert Committee therefore recommended the retention of coal tar 
in the EML.
Dithranol (deletion) – Adults
The 18th meeting of the Expert Committee requested a review of dithranol for 
possible deletion from the EML. The review was submitted by ILDS.
Expert reviews were prepared by Dr Youping Li and Dr Alar Irs.
Dithranol has been used topically for many years for the treatment of 
psoriasis. It is available in various formulations such as creams, ointments or 
pastes in strengths of 0.1–2%. However, clinical use of dithranol has decreased 
in most parts of the world and it is seldom available in resource-poor areas. The 
main reason for the decreased use has been the known risk of severe irritant 
reactions when the preparation is applied to psoriatic plaques and, in particular, 
on extra-lesional skin (190).
There is little evidence of the efficacy of dithranol as this is an old 
medication that has not been subject to substantive clinical trials. However, data 
collected in a Cochrane review of the treatment of plaque-type psoriasis with 
topical medications found that it was more effective than placebo (190). Burning 
and itching are very common adverse events that occur on skin lesions and 
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normal skin in contact with dithranol. In a systematic review of adverse events 
with topical treatments for psoriasis, dithranol performed worst with 72% of 
patients having adverse events (194).
The Expert Committee decided to delete dithranol from the EML due to 
concerns about the balance between benefits and risks and the low utilization of 
this medicine (190, 194). There are other suitable alternatives for this indication 
in the EML.
Section 17: Gastrointestinal medicines
17.1: Antiulcer medicines
Antiulcer medicines (review) – Adults
At its 18th meeting, the Expert Committee requested a review for the possible 
deletion of histamine-2 receptor (H2) antagonists (currently exemplified by 
ranitidine) and another review to consider whether adults and children with 
gastro-oesophageal reflux or non-ulcer dyspepsia should be treated with H2 
antagonists compared with proton pump inhibitors. The need for parenteral 
preparation of omeprazole was also discussed in the review.
The review was prepared for the WHO Secretariat by Dr Grigorios  I. 
Leontiadis, McMaster University, Hamilton, Ontario, Canada and Joint 
Coordinating Editor, Upper Gastrointestinal and Pancreatic Diseases Group, 
The Cochrane Collaboration, and Dr Yuhong Yuan, McMaster University, 
Hamilton, Ontario, Canada.
Expert reviews were prepared by Dr Nicola Magrini and Dr Gilles Sama 
Kwende. Comments were received from Dr Myriam Henkens, International 
Medical Coordinator, Médecins Sans Frontières.
H2 receptor antagonists (H2 RAs) versus proton pump inhibitors (PPIs) for 
gastro‑oesophageal reflux disease (GERD)
According to the most recent American Gastroenterological Association Medical 
Position Statement on the management of GERD, “for the treatment of patients 
with esophageal GERD syndromes (healing esophagitis and symptomatic relief) … 
PPIs are more effective than H2RAs, which are more effective than placebo” (195). 
All other recent consensus guidelines agree with this recommendation (196, 197).
However, H2RAs have several advantages such as faster onset and longer 
duration of action, no need to time doses before meals, less harm in pregnancy 
and lower cost. Furthermore, H2RAs can be used in patients who cannot tolerate 
PPIs because of side-effects.
H2 RAS versus PPIs for non‑ulcer dyspepsia
There is limited evidence on the efficacy of H2RAs and PPIs in patients with 
non-ulcer dyspepsia (NUD). A Cochrane systematic review and meta-analysis 
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of randomized controlled trials on pharmacological interventions for NUD 
concluded that both H2RAs and PPIs were more effective than placebo in 
symptoms of oesophagitis, and there was no evidence of a difference between 
H2RAs and PPIs (198, 199).
PPI parenteral preparation
Most patients who require PPI treatment can be treated with oral PPIs. However, 
there are some situations were intravenous PPI treatment is either preferable or 
is the only possible route of administration.
The most important and common indication for intravenous PPIs 
is peptic ulcer bleeding. Intravenous omeprazole has been approved for this 
indication in Europe, and the application is pending with the United States 
FDA. This is based mainly on the results of a large high-quality multicentre 
randomized controlled trial that was published in 2009 (200), but older Cochrane 
systematic reviews and meta-analyses of randomized controlled trials had found 
that there is strong evidence supporting the efficacy of high-dose intravenous 
PPI treatment in such patients (201).
Comparative costs
H2RAs cost less than PPIs and this is particularly important for low- and middle-
income countries.
The Expert Committee recommended that no changes to the EML should 
be made at this time. A more extensive application would be needed to justify 
the addition of a parenteral PPI, including its place in the management of acute 
gastrointestinal bleeds where immediate access to endoscopy is not possible.
Section 18: Hormones, other endocrine 
medicines and contraceptives
18.5: Insulins and other medicines used for diabetes
Glibenclamide (review) – Adults
At its 18th meeting, the Expert Committee requested a review on the safety 
of sulfonylureas in elderly patients to determine whether updates to the EML 
were needed.
The review was prepared by Mr Harinder Singh Chahal, Doctor of 
Pharmacy Candidate at the University of California – San Francisco, San Francisco, 
CA, USA.
Expert reviews were prepared by Mr Andrew Gray and Dr Kuruvilla 
Prasad Mathews. Comments were received from Dr Shanthi Mendis, Director, 
Management of Noncommunicable Diseases, WHO, and Dr Myriam Henkens, 
International Medical Coordinator, Médecins Sans Frontières.
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The estimated worldwide prevalence of diabetes in the elderly population 
(60 years and above) is 18.6% or 134.6 million people (202). In 2013 the Expert 
Committee noted that the EML listed only glibenclamide from the sulfonylurea 
category. Elderly patients are a significant proportion of type II diabetics and the 
safety of sulfonylureas in this group is therefore important.
The review evaluated the comparative safety and efficacy of four second-
generation sulfonylureas for the treatment of type 2 non-insulin dependent 
diabetes in elderly patients. The medications reviewed were glibenclamide (also 
called glyburide), gliclazide, glimepiride and glipizide. The review also analysed 
the cost of the four medications as well as their availability on the national 
essential medicines lists of 40 low- and middle-income countries.
A 2007 meta-analysis of 21 studies showed that, on the basis of HbA1c 
results, glibenclamide compared with other sulfonylureas – including gliclazide, 
glimepiride and glipizide – did not have an increased efficacy in the treatment 
of diabetes (203).
The same meta-analysis showed that there was an increased risk of 
hypoglycaemia of 52% with glibenclamide when compared with other insulin-
secreting anti-diabetes medicines and an 83% higher risk compared with other 
sulfonylureas (203).
A retrospective cohort study of more than 13 000 patients concluded that 
glibenclamide had the highest rate of hypoglycaemia at 16.9 per 1000 person-
years, compared with all other sulfonylureas (204). The authors also concluded 
that the physiological changes associated with increasing age, such as declining 
renal and hepatic function, as well as polypharmacy and concurrent illnesses, 
additionally predispose elderly patients to hypoglycaemia; this predisposition is 
further compounded by the use of glibenclamide. Another retrospective, cohort 
study of more than 33 000 patients in the United Kingdom showed that the risk 
of hypoglycaemia was higher with glibenclamide when compared with other 
sulfonylureas (205). The authors also concluded that patients older than 65 years 
were at higher risk of hypoglycaemia compared with adults less than 65 years of 
age with a relative risk of 1.27 (95% CI: 1.06–1.51).
In the analysis of the national essential medicines lists, the most widely 
available second-generation sulfonylurea was glibenclamide, with an overall 
listing on 39 of the 40 national essential medicines lists (97.5%), followed by 
gliclazide and glipizide which were available on 50% and 27.5% of the national 
lists, respectively.
The Expert Committee discussed the fact that all four sulfonylureas 
are available as generics, but there is considerable variation in price between 
countries and therefore it is not possible to make a clear decision on the basis 
of cost. However, glibenclamide appeared to be the cheapest in most countries.
The Expert Committee decided that glibenclamide should be replaced 
in the core list with gliclazide (30 mg, 60 mg, 80 mg), with a square box symbol 
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as the example of a second-generation sulfonylurea, and that a note should 
be added to the effect that glibenclamide should not be used in patients aged 
60 years and older.
Oral hypoglycaemics (review) – Adults
At its 18th meeting, the Expert Committee requested a review on oral 
hypoglycaemics. The Committee asked: “Should adults with type 2 diabetes 
be treated with (1) alpha-glucosidase inhibitors, such as acarbose; (2) amylin 
analogues, such as pramlintide; and (3) dipeptidyl peptidase-4 inhibitors such 
as sitagliptin and meglitinides such as repaglinide and mitiglinide compared 
with other classes of oral hypoglycaemic medicines (metformin; sulfonylureas 
such as glibenclamide, glimepiride, and gliclazide; thiazolidinediones such as 
pioglitazone and rosiglitazone)?”
The review was prepared by Mr Harinder Singh Chahal, Doctor of 
Pharmacy Candidate at the University of California – San Francisco, San Francisco, 
CA, USA. The review excluded pramlintide as it was a peptide for injection.
Expert reviews were provided by Mr Andrew Gray and Dr Kuruvilla 
Prasad Mathew. Comments were received from Dr Shanthi Mendis, Director, 
Management of Noncommunicable Diseases, WHO.
The review compared the four groups of oral hypoglycaemics: (1) dipeptidyl 
peptidase-4 (DPP-4) inhibitors, (2) thiazolidinediones, (3) alpha-glucosidase 
inhibitors, such as acarbose, and (4) meglitinides, against metformin (biguanide) 
and sulfonylureas. The base was a systematic review in 2010 (206), which was 
combined with other systematic reviews of oral hypoglycaemics (207–213).
A detailed comparison using the GRADE methodology was done of 
metformin with each of the four groups, and also of sulfonylureas and each 
of the four groups. The tables are available at: http://www.who.int/selection_
medicines/committees/expert/19/applications/Sulfonylurea_18_5_A_R.pdf.
It was not possible to carry out an evaluation for each of the four 
groups versus metformin and sulfonylureas for all clinically relevant outcomes 
as there were insufficient studies. For instance, while there were studies 
reporting all-cause mortality (a critical outcome) for metformin versus DPP-4, 
thiazolidinediones and meglitinides, there was insufficient data to compare 
metformin versus acarbose.
For the effect on HbA1c, none of the medicines in the four groups were 
better than either metformin or sulfonylurea; the strength of the evidence 
ranged from low to high. For weight loss, metformin was better than the DPP-4 
inhibitors and thiazolidinediones but there was no difference with alpha-
glucosidase inhibitors and meglitinides. Sulfonylureas had a better effect on 
weight loss than the thiazolidinediones did but there was no difference between 
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sulfonylureas and the other three groups (DPP-4 inhibitors, alpha-glucosidase 
inhibitors and meglitinides).
As for the effect on high-density glycoprotein, triglycerides, hypoglycaemia 
and gastrointestinal adverse events, again none of the medicines in the four groups 
had a consistently favourable effect, or even a trend, compared with metformin 
and sulfonylureas.
For comparison of cost, all medicines in the four groups were more 
expensive than metformin and sulphonylureas.
None of the medicines in the four groups were shown to be better than 
metformin and sulphonylureas and at the most were equivalent only in some 
aspects. There were safety concerns with some medicines in the groups, and 
none of them offered any safety advantages over biguanides and sulphonylureas. 
Rosiglitazone had been withdrawn from European markets and pioglitazone was 
also withdrawn in France and Germany. The most recent concern about safety 
was on a potential increased risk of pancreatitis and pancreatic duct metaplasia 
in patients with type II diabetes treated with glucagon-like peptide (GLP)-1 
receptor agonists and DPP-4 inhibitors (214).
The convenience sample of the national essential medicines lists of 15 
low- and middle-income countries showed that only five countries had products 
from this group (rosiglitazone, pioglitazone, acarbose and repaglinide).
The Expert Committee decided that there was insufficient evidence to 
show that any of the medicines in the four groups (DPP-4 inhibitors, alpha-
glucosidase inhibitors, meglitinides, or thiazolidinediones) offered any efficacy 
or safety advantages over the existing medicines included in the EML. WHO 
guidelines also do not recommend any medicines from these four groups.
The Expert Committee recommended that no medicines from the four 
groups should be added to the EML.
Section 21: Ophthalmological preparations
Azithromycin (addition) – Adults and Children
An application was submitted by the International Council of Ophthalmology for 
the addition of topical azithromycin 1.5% eye drops for the treatment of chronic 
keratoconjunctivitis caused by recurrent infection with Chlamydia trachomatis.
Expert reviews were provided by Dr Gitanjali Batmanabane and Dr Abdol 
Majid Cheraghali.
Trachoma, a chronic keratoconjunctivitis caused by recurrent infection 
from C. trachomatis, is the leading cause of infectious blindness worldwide (215). 
The current WHO guidelines recommend a single oral dose of azithromycin as 
the treatment. It was noted that oral azithromycin is not included in Section 21.1 
of the EML.
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Two studies were submitted in support of the application.
A randomized, controlled, double-masked, double-dummy, non-
inferiority study including 670 children from Guinea and Pakistan was 
conducted. Three groups received one of three treatments: azithromycin 1.5% 
eye drops twice daily for two days, azithromycin 1.5% eye drops twice daily for 
three days, or azithromycin single 20 mg/kg oral dose.
The cure rate at day 60 in the per protocol analysis was 93.0%, 96.3% 
and 96.6% in the two-day group, three-day group, and oral treatment group, 
respectively. The azithromycin 1.5% eye drops groups were non-inferior to oral 
azithromycin. There were no significant differences between the groups with 
respect to re-emergence of trachoma (P > 0.545).
All three treatments markedly reduced the trachomatous grading on 
days 30 and 60. It was noted that there were no significant differences between 
the treatment groups with respect to trachomatous grading (P > 0.170) (216).
The second study was a mass treatment programme with no comparator. 
In February 2008, a programme was undertaken to treat the entire population of 
the Kolofata Health District in Cameroon (115 274 residents) with azithromycin 
1.5% eye drops twice daily for three days. A total of 51 659 adults and 59 681 
children over 15 years of age were treated. It was reported that: “One year after 
two rounds of topical treatment, prevalence dropped to 3.1% (95% CI 2.0–4.9) 
(P < 0.0001), a decrease of 90%. The prevalence of trachomatous inflammation 
decreased significantly (P = 0.0001) to 3.1% one year after the second round of 
treatment. The prevalence of intense trachomatous inflammation disappeared 
after two annual treatments (0% after second treatment (P = 0.0005))” (217, 218).
The first trial showed similar efficacy of azithromycin eye drops 
compared with single-dose oral treatment. In the second study, the cure rates in 
the mass treatment were similar to what would have been achieved with single-
dose oral treatment.
The WHO Prevention of Blindness and Deafness unit supported the 
application and mentioned future activities – including revision of WHO’s 
trachoma control manual – that would support azithromycin eye drops.
In summary, azithromycin eye drops produced similar results to the 
single-dose oral treatment but required three days of topical application. There 
appeared to be better safety with azithromycin eye drops. It was noted that 
donation programmes with suitable presentations of the ophthalmic solution 
were planned. The oral preparation is not recommended for pregnant women 
or children under 1 year of age; for these patient groups the ophthalmic solution 
offers an important option. The use of oral azithromycin and its limitations are 
given in the WHO guidelines (219). The only alternative for such patients is 
topical tetracycline, which requires a protracted course (six weeks or six months, 
depending on the dose regimen used).
70
W
H
O
 T
ec
hn
ic
al
 R
ep
or
t S
er
ie
s, 
N
o.
 9
85
, 2
01
4
The Selection and Use of Essential Medicines   Report of the 19th WHO Expert Committee
The Expert Committee recognized the need for topical azithromycin 
in particular patient groups, and acknowledged the superiority of this option 
compared with topical tetracycline. The Committee therefore recommended 
the addition of azithromycin 1.5% ophthalmic solution to Section 21.1 of both 
the EML and EMLc.
Bevacizumab (addition) – Adults
An application was submitted by the International Council of Ophthalmology 
for the inclusion of bevacizumab for the treatment of proliferative (neovascular) 
eye diseases.
Expert reviews were provided by Dr Gitanjali Batmanabane, Dr Abdol 
Majid Cheraghali and Dr Nicola Magrini. The application was supported by the 
Prevention of Blindness and Deafness unit, WHO.
Age-related macular degeneration (AMD) is the leading cause of 
blindness in persons over 50 years of age in developed countries. It is estimated 
that by 2020 as many as 7.5 million people worldwide over the age of 65 years 
may have vision loss attributable to this disease (220). Between 10% and 20% of 
patients with AMD are expected to have the neovascular form of AMD which 
is responsible for 90% of all cases of severe vision loss. The Expert Committee 
consequently accepted that there is a clear public health need for the treatment 
of neovascular AMD.
The application for bevacizumab was based on a large, randomized, 
controlled trial – the Comparison of AMD Treatments Trials (CATT) funded 
by the National Institutes of Health, USA – which compared bevacizumab 
with ranibizumab (221, 222). The trial randomized 1200 patients to one of 
four treatments: either bevacizumab or ranibizumab and either monthly or “as 
needed” treatment regimens. For the primary outcome of change in visual acuity 
at one and two years of follow-up, bevacizumab and ranibizumab were equivalent. 
Bevacizumab administered monthly was equivalent to ranibizumab administered 
monthly, with 8.0 and 8.5 letters gained on the visual acuity scores, respectively. 
Bevacizumab administered as needed was equivalent to ranibizumab as needed, 
with 5.9 and 6.8 letters gained, respectively.
The analysis of adverse outcomes showed that rates of death, myocardial 
infarction and stroke were similar for patients receiving either bevacizumab or 
ranibizumab. The Expert Committee also considered the hospitalization events 
with bevacizumab compared with ranibizumab (24.1% versus 19.0%; RR: 1.29, 
95% CI: 1.01–1.66), and noted that the excess events were broadly distributed in 
disease categories that had not been identified in previous studies. The Committee 
accepted the explanation given in the study that the differences in hospitalization 
rates were probably due to baseline imbalances. The Committee also noted that 
in the trial the higher doses of bevacizumab (monthly regimen) were associated 
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with a lower hospitalization rate than the lower dose (“as needed” regimen), 
which might be explained by chance or by baseline imbalances in the groups for 
comorbidities or other patient characteristics.
The Expert Committee also considered the results from a second trial 
that was not mentioned in the application. This British study (IVAN)6 with 
300 patients per arm was funded by the National Institute for Health Research 
(NIHR) Health Technology Assessment programme (223). The results of the 
trial showed that the two treatments had similar efficacy and safety, including 
comparisons of monthly versus “as needed” treatment regimens. In the IVAN 
trial systemic arteriothrombotic events and heart failure were less frequent 
for  bevacizumab than for ranibizumab (0.7% versus 2.9%, OR: 0.23, 95% 
CI: 0.05–1.07, P = 0.03).
The Expert Committee considered the observational studies evaluating 
the safety of bevacizumab, or comparing bevacizumab and ranibizumab. These 
data were mostly from record-linkage studies or large pharmacoepidemiology 
databases. The European Medicines Agency report of July 2012 which reviewed 
all these safety studies of bevacizumab concluded that: “… the CHMP agreed 
that detailed safety information provided from the CATT and IVAN studies is 
reassuring and no evidence can be provided that bevacizumab is systemically 
more unsafe than ranibizumab and vice-versa. The CATT study was not powered 
to detect rare adverse events or to show differences in the number of events with 
a relatively high background incidence in elderly people with AMD” (224).
The Expert Committee noted that currently available formulations 
of bevacizumab are not specifically formulated for intravitreal injections. 
Bevacizumab comes in a sterile solution of 25 mg/ml (i.e. 1.25 mg per 0.05 ml) so 
it does not need to be diluted, reconstituted or altered in any way. The Committee 
considered that reports of adverse events (e.g. endophthalmitis) resulting from 
reformulation of the vial size currently available for use for multiple injections had 
been traced to inadequate sterility in the compounding process. The Committee 
noted, therefore, that safe use of bevacizumab as currently formulated requires 
that use may need to be restricted to a single patient per vial, notwithstanding 
the wastage. Any alternative approach to using a single vial for multiple patients 
would have to comply with appropriate safe and sterile injection practices, 
including any requirements for storage of the product, to ensure that there would 
be no possibility of contamination. However, even allowing for wastage, on the 
basis of anecdotal cost comparisons the cost of using currently available vials of 
bevacizumab for intravitreal injection may be less than one-twentieth of the cost 
of using alternative products such as ranibizumab.
6  A randomized controlled trial of alternative treatments to inhibit vascular endothelial growth factor 
(VEGF) in age-related choroidal neovascularization.
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The Expert Committee concluded that, on the basis of the head-to-head 
comparative trials and the observational safety data, intraocular bevacizumab is 
effective and safe for the treatment of neovascular AMD.
While noting the absence of stringent regulatory authority approval 
for the use of bevacizumab for the indication of AMD, the Expert Committee 
recommended that it be included in the EML on grounds of public health 
need, demonstrated safety and effectiveness, and favourable cost–effectiveness. 
The Committee again drew attention to the need for safe preparation and 
administration of intravitreal bevacizumab. The Committee recommended the 
listing of bevacizumab 25 mg/ml injection (100-mg vial) in the complementary 
list in a new Section 21.6 on anti-vascular endothelial growth factor (VEGF) 
preparations.
Ketorolac (addition) – Adults
An application was submitted by the International Council of Ophthalmology 
for the addition of ketorolac eye drops to the EML.
Expert reviews were provided by Dr Gitanjali Batmanabane and Dr Abdol 
Majid Cheraghali. The WHO Prevention of Blindness and Deafness unit 
supported the application. The unit drew attention to the increased risk of post-
surgical inflammatory reactions associated with modern surgical techniques, 
such as in high-throughput cataract procedures.
The claim of public health relevance for this proposed listing was based 
on multiple uses of ketorolac in seasonal allergic rhinoconjunctivitis, prevention 
of surgically-induced miosis, post operative inflammation after cataract surgery, 
postoperative inflammation after glaucoma surgery, postoperative inflammation 
after vitreoretinal surgery and for relieving discomfort and pain after ocular 
surgery and trauma.
There are no WHO guidelines for these conditions and it was unclear 
from the application whether NSAIM eye drops are recommended as routine 
after surgery for the conditions mentioned above. Ketorolac was found to be 
effective in moderate-to-severe ocular inflammation after cataract surgery but 
the comparison was with the vehicle solution rather than with another medicine 
(225). A Cochrane review states that the role of NSAIM in the treatment of 
cystoid macular oedema following cataract surgery is unclear (226).
In allergic conjunctivitis, a double-blind, placebo-controlled study of 
148 patients evaluated treatment given four times daily over a seven–day period 
and showed that ketorolac was significantly better than placebo with regard to 
ocular itching, conjunctival inflammation, conjunctival injection, swollen eyes, 
foreign-body sensation and ocular discharge (227). A second study of 93 subjects 
with a similar design but lacking slit-lamp observations reported that ketorolac 
was significantly better than placebo in reducing conjunctival inflammation and 
photophobia after seven days of treatment (228). A significant placebo effect 
Applications for the 18th Model List and the 4th EMLc
73
(as seen in improvement from baseline in the control group) was noted in both 
trials. Ketorolac appears to be used widely but the application did not contain 
any systematic reviews of efficacy and safety or any comparative trials with other 
NSAIM eye preparations. Seasonal allergic conjunctivitis was also not considered 
by the Expert Committee to be of sufficient public health relevance to require 
that ketorolac be added to the EML.
Given that the evidence for effectiveness was not consistent, and noting 
that allergic conjunctivitis was not a major public health problem, the Expert 
Committee recommended that ketorolac should not be added to the EML at this 
time. However, the Committee indicated that it would welcome resubmission of 
an application for an ophthalmic NSAIM with data showing effectiveness and 
safety, particularly in use in ocular surgery.
Ketotifen (addition) – Adults and Children
An application was submitted by the International Council of Ophthalmology 
for the addition of ketotifen eyedrops for seasonal allergic rhinoconjunctivitis 
and as a topical anti-inflammatory for the eye.
Expert reviews were provided by Dr Gitanjali Batmanabane and 
Dr Abdol Majid Cheraghali. The WHO Prevention of Blindness and Deafness 
unit supported this application “… or any other suitable non-steroidal anti-
inflammatory drug” and suggested that treatment with ketotifen may prevent the 
overuse of steroids and subsequent severe eye and systemic complications.
In the application, seasonal allergic conjunctivitis was quoted as being a 
common (20%), mild condition. However, this is based on estimates and there are 
no surveys to validate this figure (229). The application did not include estimates 
of the disability caused by this condition.
The current EML does not have a medicine for seasonal allergic 
conjunctivitis and there are no WHO guidelines for the treatment of this 
condition. There are no topical ocular antihistamines in the EML.
The application did not contain any systematic reviews of ketotifen 
efficacy in seasonal allergic conjunctivitis; the studies were mainly of conjunctival 
allergen challenge models, some of which compared ketotifen to placebo (230). 
A Cochrane review on “Topical antihistamines for treating perennial allergic 
conjunctivitis” is at the protocol stage (231).
The Expert Committee recommended that ketotifen should not be added 
to the EML in view of the lack of public health relevance and lack of evidence of 
efficacy of ketotifen in seasonal allergic conjunctivitis.
Latanoprost (addition) – Adults
An application was submitted by the International Council of Ophthalmology 
for the addition of latanoprost for the treatment of glaucoma.
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Expert reviews were provided by Dr Gitanjali Batmanabane and Dr Abdol 
Majid Cheraghali. Comments were received from the WHO Prevention of 
Blindness and Deafness unit.
Glaucoma is the second leading cause of blindness worldwide (232), and 
acetazolamide tablets and timolol and pilocarpine eye drops are included in the 
EML for glaucoma.
The application summarized the older clinical trials for once-daily 
latanoprost in open-angle glaucoma. These showed a sustained decrease of 
intraocular pressure in 84% of patients, lasting up to 24 months.
Bron & Emmerich concluded: “Timolol, the leading topical beta-
adrenergic antagonist, is often used as a first line therapy for the treatment 
of glaucoma. Dorzolamide, the first topical carbonic anhydrase inhibitor to 
become available on the market, is often prescribed as an add-on therapy. 
A review of studies comparing the efficacy of latanoprost to combined timolol 
and dorzolamide suggested that the intraocular pressure lowering effect of 
latanoprost is equivalent to that of concomitant timolol dorzolamide therapy. 
In addition, data suggests that adding latanoprost to timolol and dorzolamide 
leads to a further 16% reduction of intraocular pressure”(233).
A recent systematic review judged the prostaglandin agents to be superior 
to other monotherapies “We judged the strength of evidence from these 3 
most recent trials to be low. However, with the addition of the consistent high-
quality systematic reviews, the conclusion that topical glaucoma medications 
decrease intraocular pressure (IOP) is well supported, as is the conclusion 
that prostaglandin agents are superior to other monotherapies with regard to 
decreasing IOP”(234).
A meta-analysis that evaluated trials comparing latanoprost with timolol 
found latanoprost to be more effective than timolol. Additionally, latanoprost 
had the advantage of once-daily administration (235).
The main adverse effect is iris pigmentation which is seen in 12% of 
patients with light-coloured irises and which occurs with long-term use. It is 
seen in 18% of patients when used for two years. Other adverse effects are mild, 
are not very common and do not lead to stopping treatment.
The Expert Committee decided to recommend that latanoprost be added 
to the core list in the EML. Timolol is to be retained as there is evidence that 
timolol and latanoprost have additive effects.
Ofloxacin (addition) – Adults and Children
An application was submitted by the International Council of Ophthalmology 
for the addition of ofloxacin 0.3% for infectious keratitis in Section 21.1 which 
included only gentamicin 0.3%.
Applications for the 18th Model List and the 4th EMLc
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Expert reviews were provided by Dr Gitanjali Batmanabane and Dr Abdol 
Majid Cheraghali.
It has been estimated that up to 5% of all blinding conditions in 
developing countries are directly related to ocular trauma and the subsequent 
infection (236). This estimate is supported by population-based studies in 
several countries. In a blindness survey in Nepal, corneal trauma and ulceration 
were found to be the second leading cause of unilateral visual loss after cataract, 
accounting for 7.9% of all blind eyes. A study in south India found that the 
incidence of ulcerative keratitis was 11.3 cases per 10 000 persons, resulting in an 
estimate of 840 000 new ulcers annually in India alone.
The application provided data on one clinical trial in which ofloxacin 
0.3% was compared with fortified gentamicin (1.5%) plus cefuroxime (5%) in 
microbial keratitis, and which showed similar rates of cure. The authors stated 
that treatment with ofloxacin monotherapy was associated with less toxicity but 
did not provide data (237). Another trial was identified in the expert reviews in 
which ofloxacin was found to be more effective than gentamicin (238).
Ofloxacin eye drops have been approved for the treatment of bacterial 
keratitis by Australia, the United Kingdom and the US FDA.
In summary, ofloxacin eye drops have been shown to be as effective as 
other antibiotic eye drops and potentially to have less toxicity. The clinical trials 
cited in the application did not show ofloxacin to be clearly superior to any of the 
commonly used antibiotic eye drops. It has the advantage of being affordable and 
widely available. However, the other fluoroquinolones may be widely available 
and equally affordable in different settings.
The Expert Committee recommended that ofloxacin ophthalmic solution 
should be added to the EML and the EMLc with a square box symbol.
Section 22: Oxytocics and antioxytocics
22.1: Oxytocics
Misoprostol (deletion) for prevention of postpartum haemorrhage – Adults
An application was submitted by Professor Allyson Pollock, Dr Petra Sevcikova-
Brhlikova, Barts and The London School of Medicine and Dentistry, London, 
United Kingdom, for the deletion of the indication of misoprostol for the 
prevention of postpartum haemorrhage.
Expert reviews were provided by Dr Lisa Bero, Dr Alar Irs and Dr Hany 
Abdel-Aleem. Comments were received from the Concept Foundation, Bangkok 
and Geneva, Gynuity Health Projects, New York, NY, USA, and Professor 
Anthony Mbonye, Ministry of Health, Kampala, Uganda.
Misoprostol was considered by the Expert Committee at its 18th meeting 
and was added to the 17th EML for prevention of postpartum haemorrhage. 
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However, a note was added, stating: “For prevention of postpartum haemorrhage 
where oxytocin is not available or cannot be safely used”.
The application for deletion presented no new data and was based on a 
reinterpretation of the data previously presented to the Expert Committee. The 
Expert Committee considered that, in the absence of new evidence to support 
a change to its previous recommendation, the existing listing and note should 
stand, i.e. the retention of misoprostol in Section 22.1 with the note stating that it 
is for the prevention of postpartum haemorrhage where oxytocin is not available 
or cannot be safely used.
Misoprostol (new indication) – Adults
An application was submitted by Gynuity Health Projects, New York, NY, USA, 
for the inclusion of misoprostol for the treatment of postpartum haemorrhage 
attributable to uterine atony.
Expert reviews were provided by Dr Lisa Bero, Dr Alar Irs and Dr Hany 
Abdel-Aleem.
Comments were received from the International Federation of Gynecology 
and Obstetrics, the Bill & Melinda Gates Foundation and Dr Myriam Henkens, 
International Medical Coordinator, Médecins Sans Frontières.
The application requested that misoprostol be listed with an indication 
for the treatment of postpartum haemorrhage when oxytocin is unavailable. 
Specifically “Intravenous oxytocin should be used when available, but misoprostol 
could be an effective alternative in settings in which IV oxytocin is not feasible”.
Misoprostol for treatment of postpartum haemorrhage was considered 
at the 18th meeting of the Expert Committee (157). The data presented in the 
application to the 19th meeting of the Committee had already been considered 
at the 18th meeting and there were no new clinical trials. Since the 18th meeting, 
however, there had been a change in WHO treatment guidelines, with the use of 
misoprostol in the treatment of postpartum haemorrhage now recommended as 
follows (239):
 ■ Intravenous oxytocin alone is the recommended uterotonic drug for 
the treatment of PPH.
 ■ If intravenous oxytocin is unavailable, or if the bleeding does not 
respond to oxytocin, the use of intravenous ergometrine, oxytocin-
ergometrine fixed dose, or a prostaglandin drug (including 
sublingual misoprostol, 800 μg) is recommended.
The Expert Committee has previously recommended misoprostol for 
prevention of postpartum haemorrhage where oxytocin is not available or cannot 
Applications for the 18th Model List and the 4th EMLc
77
be safely used. It had, however, not recommended the use of misoprostol for the 
treatment of postpartum haemorrhage.
The Expert Committee noted that the evidence showed that, for 
important clinical outcomes such as overall blood loss, misoprostol was inferior 
to oxytcocin. The Committee also noted the concern that including misoprostol 
for treatment of postpartum haemorrhage might detract from efforts to ensure 
that the more effective and safer medicine – oxytocin – is available.
While recognizing the importance of effective management strategies for 
postpartum haemorrhage in resource-constrained settings, the Expert Committee 
decided not to add misoprostol to the EML for the treatment of postpartum 
haemorrhage, as the evidence relied on at the 18th meeting remained valid. 
The Committee also emphasized the need for active management of the third 
stage of labour, beyond pharmacological interventions. The Committee noted 
that the use of sublingual misoprostol, as described in the WHO guideline, was 
for last-resort use or “rescue” where all other alternatives were unavailable. This 
was by no means a preferred option, nor should it be a reason not to pursue 
improved availability of parenteral uterotonics. However, in settings where 
oxytocin was not available or could not be safely used, the existing listing 
of misoprostol for prevention of postpartum haemorrhage should ensure its 
availability for rescue purposes.
Section 24: Medicines for mental and behavioural disorders
24.1: Medicines used in psychotic disorders
Referring to Section 24 of the EML and EMLc, the Expert Committee at its 
18th meeting in 2011 noted “… the potential importance of these medicines in 
children for a variety of disorders” and requested a review of the entire section.
The following applications were received:
 ■ a proposal for the deletion of haloperidol and chlorpromazine from 
the EMLc;
 ■ a request for inclusion of clozapine as a complementary medicine 
for treatment-resistant schizophrenia in adults;
 ■ two applications for inclusion of the second-generation 
antipsychotic risperidone (one proposing inclusion in the core EML 
only and the other proposing inclusion of tablets in the core list and 
other formulations in the complementary list in both the EML and 
the EMLc);
 ■ a proposal to modify the minimum age for the use of fluoxetine as a 
complementary medication in childhood depression.
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Clozapine (addition as complementary medicine) – Adults
An application to include clozapine as a complementary medicine for treatment-
resistant schizophrenia in adults was submitted by the Department of Mental 
Health and Substance Abuse, WHO.
Expert reviews were prepared by Dr Kuruvilla Prasad Mathews and 
Mr Andrew Gray.
The 17th EML includes haloperidol and chlorpromazine in Section 24.1 
(Medicines used in psychotic disorders). In 2009 the evidence review and 
the consequent recommendations of the guideline development group for 
WHO’s Mental Health Gap Action Programme Intervention Guide identified 
some medicines, in addition to psychosocial interventions, for the treatment 
of psychotic disorders. The recommendations identified first-generation 
antipsychotics (broadly equivalent to typical antipsychotics) haloperidol or 
chlorpromazine as a first choice, and second-generation antipsychotics (broadly 
equivalent to the group of atypical antipsychotics) as their alternatives if 
availability and cost are not constraints (66).
The same recommendations reserved clozapine for individuals with 
psychosis who do not respond to other antipsychotics provided that laboratory 
facilities are available for regular monitoring of white blood cells.
In the pivotal trial comparing clozapine to chlorpromazine published in 
1988, 30% of treatment-resistant patients responded to clozapine as compared 
with 4% to chlorpromazine (240). Later clinical trials have shown a response rate 
of 30–50% (241).
A 2010 guideline from the United Kingdom’s National Institute for 
Health and Care Excellence suggests that clozapine be offered “to people with 
schizophrenia whose illness has not responded adequately to treatment despite 
the sequential use of adequate doses of at least two different antipsychotic 
drugs …” (242).
Randomized clinical trials involving a large number of patients have 
been done with second-generation antipsychotics and two major long-term 
studies have been conducted by the United States National Institute of Mental 
Health (243, 244). These studies have shown a broadly similar response rate but 
differences in adverse effects (243, 244). Clozapine has been shown to be better 
than other second-generation antipsychotics in patients with an inadequate 
response to other antipsychotics (245).
However, although uncommon, agranulocytosis associated with 
clozapine treatment is a potentially fatal adverse event. Thus the use of clozapine is 
restricted to refractory patients principally because of the risk of agranulocytosis 
and the associated need for white cell monitoring.
The application requested the addition of clozapine for the management of 
cases refractory to other antipsychotics. The Expert Committee therefore decided 
to recommend addition of clozapine to the complementary list of the EML.
Applications for the 18th Model List and the 4th EMLc
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24.2: Medicines used in mood disorders
24.2.1: Medicines used in depressive disorders
Fluoxetine (change to age restriction/deletion from EMLc) – Adults and Children
An application was submitted by the Mental Health: Evidence and Research 
team, WHO, to update the fluoxetine age restriction from > 8 years to > 12 years.
Expert reviews were provided by Dr Nicola Magrini and Dr Gitanjali 
Batmanabane. Comments were received from Dr Myriam Henkens, International 
Medical Coordinator, Médecins Sans Frontières.
Depression appears to be rare in children younger than 6 years; the 
prevalence from 6 years to adolescence is less than that in adolescents. In 
a meta-analysis of 26 studies including 60 000 observations on children, 
the overall prevalence estimate for children under 13 years of age was 2.8% 
(standard  error, SE = 0.5%), and for those aged 13–18 years it was 5.6% 
(SE = 0.3%) which is close to adult figures (246).
WHO’s Mental Health Gap Action Programme Intervention Guide was 
published in 2010 based on WHO guidelines, which in turn were based on a 
series of evidence reviews conducted in 2009. The guideline development group 
for the intervention guide made the following strong recommendation:
“Antidepressants [tricyclic antidepressants (TCA), selective serotonin 
reuptake inhibitors (SSRI)] should not be used for the treatment of 
children 6–12 years of age with depressive episode/disorder in non-
specialist settings.”
For the above reasons, the guideline development group made a strong 
recommendation to set the age limit of 12 years, as mentioned above (66, 67).
In 2007 the Subcommittee of the Expert Committee had noted the 
discrepancies in the minimum age for fluoxetine approved by several regulatory 
authorities and endorsed the inclusion of fluoxetine in EMLc with an age 
restriction of 8 years (247).
At its 19th meeting in 2013 the Expert Committee decided to retain the 
minimum age for fluoxetine at 8 years as the evidence submitted to raise the 
age to 12 years was not considered sufficient. However, the need for a thorough 
review of the section was noted as a priority.
Risperidone (addition) – Adults
The Expert Committee received two applications to include risperidone in the 
WHO Essential Medicines List, as follows:
The Mount Sinai School of Medicine, Program in Global Mental 
Health, New York, NY, USA, proposed the inclusion of the second-generation 
antipsychotic risperidone formulations in the core and complementary EML 
and EMLc.
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Massachusetts General Hospital, The Chester M. Pierce MD Division 
of Global Psychiatry, Boston, MA, USA, (Young Professionals Chronic Disease 
Network) proposed the inclusion of the second-generation antipsychotic 
risperidone in the core EML.
Expert reviews were prepared by Mr Andrew Gray and Dr Kuruvilla 
Prasad Mathews. Comments were received from Dr Shekar Saxena, Director, 
Mental Health and Substance Abuse, WHO and Dr Myriam Henkens, 
International Medical Coordinator, Médecins Sans Frontières.
An application to add risperidone to the EML was first made in 1998. 
At that time risperidone had been available for only four years and it was still 
under patent and was expensive. A second application was made in 2009 several 
years after generic products of risperidone had become available but was rejected 
because of the incompleteness of the literature review and pricing data.
It is estimated that some 41.7 million people need treatment for 
schizophrenia and related disorders in low- and middle-income countries. The 
majority of these cases are in Asia (70%) and Africa (16%) (248). Schizophrenia 
is a significant contributor to the global disease burden, accounting for 1.1% of 
disability-adjusted life-years lost (249).
The Mental Health Gap Action Programme Intervention Guide published 
by WHO in 2010 (67) has three antipsychotics (haloperidol, chlorpromazine 
and fluphenazine), all of which are currently in the EML. The intervention guide 
states that, if the responses to these medications are inadequate, providers may 
choose to treat patients with a second-generation antipsychotic, if available and 
affordable. An excerpt from the guide states:
“If the response is inadequate to more than one antipsychotic medication 
using one medicine at a time at adequate dosage for adequate duration 
… consider second-generation antipsychotics (with the exception of 
clozapine), if cost and availability is not a constraint, as an alternative to 
haloperidol or chlorpromazine.”
A 2010 Cochrane review of 23 randomized controlled trials including 4445 
patients found risperidone to be more effective than typical antipsychotics 
in treating schizophrenia and schizoaffective disorder (250). On the basis of 
pooled data from nine randomized controlled trials, risperidone was more 
likely than haloperidol to produce clinical improvement in the short and longer 
term. Another more recent Cochrane review found that risperidone was more 
efficacious than both quetiapine and ziprasidone, though less efficacious than 
clozapine and olanzapine. Importantly, risperidone has a safer side-effect profile 
than both clozapine and olanzapine (250–253). Other reviews have also shown 
the overall efficacy of risperidone compared with first-generation antipsychotics 
(254, 255).
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While risperidone and other second-generation antipsychotics are 
less likely to cause extrapyramidal side-effects when compared with typical 
antipsychotics, they are more likely to cause metabolic side-effects such as weight 
gain, hyperlipidaemia and hyperglycaemia.
The unit price of risperidone, including generics, has fallen substantially 
since 2008. A comparison of pre-generic and post-generic production data 
revealed the impact of generic production on the price. In 2002, the cost of a 
2-mg tablet of risperidone ranged from US$ 0.070 to US$ 1.33, with the median 
price being roughly 70 US cents. In 2011, however, the cost of a 2-mg tablet of 
risperidone ranged from US$ 0.0080 to US$ 0.067, with the median price being 
just US$ 0.034 (or roughly 3 US cents) (48). Data were also compared in the 
Indian market. Among 12 branded generic manufacturers the price of 10 units 
of 1-mg tablets ranged from 7.00 rupees to 19.70 rupees (256).
The Expert Committee considered the efficacy and safety of the atypical 
antipsychotics, apart from clozapine, to be broadly comparable but noted that 
availability of generics varies considerably.
The Expert Committee recommended that risperidone solid oral dosage 
forms should be added to the core list of the EML without the square box symbol. 
The Committee added that it would welcome further applications for additional 
second-generation (atypical) antipsychotics, based on careful consideration of 
suitable alternatives or additions to risperidone.
Section 27: Vitamins and minerals
Calcium (addition) – Adults
An application to include tablets of calcium (500 mg of elemental calcium as 
calcium carbonate) was prepared by the Department of Nutrition for Health and 
Development, Evidence and Programme Guidance unit, WHO.
Expert reviews were prepared by Dr Eva Njenga and Dr Shalini Sri 
Ranganathan.
The Expert Committee noted that the proposed inclusion of calcium 
supplementation in the EML followed two recent WHO guidelines assessing the 
use of calcium supplements in pregnant women: WHO recommendations for the 
prevention and treatment of pre-eclampsia and eclampsia, published in 2011, and 
Calcium supplementation in pregnant women, developed in 2012 (257, 258).
In both guidelines, WHO makes a strong recommendation for 
supplementation for pregnant women with 1.5–2 g of elemental calcium per 
day in areas where dietary calcium intake is low, and for women at high risk of 
developing hypertensive disorders during pregnancy.
Two recent Cochrane systematic reviews investigated whether calcium 
supplements consumed on a daily basis during pregnancy safely improved 
maternal and infant outcomes (259, 260). Calcium supplementation during 
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pregnancy significantly reduced the risk of pre-eclampsia and high blood pressure 
(with or without proteinuria).
Two types of calcium salts (lactate and carbonate) for oral supplementation 
are listed in the Management Sciences for Health International Drug Price 
Indicator Guide (48), with estimated monthly costs of approximately US$ 11 and 
US$ 4 respectively. However, given the scarcity of comparative price data for such 
products, the exact choice should be guided by local availability and cost.
The Executive Committee recommended the listing of solid oral dosage 
forms of calcium, providing 500 mg of elemental calcium per dose. The 
Committee also indicated that an application for calcium and other micronutrient 
supplementation in children would be required before this item could be 
considered for addition to the EMLc.
Section 28: Ear, nose and throat medicines
Ear, nose and throat (review) – Adults and Children
A review of the existing recommendations for essential medicines for ear, nose 
and throat conditions in adults and children and suggested modifications was 
submitted by Dr Shelly Chadha and Dr Andnet Kebede, Prevention of Blindness 
and Deafness unit, WHO, with a request for the inclusion of medicines and 
dosages for adults.
Expert reviews were prepared by Dr Shalini Sri Ranganathan and 
Dr Abdol Majid Cheraghali.
The Expert Committee supported the request in the review to change 
the title of Section 28 of the EMLc to “Ear, nose and throat medicines”. However, 
the proposal to review and update the EML to include adult formulations of 
topical or nasal spray medications analogous to those in the EMLc was not 
accepted. The medicines listed for children were based on the public health 
relevance of suppurative ear conditions, including otitis media and otitis externa. 
These conditions are not of equivalent public health relevance in adults. The 
Expert Committee therefore recommended no change to the existing listing. 
The Committee stated that any future application for medicines for the treatment 
of these conditions in adults must first demonstrate the public health relevance 
of the condition(s) to be treated or prevented, as well as presenting evidence of 
efficacy, safety and cost–effectiveness.
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6. Summary of recommendations
18th WHO Model List of Essential Medicines
Additions to Model List
Section 2. Amitriptyline, diazepam, dexamethasone, docusate sodium, haloperidol, 
loperamide, hyoscine butylbromide, ibuprofen, metoclopramide and morphine 
were added to the core list for symptomatic treatment of palliative care.
Section 3. Loratadine solid oral dosage form and oral liquid were added to the 
core list because of their superior safety when compared with first-generation 
antihistamines.
Section 4. Fomepizole was added to the complementary list for the treatment of 
toxic alcohol and glycol poisoning.
Section 6.4.3. Pegylated interferon alfa-2a and alfa-2b were added to the 
complementary list to be used with ribavirin for treatment of hepatitis C.
Section 6.5.3.1. Artesunate + mefloquine 25 + 55 mg and 100 + 220 mg (as fixed-
dose combinations) were added to the core list for treatment of uncomplicated 
falciparum malaria.
Section 9. Levodopa/carbidopa 100 mg + 25 mg was added to the core list for the 
treatment of Parkinson disease. A square box symbol was added to biperiden to 
allow for the option of procuring trihexphenidyl.
Section 11.1. Fresh–frozen plasma, platelets, red blood cells and whole blood were 
added to the core list. The Expert Committee strongly supported the principles of 
voluntary, nonremunerated blood donation contained in World Health Assembly 
resolution WHA63.12.
Section 18.5. Gliclazide (30 mg, 60 mg, 80 mg) replaced glibenclamide in the core 
list with a square box symbol to indicate it as the example of a second-generation 
sulfonylurea. A note that glibenclamide should not be used in patients aged 
60 years and older was added.
Section 21. Azithromycin 1.5% eye drops were added to the core list for treatment 
of trachoma in pregnant women and children under one year of age. Bevacizumab 
was added to the complementary list for intravitreal injection for neovascular 
age-related macular degeneration. Latanoprost eye drops (50 µg/ml) were added 
to the core list, based on evidence of efficacy in multiple trials, for the treatment 
of open-angle glaucoma. Ofloxacin 0.3% eye drops were added to the core list for 
the treatment of bacterial keratitis based on efficacy in clinical trials.
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Section 24.1. Risperidone solid oral dosage forms 0.25–6.0 mg were added to 
the core list for the treatment of schizophrenia.
Section 24.1. Clozapine solid oral dosage forms 25–200 mg were added to the 
complementary list for the treatment of patients with schizophrenia refractory 
to other treatments.
Section 27. Calcium tablets (500 mg of elemental calcium) were added to the 
core list for pregnant women in areas where dietary calcium intake is low and 
for women at high risk of developing hypertensive disorders during pregnancy.
Deletions from Model List
Section 3. Chlorphenamine was deleted because of inferior safety when compared 
with second-generation antihistamines and loratadine, a second-generation 
antihistamine, was substituted.
Section 13.4. Dithranol (for topical treatment of psoriasis) was deleted because 
of concerns about the balance between benefits and risks and the low utilization.
Changes to sections
Section 2. The section was renamed “Medicines for pain and palliative care” to 
include medicines for symptomatic treatment in palliative care.
Section 6.3. Amphotericin B and flucytosine for cryptococcal disease in HIV-
infected adults and adolescents were moved from the complementary list to the 
core list.
Section 8. The heading was changed to “Antineoplastics and immunosuppressives” 
as medicines used in palliative care were moved to Section 2.
Section 11. The heading was changed to “Blood products of human origin and 
plasma substitutes”. Subsection 11.1 was retitled “Blood and blood components” 
and Subsection 11.2 was renamed “Plasma-derived medicinal products” with 
a Subsection 11.2.1 on “Human immunoglobulins” and a Subsection 11.2.2 
on “Blood coagulation factors”. The title of Subsection 11.3 was changed to 
“Plasma substitutes”.
Section 12.4. Indications for spironolactone were expanded to include heart failure.
Section 29.2. A new section on “Medicines administered to the mother” was 
added to include dexamethasone under “Specific medicines for neonatal care”.
Section 30. A new section on “Medicines for diseases of joints” was created to list 
the treatments for gout, disease-modifying agents used in rheumatoid disorders 
and juvenile joint diseases that were moved from Section 2.
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Deferred applications
Section 6.4.2. Antiretroviral formulations to be added and deleted were not 
considered as the guidelines for treatment of both adults and children living with 
HIV/AIDS were as yet incomplete.
Section 8.2. The decisions on imatinib for chronic myeloid leukaemia and on 
trastuzumab for breast cancer were deferred until the medicines in the section 
are reviewed at the next meeting of the Expert Committee.
Section 11.2. The decision on human normal immunoglobulin 20% (a new 
concentration) for primary immune deficiencies was deferred pending 
amendments to the pharmacopoeial monographs applicable to such products.
Rejected applications
Section 2.1. The application for the inclusion of naproxen was rejected as there 
was insufficient justification to include both ibuprofen and naproxen in the EML.
Section 2.3. The application for the reinstatement of colchicine for gout was 
rejected as commonly available NSAIMs are equally effective in the treatment of 
gout. Colchicine for familial Mediterranean fever was rejected since the relatively 
limited population affected did not justify its inclusion in a global list.
Section 6.2.2. The application regarding isoniazid + pyridoxine + 
sulfamethoxazole + trimethoprim (fixed-dose combination) was rejected because 
the product does not yet exist.
Section 6.2.4. The application for inclusion of bedaquiline was rejected as further 
efficacy and safety data from clinical trials conducted in different backgrounds 
were needed.
Section 6.4.3. The application to delete oseltamivir was rejected. Oseltamivir 
was retained for the restricted indication of potentially severe or complicated 
illness due to confirmed or suspected influenza virus infection, in accordance 
with WHO treatment guidelines.
Section 10.2. The application regarding a formulation of ferrous salt and folic 
acid (60 mg elemental iron in a ferrous form plus folic acid 2.8 mg tablet/capsule) 
for the prevention of anaemia in menstruating women and adolescent girls was 
rejected as data were lacking to show it to be at least equivalent to existing options 
(and not placebo) for the prevention of anaemia and/or neural tube defects and 
there was no commercial preparation of this fixed-dose combination.
Section 12. The application for fixed-dose combinations (various) of aspirin, 
simvastatin, ramipril, atenolol and hydrocholorothiazide for secondary prophylaxis 
86
W
H
O
 T
ec
hn
ic
al
 R
ep
or
t S
er
ie
s, 
N
o.
 9
85
, 2
01
4
The Selection and Use of Essential Medicines   Report of the 19th WHO Expert Committee
for cardiovascular diseases was rejected as there were gaps in the data presented 
for bioavailability, morbidity and mortality outcomes.
Section 21. The application for inclusion of ketorolac eye drops for allergic 
conjunctivitis was rejected as the evidence that the condition was a major public 
health problem and evidence for effectiveness of the medicine was insufficient. An 
application for ketotifen eye drops for seasonal allergic rhinoconjunctivitis, and 
as a topical anti-inflammatory for the eye, was rejected because of a lack of public 
health relevance and lack of evidence of efficacy in seasonal allergic conjunctivitis.
Section 22.1. The application for deletion of misoprostol for prevention of 
postpartum haemorrhage was rejected as no new data were submitted. Misoprostol 
was retained with the note stating that it is for the prevention of postpartum 
haemorrhage where oxytocin is not available or cannot be safely used.
4th Essential Medicines List for Children
Additions to EMLc
Section 2. Morphine granules and slow-release tablets were added to the core list.
Section 3. Loratadine solid oral dosage form (10 mg) and oral liquid (1 mg/ml) 
were added to the core list because of superior safety when compared with first-
generation antihistamines.
Section 4. Fomepizole was added to the complementary list for the treatment of 
toxic alcohol and glycol poisoning.
Section 6.2.4. Ofloxacin was replaced by levofloxacin in the complementary 
list with an asterisk to indicate that ofloxacin and moxifloxacin may be used as 
alternatives. Ethionamide had an asterisk to indicate that protionamide may be 
used as an alternative.
Section 6.5.3.1. Artesunate + mefloquine 25 + 55 mg and 100 + 220 mg (as a fixed-
dose combination) were added to the core list for the treatment of uncomplicated 
falciparum malaria.
Section 6.5.5.1. Nifurtimox tablets 120 mg were added to the core list to be 
used in combination with eflornithine, for the treatment of Trypanosoma brucei 
gambiense infection.
Section 6.5.5.2. Benznidazole 12.5 mg and 50 mg scored solid oral dosage forms 
were added to the core list for the treatment of infections of Trypanosoma cruzi.
Section 11.1. Fresh–frozen plasma, platelets, red blood cells and whole blood 
were added to the core list. The Expert Committee strongly supported the 
Summary of recommendations
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principles of voluntary, nonremunerated blood donation contained in World 
Health Assembly resolution WHA63.12.
Section 11.3. Dextran 70 was added to the core list for volume replacement when 
safer alternatives are not available.
Section 29.1. Chlorhexidine 7.1% solution or gel delivering 4% was added to the 
core list for use in umbilical cord care in community settings.
Deletions from EMLc
Section 3. Chlorphenamine was deleted because of its inferior safety when 
compared with second-generation antihistamines.
Changes to sections
Section 2. The section was renamed “Medicines for pain and palliative care” to 
include medicines for symptomatic treatment in palliative care. The listing for 
morphine had a note added that it includes both hydromorphone and oxycodone 
as alternatives.
Section 3. A note was added that there may be a role for sedating antihistamines 
for limited indications.
Section 6.3. Amphotericin B and flucytosine for cryptococcal disease in HIV-
infected adolescents were moved from the complementary list to the core list.
Section 8. The heading was changed to “Antineoplastics and immunosuppressives” 
as medicines used in palliative care were moved to Section 2.
Section 11. The heading was changed to “Blood products of human origin and 
plasma substitutes”. Subsection 11.1 was retitled “Blood and blood components” 
and Subsection 11.2 was renamed “Plasma-derived medicinal products” with 
a Subsection 11.2.1 on “Human immunoglobulins” and a Subsection 11.2.2 
on “Blood coagulation factors”. The title of Subsection 11.3 was changed to 
“Plasma substitutes”.
Section 30. A new section on “Medicines for diseases of joints” was created to list 
the treatments for gout, disease-modifying agents used in rheumatoid disorders 
and juvenile joint diseases that were deleted from Section 2.
Amended dosage strength and form
Section 6.2.4. Streptomycin injection was moved from the core list to the 
complementary list.
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Rejected applications
Section 6.4.3. The application to delete oseltamivir was rejected. Oseltamivir 
was retained for the restricted indication of potentially severe or complicated 
illness due to confirmed or suspected influenza virus infection, in accordance 
with WHO treatment guidelines.
Section 28. The application for montelukast was rejected because of a lack of 
evidence of superiority of montelukast over other modes of readily-available 
treatments for allergic rhinitis, the potential adverse events and the uncertainties 
regarding its cost and availability in low- and middle-income countries.
Recommendations for reviews
 ■ What is the place of a dopamine agonist in the treatment of 
Parkinson disease?
 ■ What is the role of a parenteral PPI compared with oral PPIs in 
peptic ulcer bleeding, including its place where immediate access to 
endoscopy is not possible?
 ■ What is the role of pharmacotherapy (especially chlorpromazine 
and haloperidol) in the treatment of severe psychiatric disorders in 
children?
 ■ Review of Section 8.2 – Cytotoxic and adjuvant medicines.
 ■ Review of the Section 6.4.2 – Antiretrovirals, after publication 
of Consolidated guidelines on the use of antiretroviral drugs for 
treating and preventing HIV infection: recommendations for a public 
health approach, at an extraordinary meeting to consider a limited 
list of applications.
 ■ Review of Subsection 11.3 as it contains dextran, and a possible 
move of the three immunoglobulins (anti-D, anti-tetanus and anti-
rabies) from Section 19.2 to the new Subsection 11.2.1.
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Annex 1
18th WHO Model List of Essential Medicines (April 2013)
Explanatory notes
The core list presents a list of minimum medicine needs for a basic health-
care system, listing the most efficacious, safe and cost–effective medicines for 
priority conditions. Priority conditions are selected on the basis of current 
and estimated future public health relevance, and potential for safe and cost-
effective treatment.
The complementary list presents essential medicines for priority 
diseases, for which specialized diagnostic or monitoring facilities, and/or 
specialist medical care, and/or specialist training are needed. In case of doubt 
medicines may also be listed as complementary on the basis of consistent higher 
costs or less attractive cost-effectiveness in a variety of settings.
The square box symbol () is primarily intended to indicate similar 
clinical performance within a pharmacological class. The listed medicine should 
be the example of the class for which there is the best evidence for effectiveness 
and safety. In some cases, this may be the first medicine that is licensed for 
marketing; in other instances, subsequently licensed compounds may be safer or 
more effective. Where there is no difference in terms of efficacy and safety data, 
the listed medicine should be the one that is generally available at the lowest 
price, based on international drug price information sources. Not all square 
boxes are applicable to medicine selection for children — see the 4th EMLc 
for details.
Therapeutic equivalence is indicated only on the basis of reviews of 
efficacy and safety and when consistent with WHO clinical guidelines. National 
lists should not use a similar symbol and should be specific in their final 
selection, which would depend on local availability and price.
The a  symbol indicates that there is an age or weight restriction on use 
of the medicine; details for each medicine can be found in Table 1.1.
Where the  [c]  symbol is placed next to the complementary list it 
signifies that the medicine(s) require(s) specialist diagnostic or monitoring 
facilities, and/or specialist medical care, and/or specialist training for their use 
in children.
Where the  [c]  symbol is placed next to an individual medicine or 
strength of medicine it signifies that there is a specific indication for restricting 
its use to children.
The presence of an entry on the Essential Medicines List carries no 
assurance as to pharmaceutical quality. It is the responsibility of the relevant 
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national or regional drug regulatory authority to ensure that each product is of 
appropriate pharmaceutical quality (including stability) and that, when relevant, 
different products are interchangeable.
For recommendations and advice concerning all aspects of the quality 
assurance of medicines see the WHO Medicines website http://www.who.int/
medicines/areas/quality_assurance.
Medicines and dosage forms are listed in alphabetical order within 
each section and there is no implication of preference for one form over 
another. Standard treatment guidelines should be consulted for information on 
appropriate dosage forms.
The main terms used for dosage forms in the Essential Medicines List can 
be found in Table 1.2.
Definitions of many of these terms and pharmaceutical quality 
requirements applicable to the different categories are published in the current 
edition of The International Pharmacopoeia http://www.who.int/medicines/
publications/pharmacopoeia.
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1. ANAESTHETICS
1.1 General anaesthetics and oxygen
1.1.1 Inhalational medicines
halothane Inhalation.
isoflurane Inhalation.
nitrous oxide Inhalation.
oxygen Inhalation (medicinal gas). 
1.1.2 Injectable medicines
ketamine Injection: 50 mg (as hydrochloride)/ml in 10-ml vial.
propofol* Injection: 10 mg/ml; 20 mg/ml.
* Thiopental may be used as an alternative depending on 
local availability and cost.
1.2 Local anaesthetics
 bupivacaine Injection: 0.25%; 0.5% (hydrochloride) in vial.
Injection for spinal anaesthesia: 0.5% 
(hydrochloride) in 4-ml ampoule to be mixed with 
7.5% glucose solution.
 lidocaine Injection: 1%; 2% (hydrochloride) in vial.
Injection for spinal anaesthesia: 5% (hydrochloride) 
in 2-ml ampoule to be mixed with 7.5% glucose 
solution.
Topical forms: 2% to 4% (hydrochloride).
lidocaine + epinephrine 
(adrenaline)
Dental cartridge: 2% (hydrochloride) + epinephrine 
1:80 000.
Injection: 1%; 2% (hydrochloride or sulfate) + 
epinephrine 1:200 000 in vial.
Complementary List
ephedrine Injection: 30 mg (hydrochloride)/ml in 1-ml ampoule.
(For use in spinal anaesthesia during delivery, to 
prevent hypotension).
1.3 Preoperative medication and sedation for short-term procedures
atropine Injection: 1 mg (sulfate) in 1-ml ampoule.
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1. ANAESTHETICS (continued)
 midazolam Injection: 1 mg/ml.
Oral liquid: 2 mg/ml  [c]  .
Tablet: 7.5 mg; 15 mg.
morphine Injection: 10 mg (sulfate or hydrochloride) in 
1-ml ampoule.
2. MEDICINES FOR PAIN AND PALLIATIVE CARE
2.1 Non-opioids and non-steroidal anti-inflammatory medicines (NSAIMs)
acetylsalicylic acid Suppository: 50 mg to 150 mg.
Tablet: 100 mg to 500 mg.
ibuprofen a Oral liquid: 200 mg/5 ml.
Tablet: 200 mg; 400 mg; 600 mg.
a  Not in children less than 3 months.
paracetamol* Oral liquid: 125 mg/5 ml.
Suppository: 100 mg.
Tablet: 100 mg to 500 mg.
* Not recommended for anti-inflammatory use due to lack of 
proven benefit to that effect.
2.2 Opioid analgesics
codeine Tablet: 30 mg (phosphate).
 morphine* Granules (slow-release; to mix with water): 20 mg – 
200 mg (morphine sulfate).
Injection: 10 mg (morphine hydrochloride or 
morphine sulfate) in 1-ml ampoule.
Oral liquid: 10 mg (morphine hydrochloride or 
morphine sulfate)/5 ml.
Tablet (slow release): 10 mg – 200mg (morphine 
hydrochloride or morphine sulfate). 
Tablet (immediate release): 10 mg (morphine 
sulfate).
* Alternatives limited to hydromorphone and oxycodone.
2.3 Medicines for other common symptoms in palliative care
amitriptyline Tablet: 10 mg; 25 mg; 75 mg.
cyclizine  [c] Injection: 50 mg/ml.
Tablet: 50 mg.
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2. MEDICINES FOR PAIN AND PALLIATIVE CARE (continued)
dexamethasone Injection: 4 mg/ml in 1-ml ampoule (as disodium 
phosphate salt).
Oral liquid: 2 mg/5 ml. 
Tablet: 2 mg  [c]  ; 4 mg.
diazepam Injection: 5 mg/ml.
Oral liquid: 2 mg/5 ml.
Rectal solution: 2.5 mg; 5 mg; 10 mg.
Tablet: 5 mg; 10 mg.
docusate sodium Capsule: 100 mg. 
Oral liquid: 50 mg/5 ml.
fluoxetine a Solid oral dosage form: 20 mg (as hydrochloride).
a  >8 years.
haloperidol Injection: 5 mg in 1‐ml ampoule.
Oral liquid: 2 mg/ml.
Solid oral dosage form: 0.5 mg; 2mg; 5 mg.
hyoscine butylbromide Injection: 20 mg/ml.
hyoscine hydrobromide  [c] Injection: 400 micrograms/ml; 600 micrograms/ml.
Transdermal patches: 1 mg/72 hours.
lactulose  [c] Oral liquid: 3.1–3.7 g/5 ml.
loperamide Solid oral dosage form: 2 mg.
metoclopramide Injection: 5 mg (hydrochloride)/mL in 2‐mL ampoule.
Oral liquid: 5 mg/5 ml.
Solid oral form: 10 mg (hydrochloride).
midazolam Injection: 1 mg/ml; 5 mg/ml.
Solid oral dosage form: 7.5 mg; 15 mg.
Oral liquid: 2mg/ml  [c]  .
ondansetron  [c]  a Injection: 2 mg base/ml in 2-ml ampoule 
(as hydrochloride).
Oral liquid: 4 mg base/5 ml.
Solid oral dosage form: Eq 4 mg base; Eq 8 mg base.
a  >1 month.
senna Oral liquid: 7.5 mg/5 ml.
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3. ANTIALLERGICS AND MEDICINES USED IN ANAPHYLAXIS
dexamethasone Injection: 4 mg/ml in 1-ml ampoule (as disodium 
phosphate salt).
epinephrine (adrenaline) Injection: 1 mg (as hydrochloride or hydrogen 
tartrate) in 1-ml ampoule.
hydrocortisone Powder for injection: 100 mg (as sodium succinate) 
in vial.
 loratadine * Oral liquid: 1 mg/ml.
Tablet: 10 mg.
* There may be a role for sedating antihistamines for limited 
indications (EMLc).
 prednisolone Oral liquid: 5 mg/ml  [c]  .
Tablet: 5 mg; 25 mg.
4. ANTIDOTES AND OTHER SUBSTANCES USED IN POISONINGS
4.1 Non-specific
charcoal, activated Powder.
4.2 Specific
acetylcysteine Injection: 200 mg/ml in 10-ml ampoule.
Oral liquid: 10%  [c]  ; 20%  [c]  .
atropine Injection: 1 mg (sulfate) in 1-ml ampoule.
calcium gluconate Injection: 100 mg/ml in 10-ml ampoule.
methylthioninium chloride 
(methylene blue)
Injection: 10 mg/ml in 10-ml ampoule.
naloxone Injection: 400 micrograms (hydrochloride) in 
1-ml ampoule.
penicillamine Solid oral dosage form: 250 mg.
potassium ferric hexacyano-
ferrate(II) -2H2O (Prussian blue)
Powder for oral administration.
sodium nitrite Injection: 30 mg/ml in 10-ml ampoule.
sodium thiosulfate Injection: 250 mg/ml in 50-ml ampoule.
Complementary List
deferoxamine Powder for injection: 500 mg (mesilate) in vial.
dimercaprol Injection in oil: 50 mg/ml in 2-ml ampoule.
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4. ANTIDOTES AND OTHER SUBSTANCES USED IN POISONINGS (continued)
fomepizole Injection: 5 mg/ml (sulfate) in 20-ml ampoule or  
1 g/ml (base) in 1.5-ml ampoule.
sodium calcium edetate Injection: 200 mg/ml in 5-ml ampoule.
succimer Solid oral dosage form: 100 mg.
5. ANTICONVULSANTS/ANTIEPILEPTICS
carbamazepine Oral liquid: 100 mg/5 ml.
Tablet (chewable): 100 mg; 200 mg.
Tablet (scored): 100 mg; 200 mg.
diazepam Gel or rectal solution: 5 mg/ml in 0.5 ml; 2-ml; 
4-ml tubes.
 lorazepam Parenteral formulation: 2 mg/ml in 1-ml ampoule; 
4 mg/ml in 1-ml ampoule.
magnesium sulfate* Injection: 500 mg/ml in 2-ml ampoule; 500 mg/ml 
in 10-ml ampoule.
* For use in eclampsia and severe pre-eclampsia and not for 
other convulsant disorders.
phenobarbital Injection: 200 mg/ml (sodium).
Oral liquid: 15 mg/5 ml.
Tablet: 15 mg to 100 mg.
phenytoin Injection: 50 mg/ml in 5-ml vial (sodium salt).
Oral liquid: 25 mg to 30 mg/5 ml.*
Solid oral dosage form: 25 mg; 50 mg; 100 mg 
(sodium salt).
Tablet (chewable): 50 mg.
* The presence of both 25 mg/5 ml and 30 mg/5 ml strengths 
on the same market would cause confusion in prescribing 
and dispensing and should be avoided.
valproic acid 
(sodium valproate)
Oral liquid: 200 mg/5 ml.
Tablet (crushable): 100 mg.
Tablet (enteric-coated): 200 mg; 500 mg 
(sodium valproate).
Complementary List
ethosuximide Capsule: 250 mg.
Oral liquid: 250 mg/5 ml.
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6. ANTI-INFECTIVE MEDICINES
6.1 Anthelminthics
6.1.1 Intestinal anthelminthics
albendazole Tablet (chewable): 400 mg.
levamisole Tablet: 50 mg; 150 mg (as hydrochloride).
mebendazole Tablet (chewable): 100 mg; 500 mg.
niclosamide Tablet (chewable): 500 mg.
praziquantel Tablet: 150 mg; 600 mg.
pyrantel Oral liquid: 50 mg (as embonate or pamoate)/ml.
Tablet (chewable): 250 mg (as embonate 
or pamoate).
6.1.2 Antifilarials
albendazole Tablet (chewable): 400 mg.
diethylcarbamazine Tablet: 50 mg; 100 mg (dihydrogen citrate).
ivermectin Tablet (scored): 3 mg.
6.1.3 Antischistosomals and other antitrematode medicines
praziquantel Tablet: 600 mg.
triclabendazole Tablet: 250 mg.
Complementary List
oxamniquine* Capsule: 250 mg.
Oral liquid: 250 mg/5 ml.
* Oxamniquine is listed for use when praziquantel treatment fails.
6.2 Antibacterials
6.2.1 Beta lactam medicines
amoxicillin Powder for oral liquid: 125 mg (as trihydrate)/5 ml; 
250 mg (as trihydrate)/5 ml  [c]  .
Solid oral dosage form: 250 mg; 500 mg 
(as trihydrate).
amoxicillin + clavulanic acid Oral liquid: 125 mg amoxicillin + 31.25 mg 
clavulanic acid/5 ml AND 250 mg amoxicillin + 
62.5 mg clavulanic acid/5 ml  [c]  .
Tablet: 500 mg (as trihydrate) + 125 mg (as 
potassium salt).
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6. ANTI-INFECTIVE MEDICINES (continued)
ampicillin Powder for injection: 500 mg; 1 g (as sodium salt) 
in vial.
benzathine benzylpenicillin Powder for injection: 900 mg benzylpenicillin 
(= 1.2 million IU) in 5-ml vial  [c]  ; 1.44 g 
benzylpenicillin (= 2.4 million IU) in 5-ml vial.
benzylpenicillin Powder for injection: 600 mg (= 1 million IU); 
3 g (= 5 million IU) (sodium or potassium salt) in vial.
cefalexin  [c] Powder for reconstitution with water: 125 mg/5 ml; 
250 mg/5 ml (anhydrous).
Solid oral dosage form: 250 mg (as monohydrate).
 cefazolin* a Powder for injection: 1 g (as sodium salt) in vial.
* For surgical prophylaxis.
a  >1 month.
cefixime* Capsule: 400 mg (as trihydrate).
* Listed only for single-dose treatment of uncomplicated 
anogenital gonorrhoea.
ceftriaxone* a Powder for injection: 250 mg; 1 g (as sodium salt) 
in vial.
* Do not administer with calcium and avoid in infants 
with hyperbilirubinaemia.
a  >41 weeks corrected gestational age.
 cloxacillin Capsule: 500 mg; 1 g (as sodium salt).
Powder for injection: 500 mg (as sodium salt) in vial.
Powder for oral liquid: 125 mg (as sodium salt)/5 ml.
phenoxymethylpenicillin Powder for oral liquid: 250 mg (as potassium 
salt)/5 ml.
Tablet: 250 mg (as potassium salt).
procaine benzylpenicillin* Powder for injection: 1 g (=1 million IU); 
3 g (=3 million IU) in vial. 
* Procaine benzylpenicillin is not recommended as first-line 
treatment for neonatal sepsis except in settings with high 
neonatal mortality, when given by trained health workers in 
cases where hospital care is not achievable.
Complementary List
cefotaxime*  [c] Powder for injection: 250 mg per vial (as sodium salt).
* 3rd generation cephalosporin of choice for use in 
hospitalized neonates.
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6. ANTI-INFECTIVE MEDICINES (continued)
ceftazidime Powder for injection: 250 mg or 1 g (as pentahydrate) 
in vial.
imipenem* + cilastatin* Powder for injection: 250 mg (as monohydrate) + 
250 mg (as sodium salt); 500 mg (as monohydrate) + 
500 mg (as sodium salt) in vial.
* Listed only for the treatment of life-threatening hospital-
based infection due to suspected or proven multidrug-
resistant infection.
Meropenem is indicated for the treatment of meningitis and is 
licensed for use in children over the age of 3 months.
6.2.2 Other antibacterials
azithromycin* Capsule: 250 mg; 500 mg (anhydrous).
Oral liquid: 200 mg/5 ml.
* Only listed for single-dose treatment of genital Chlamydia 
trachomatis and of trachoma.
chloramphenicol Capsule: 250 mg.
Oily suspension for injection*: 0.5 g (as sodium 
succinate)/ml in 2-ml ampoule.
* Only for the presumptive treatment of epidemic meningitis 
in children older than 2 years.
Oral liquid: 150 mg (as palmitate)/5 ml.
Powder for injection: 1 g (sodium succinate) in vial.
 ciprofloxacin* Oral liquid: 250 mg/5 ml (anhydrous)  [c]  .
Solution for IV infusion: 2 mg/ml (as hyclate)  [c]  .
Tablet: 250 mg (as hydrochloride).
* Square box applies to adults only.
clarithromycin* Solid oral dosage form: 500 mg.
* For use in combination regimens for eradication of H. Pylori 
in adults.
doxycycline a Oral liquid: 25 mg/5 ml  [c]  ; 50 mg/5 ml 
(anhydrous)  [c]  .
Solid oral dosage form: 50 mg  [c]  ; 100 mg 
(as hyclate).
a  Use in children <8 years only for life-threatening infections 
when no alternative exists.
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6. ANTI-INFECTIVE MEDICINES (continued)
 erythromycin Powder for injection: 500 mg (as lactobionate) in vial.
Powder for oral liquid: 125 mg/5 ml (as stearate or 
estolate or ethyl succinate).
Solid oral dosage form: 250 mg (as stearate or 
estolate or ethyl succinate).
 gentamicin Injection: 10 mg; 40 mg (as sulfate)/ml in 2-ml vial.
 metronidazole Injection: 500 mg in 100-ml vial.
Oral liquid: 200 mg (as benzoate)/5 ml.
Suppository: 500 mg; 1 g.
Tablet: 200 mg to 500 mg.
nitrofurantoin Oral liquid: 25 mg/5 ml  [c]  .
Tablet: 100 mg.
spectinomycin Powder for injection: 2 g (as hydrochloride) in vial.
sulfamethoxazole + 
trimethoprim
Injection: 
80 mg + 16 mg/ml in 5-ml ampoule;
80 mg + 16 mg/ml in 10-ml ampoule.
Oral liquid: 200 mg + 40 mg/5 ml.
Tablet: 100 mg + 20 mg; 400 mg + 80 mg; 800 mg + 
160 mg.
trimethoprim a Oral liquid: 50 mg/5 ml  [c]  .
Tablet: 100 mg; 200 mg.
a  >6 months.
Complementary List
clindamycin Capsule: 150 mg (as hydrochloride).
Injection: 150 mg (as phosphate)/ml.
Oral liquid: 75 mg/5 ml (as palmitate)  [c]  .
vancomycin Powder for injection: 250 mg (as hydrochloride) in vial.
6.2.3 Antileprosy medicines
Medicines used in the treatment of leprosy should never be used except in combination. 
Combination therapy is essential to prevent the emergence of drug resistance. 
Colour-coded blister packs (MDT blister packs) containing standard two-medicine 
(paucibacillary leprosy) or three-medicine (multibacillary leprosy) combinations for 
adult and childhood leprosy should be used. MDT blister packs can be supplied free 
of charge through WHO.
clofazimine Capsule: 50 mg; 100 mg.
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6. ANTI-INFECTIVE MEDICINES (continued)
dapsone Tablet: 25 mg; 50 mg; 100 mg.
rifampicin Solid oral dosage form: 150 mg; 300 mg.
6.2.4 Antituberculosis medicines
WHO recommends and endorses the use of fixed-dose combinations and the 
development of appropriate new fixed-dose combinations, including modified 
dosage forms, non-refrigerated products and paediatric dosage forms of assured 
pharmaceutical quality.
ethambutol Oral liquid: 25 mg/ml  [c]  .
Tablet: 100 mg to 400 mg (hydrochloride).
ethambutol + isoniazid Tablet: 400 mg + 150 mg.
ethambutol + isoniazid + 
pyrazinamide + rifampicin
Tablet: 275 mg + 75 mg + 400 mg + 150 mg.
ethambutol + isoniazid + 
rifampicin
Tablet: 275 mg + 75 mg + 150 mg.
isoniazid Oral liquid: 50 mg/5 ml  [c]  .
Tablet: 100 mg to 300 mg.
Tablet (scored): 50 mg.
isoniazid + pyrazinamide + 
rifampicin
Tablet: 
75 mg + 400 mg + 150 mg.
150 mg + 500 mg + 150 mg (For intermittent use 
three times weekly).
isoniazid + rifampicin Tablet: 
75 mg + 150 mg; 150 mg + 300 mg.
60 mg + 60 mg (For intermittent use three 
times weekly).
150 mg + 150 mg (For intermittent use three 
times weekly).
pyrazinamide Oral liquid: 30 mg/ml  [c]  .
Tablet: 400 mg.
Tablet (dispersible): 150 mg.
Tablet (scored): 150 mg.
rifabutin Capsule: 150 mg.*
* For use only in patients with HIV receiving protease inhibitors.
rifampicin Oral liquid: 20 mg/ml  [c]  .
Solid oral dosage form: 150 mg; 300 mg.
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6. ANTI-INFECTIVE MEDICINES (continued)
streptomycin Powder for injection: 1 g (as sulfate) in vial.
Complementary List
Reserve second-line drugs for the treatment of multidrug-resistant tuberculosis (MDR-TB) 
should be used in specialized centres adhering to WHO standards for TB control.
amikacin Powder for injection: 100 mg; 500 mg; 1 g (as sulfate) 
in vial.
capreomycin Powder for injection: 1 g (as sulfate) in vial.
cycloserine Solid oral dosage form: 250 mg.
ethionamide* Tablet: 125 mg; 250 mg.
* Protionamide may be an alternative.
kanamycin Powder for injection: 1 g (as sulfate) in vial.
levofloxacin* Tablet: 250mg; 500 m; 750 mg.
* Ofloxacin and moxifloxacin may be alternatives based on 
availability and programme considerations.
p-aminosalicylic acid Granules: 4 g in sachet.
Tablet: 500 mg.
streptomycin  [c]  Powder for injection: 1 g (as sulfate) in vial.
6.3 Antifungal medicines
amphotericin B Powder for injection: 50 mg in vial (as sodium 
deoxycholate or liposomal complex).
clotrimazole Vaginal cream: 1%; 10%.
Vaginal tablet: 100 mg; 500 mg.
 fluconazole Capsule: 50 mg.
Injection: 2 mg/ml in vial.
Oral liquid: 50 mg/5 ml.
flucytosine Capsule: 250 mg.
Infusion: 2.5 g in 250 ml.
griseofulvin Oral liquid: 125 mg/5 ml  [c]  .
Solid oral dosage form: 125 mg; 250 mg.
nystatin Lozenge: 100 000 IU.
Oral liquid: 50 mg/5 ml  [c]  ; 100 000 IU/ml  [c]  .
Pessary: 100 000 IU.
Tablet: 100 000 IU; 500 000 IU.
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6. ANTI-INFECTIVE MEDICINES (continued)
Complementary List
potassium iodide Saturated solution.
6.4 Antiviral medicines
6.4.1 Antiherpes medicines
 aciclovir Oral liquid: 200 mg/5 ml  [c]  .
Powder for injection: 250 mg (as sodium salt) in vial.
Tablet: 200 mg.
6.4.2 Antiretrovirals
Based on current evidence and experience of use, medicines in the following three 
classes of antiretrovirals are included as essential medicines for treatment and 
prevention of HIV (prevention of mother-to-child transmission and post-exposure 
prophylaxis). WHO emphasizes the importance of using these products in accordance 
with global and national guidelines. WHO recommends and endorses the use of fixed-
dose combinations and the development of appropriate new fixed-dose combinations, 
including modified dosage forms, non-refrigerated products and paediatric dosage 
forms of assured pharmaceutical quality.
Scored tablets can be used in children and therefore can be considered for inclusion 
in the listing of tablets, provided that adequate quality products are available.
6.4.2.1 Nucleoside/Nucleotide reverse transcriptase inhibitors
abacavir (ABC) Oral liquid: 100 mg (as sulfate)/5 ml.
Tablet: 300 mg (as sulfate).
didanosine (ddI) Buffered powder for oral liquid: 100 mg; 167 mg; 
250 mg packets.
Capsule (unbuffered enteric-coated): 125 mg; 
200 mg; 250 mg; 400 mg.
Tablet (buffered chewable, dispersible): 25 mg; 
50 mg; 100 mg; 150 mg; 200 mg.
emtricitabine (FTC)* a Capsule: 200 mg.
Oral liquid: 10 mg/ml.
* FTC is an acceptable alternative to 3TC, based on 
knowledge of the pharmacology, the resistance patterns 
and clinical trials of antiretrovirals.
a  >3 months.
lamivudine (3TC) Oral liquid: 50 mg/5 ml.
Tablet: 150 mg.
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6. ANTI-INFECTIVE MEDICINES (continued)
stavudine (d4T) Capsule: 15 mg; 20 mg; 30 mg.
Powder for oral liquid: 5 mg/5 ml.
tenofovir disoproxil fumarate 
(TDF)
Tablet: 300 mg (tenofovir disoproxil fumarate – 
equivalent to 245 mg tenofovir disoproxil).
zidovudine (ZDV or AZT) Capsule: 100 mg; 250 mg.
Oral liquid: 50 mg/5 ml.
Solution for IV infusion injection: 10 mg/ml in 
20-ml vial.
Tablet: 300 mg.
6.4.2.2 Non‑nucleoside reverse transcriptase inhibitors
efavirenz (EFV or EFZ) a Capsule: 50 mg; 100 mg; 200 mg.
Oral liquid: 150 mg/5 ml.
Tablet: 600 mg.
a  >3 years or >10 kg weight.
nevirapine (NVP) Oral liquid: 50 mg/5 ml.
Tablet: 200 mg.
6.4.2.3 Protease inhibitors
Selection of protease inhibitor(s) from the Model List will need to be determined by 
each country after consideration of international and national treatment guidelines 
and experience. Ritonavir is recommended for use in combination as a pharmacological 
booster, and not as an antiretroviral in its own right. All other protease inhibitors should 
be used in boosted forms (e.g. with ritonavir).
atazanavir a Solid oral dosage form: 100 mg; 150 mg; 300 mg 
(as sulfate).
a  >25 kg.
indinavir (IDV) Solid oral dosage form: 400 mg (as sulfate).
lopinavir + ritonavir (LPV/r) Capsule: 133.3 mg + 33.3 mg. 
Oral liquid: 400 mg + 100 mg/5 ml.
Tablet (heat stable): 100 mg + 25 mg; 200 mg + 50 mg.
ritonavir Oral liquid: 400 mg/5 ml.
Solid oral dosage form: 100 mg.
Tablet (heat stable): 25 mg; 100 mg.
saquinavir (SQV) a Solid oral dosage form: 200 mg; 500 mg (as mesilate).
a  >25 kg.
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6. ANTI-INFECTIVE MEDICINES (continued)
FIXED‑DOSE COMBINATIONS
efavirenz + emtricitabine* + 
tenofovir
Tablet: 600 mg + 200 mg + 300 mg (disoproxil 
fumarate equivalent to 245 mg tenofovir disoproxil).
* FTC is an acceptable alternative to 3TC, based on 
knowledge of the pharmacology, the resistance patterns 
and clinical trials of antiretrovirals.
emtricitabine* + tenofovir Tablet: 200 mg + 300 mg (disoproxil fumarate 
equivalent to 245 mg tenofovir disoproxil).
* FTC is an acceptable alternative to 3TC, based on 
knowledge of the pharmacology, the resistance patterns 
and clinical trials of antiretrovirals.
lamivudine + nevirapine + 
stavudine
Tablet: 150 mg + 200 mg + 30 mg.
Tablet (dispersible): 30 mg + 50 mg + 6 mg  [c]  ; 
60 mg + 100 mg + 12 mg  [c]  .
lamivudine + nevirapine + 
zidovudine
Tablet: 30 mg + 50 mg + 60 mg  [c]  ; 150 mg + 
200 mg + 300 mg.
lamivudine + zidovudine Tablet: 30 mg + 60 mg  [c]  ; 150 mg + 300 mg.
6.4.3 Other antivirals
oseltamivir* Capsule: 30 mg; 45 mg; 75 mg (as phosphate).
Oral powder: 12 mg/ml.
* Potentially severe or complicated illness due to confirmed 
or suspected influenza virus infection in accordance with 
WHO treatment guidelines.
ribavirin* Injection for intravenous administration: 800 mg 
and 1 g in 10-ml phosphate buffer solution.
Solid oral dosage form: 200 mg; 400 mg; 600 mg.
* For the treatment of viral haemorrhagic fevers and in 
combination with pegylated interferons for the treatment 
of hepatitis C.
Complementary List
pegylated interferon alfa 
(2a or 2b)*
Vial or prefilled syringe: 
180 micrograms (peginterferon alfa-2a),
80 microgram, 100 microgram (peginterferon alfa-2b).
* To be used in combination with ribavirin.
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6. ANTI-INFECTIVE MEDICINES (continued)
6.5 Antiprotozoal medicines
6.5.1 Antiamoebic and antigiardiasis medicines
diloxanide a Tablet: 500 mg (furoate).
a  >25 kg.
 metronidazole Injection: 500 mg in 100-ml vial.
Oral liquid: 200 mg (as benzoate)/5 ml.
Tablet: 200 mg to 500 mg.
6.5.2 Antileishmaniasis medicines
amphotericin B Powder for injection: 50 mg in vial (as sodium 
deoxycholate or liposomal complex).
miltefosine Solid oral dosage form: 10 mg; 50 mg.
paromomycin Solution for intramuscular injection: 750 mg of 
paromomycin base (as the sulfate).
sodium stibogluconate or 
meglumine antimoniate
Injection: 100 mg/ml, 1 vial = 30 ml or 30%, 
equivalent to approximately 8.1% antimony 
(pentavalent) in 5-ml ampoule.
6.5.3 Antimalarial medicines
6.5.3.1 For curative treatment
Medicines for the treatment of P. falciparum malaria cases should be used in 
combination. The list currently recommends combinations according to treatment 
guidelines. WHO recognizes that not all of the fixed dose combinations (FDCs) in the 
WHO treatment guidelines exist, and encourages their development and rigorous 
testing. WHO also encourages development and testing of rectal dosage formulations.
amodiaquine* Tablet: 153 mg or 200 mg (as hydrochloride).
* To be used in combination with artesunate 50 mg.
artemether* Oily injection: 80 mg/ml in 1-ml ampoule.
* For use in the management of severe malaria.
artemether + lumefantrine* Tablet: 20 mg + 120 mg.
Tablet (dispersible): 20 mg + 120 mg  [c]  .
* Not recommended in the first trimester of pregnancy or in 
children below 5 kg.
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6. ANTI-INFECTIVE MEDICINES (continued)
artesunate* Injection: ampoules, containing 60 mg anhydrous 
artesunic acid with a separate ampoule of 5% 
sodium bicarbonate solution.
For use in the management of severe malaria.
Rectal dosage form: 50 mg  [c]  ; 200 mg capsules 
(for pre-referral treatment of severe malaria only; 
patients should be taken to an appropriate health 
facility for follow-up care)  [c]  .
Tablet: 50 mg.
* To be used in combination with either amodiaquine, 
mefloquine or sulfadoxine + pyrimethamine.
artesunate + amodiaquine* Tablet: 25 mg + 67.5 mg; 50 mg + 135 mg; 100 mg + 
270 mg.
* Other combinations that deliver the target doses required 
such as 153 mg or 200 mg (as hydrochloride) with 50 mg 
artesunate can be alternatives.
artesunate + mefloquine Tablet: 25 mg + 55 mg; 100 mg + 220 mg.
chloroquine* Oral liquid: 50 mg (as phosphate or sulfate)/5 ml.
Tablet: 100 mg; 150 mg (as phosphate or sulfate).
* For use only for the treatment of P. vivax infection.
doxycycline* Capsule: 100 mg (as hydrochloride or hyclate).
Tablet (dispersible): 100 mg (as monohydrate).
* For use only in combination with quinine.
mefloquine* Tablet: 250 mg (as hydrochloride).
* To be used in combination with artesunate 50 mg.
primaquine* Tablet: 7.5 mg; 15 mg (as diphosphate).
* Only for use to achieve radical cure of P. vivax and P. ovale 
infections, given for 14 days.
quinine* Injection: 300 mg quinine hydrochloride/ml in 
2-ml ampoule.
Tablet: 300 mg (quinine sulfate) or 300 mg 
(quinine bisulfate).
* For use only in the management of severe malaria, and 
should be used in combination with doxycycline.
sulfadoxine + pyrimethamine* Tablet: 500 mg + 25 mg.
* Only in combination with artesunate 50 mg.
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6. ANTI-INFECTIVE MEDICINES (continued)
6.5.3.2 For prophylaxis
chloroquine* Oral liquid: 50 mg (as phosphate or sulfate)/5 ml.
Tablet: 150 mg (as phosphate or sulfate).
* For use only in central American regions, for P. vivax infections.
doxycycline a Solid oral dosage form: 100 mg (as hydrochloride 
or hyclate).
a  >8 years.
mefloquine a Tablet: 250 mg (as hydrochloride).
a  >5 kg or >3 months.
proguanil* Tablet: 100 mg (as hydrochloride).
* For use only in combination with chloroquine.
6.5.4 Antipneumocystosis and antitoxoplasmosis medicines
pyrimethamine Tablet: 25 mg.
sulfadiazine Tablet: 500 mg.
sulfamethoxazole + 
trimethoprim
Injection:
80 mg + 16 mg/ml in 5-ml ampoule;
80 mg + 16 mg/ml in 10-ml ampoule.
Oral liquid: 200 mg + 40 mg/5 ml  [c]  .
Tablet: 100 mg + 20 mg; 400 mg + 80 mg  [c]  .
Complementary List
pentamidine Tablet: 200 mg; 300 mg (as isethionate).
6.5.5 Antitrypanosomal medicines
6.5.5.1 African trypanosomiasis
Medicines for the treatment of 1st stage African trypanosomiasis
pentamidine* Powder for injection: 200 mg (as isetionate) in vial.
* To be used for the treatment of Trypanosoma brucei 
gambiense infection.
suramin sodium* Powder for injection: 1 g in vial.
* To be used for the treatment of the initial phase of 
Trypanosoma brucei rhodesiense infection.
Medicines for the treatment of 2nd stage African trypanosomiasis
eflornithine* Injection: 200 mg (hydrochloride)/ml in 100-ml bottle.
* To be used for the treatment of Trypanosoma brucei 
gambiense infection.
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6. ANTI-INFECTIVE MEDICINES (continued)
melarsoprol Injection: 3.6% solution, 5-ml ampoule (180 mg of 
active compound).
nifurtimox* Tablet: 120 mg.
* Only to be used in combination with eflornithine, for the 
treatment of Trypanosoma brucei gambiense infection.
Complementary List  [c] 
melarsoprol Injection: 3.6% solution in 5-ml ampoule (180 mg of 
active compound).
6.5.5.2 American trypanosomiasis
benznidazole Tablet: 12.5 mg  [c]  ;100 mg.
Tablet (scored): 50 mg.
nifurtimox Tablet: 30 mg; 120 mg; 250 mg.
7. ANTIMIGRAINE MEDICINES
7.1 For treatment of acute attack
acetylsalicylic acid Tablet: 300 mg to 500 mg.
ibuprofen  [c] Tablet: 200 mg; 400 mg.
paracetamol Oral liquid: 125 mg/5 ml  [c]  .
Tablet: 300 mg to 500 mg.
7.2 For prophylaxis
 propranolol Tablet: 20 mg; 40 mg (hydrochloride).
8. ANTINEOPLASTICS AND IMMUNOSUPPRESSIVES
This section will be reviewed and updated shortly. In view of this, no changes were 
made to this section during the meeting of the 19th Expert Committee.
8.1 Immunosuppressive medicines
Complementary List
azathioprine Powder for injection: 100 mg (as sodium salt) in vial.
Tablet (scored): 50 mg.
ciclosporin Capsule: 25 mg.
Concentrate for injection: 50 mg/ml in 1-ml ampoule 
for organ transplantation.
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8. ANTINEOPLASTICS AND IMMUNOSUPPRESSIVES (continued)
8.2 Cytotoxic and adjuvant medicines
Complementary List
allopurinol  [c] Tablet: 100 mg; 300 mg.
asparaginase Powder for injection: 10 000 IU in vial.
bleomycin Powder for injection: 15 mg (as sulfate) in vial.
calcium folinate Injection: 3 mg/ml in 10-ml ampoule.
Tablet: 15 mg.
 carboplatin Injection: 50 mg/5 ml; 150 mg/15 ml; 450 mg/45 ml; 
600 mg/60 ml.
chlorambucil Tablet: 2 mg.
cyclophosphamide Powder for injection: 500 mg in vial.
Tablet: 25 mg.
cytarabine Powder for injection: 100 mg in vial.
dacarbazine Powder for injection: 100 mg in vial.
dactinomycin Powder for injection: 500 micrograms in vial.
daunorubicin Powder for injection: 50 mg (hydrochloride) in vial.
docetaxel Injection: 20 mg/ml; 40 mg/ml.
doxorubicin Powder for injection: 10 mg; 50 mg (hydrochloride) 
in vial.
etoposide Capsule: 100 mg.
Injection: 20 mg/ml in 5-ml ampoule.
fluorouracil Injection: 50 mg/ml in 5-ml ampoule.
hydroxycarbamide Solid oral dosage form: 200 mg; 250 mg; 300 mg; 
400 mg; 500 mg; 1 g.
ifosfamide Powder for injection: 1-g vial; 2-g vial.
mercaptopurine Tablet: 50 mg.
mesna Injection: 100 mg/ml in 4-ml and 10-ml ampoules.
Tablet: 400 mg; 600 mg.
methotrexate Powder for injection: 50 mg (as sodium salt) in vial.
Tablet: 2.5 mg (as sodium salt).
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8. ANTINEOPLASTICS AND IMMUNOSUPPRESSIVES (continued)
paclitaxel Powder for injection: 6 mg/ml.
procarbazine Capsule: 50 mg (as hydrochloride).
tioguanine  [c] Solid oral dosage form: 40 mg.
vinblastine Powder for injection: 10 mg (sulfate) in vial.
vincristine Powder for injection: 1 mg; 5 mg (sulfate) in vial.
8.3 Hormones and antihormones
Complementary List
dexamethasone Injection: 4 mg/ml in 1-ml ampoule (as disodium 
phosphate salt).
Oral liquid: 2 mg/5 ml  [c]  .
hydrocortisone Powder for injection: 100 mg (as sodium succinate) 
in vial.
methylprednisolone  [c] Injection: 40 mg/ml (as sodium succinate) in 1-ml 
single-dose vial and 5-ml multi-dose vials; 80 mg/ml 
(as sodium succinate) in 1-ml single-dose vial.
 prednisolone Oral liquid: 5 mg/ml  [c]  .
Tablet: 5 mg; 25 mg.
tamoxifen Tablet: 10 mg; 20 mg (as citrate).
9. ANTIPARKINSONISM MEDICINES
 biperiden Injection: 5 mg (lactate) in 1-ml ampoule.
Tablet: 2 mg (hydrochloride).
levodopa +  carbidopa Tablet: 100 mg + 10 mg; 100 mg + 25 mg; 
250 mg + 25 mg.
10. MEDICINES AFFECTING THE BLOOD
10.1 Antianaemia medicines
ferrous salt Oral liquid: equivalent to 25 mg iron (as sulfate)/ml.
Tablet: equivalent to 60 mg iron.
ferrous salt + folic acid Tablet: equivalent to 60 mg iron + 400 micrograms 
folic acid (nutritional supplement for use during 
pregnancy).
folic acid Tablet: 1 mg; 5 mg.
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10. MEDICINES AFFECTING THE BLOOD (continued)
hydroxocobalamin Injection: 1 mg (as acetate, as hydrochloride or as 
sulfate) in 1-ml ampoule.
10.2 Medicines affecting coagulation
heparin sodium Injection: 1000 IU/ml; 5000 IU/ml; 20 000 IU/ml in 
1-ml ampoule.
phytomenadione Injection: 1 mg/ml  [c]  ; 10 mg/ml in 5-ml ampoule.
Tablet: 10 mg.
protamine sulfate Injection: 10 mg/ml in 5-ml ampoule.
tranexamic acid Injection: 100 mg/ml in 10-ml ampoule.
 warfarin Tablet: 1 mg; 2 mg; 5 mg (sodium salt).
Complementary List  [c] 
heparin sodium Injection: 1000 IU/ml; 5000 IU/ml in 1-ml ampoule.
protamine sulfate Injection: 10 mg/ml in 5-ml ampoule.
 warfarin Tablet: 0.5 mg; 1 mg; 2 mg; 5 mg (sodium salt).
10.3 Other medicines for haemoglobinopathies
Complementary List
deferoxamine* Powder for injection: 500 mg (mesilate) in vial.
* Deferasirox oral form may be an alternative, depending on 
cost and availability.
hydroxycarbamide Solid oral dosage form: 200 mg; 500 mg; 1 g.
11. BLOOD PRODUCTS OF HUMAN ORIGIN AND PLASMA SUBSTITUTES
11.1 Blood and blood components
In accordance with the World Health Assembly resolution WHA63.12, WHO recognizes 
that achieving self-sufficiency, unless special circumstances preclude it, in the supply 
of safe blood components based on voluntary, non-remunerated blood donation, and 
the security of that supply are important national goals to prevent blood shortages 
and meet the transfusion requirements of the patient population. All preparations 
should comply with the WHO requirements.
fresh–frozen plasma
platelets
red blood cells
whole blood
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11. BLOOD PRODUCTS OF HUMAN ORIGIN AND PLASMA SUBSTITUTES (continued)
11.2 Plasma-derived medicinales products
All human plasma-derived medicines should comply with the WHO requirements.
11.2.1 Human immunoglobulins
Complementary List
human normal 
immunoglobulin
Intramuscular administration: 16% protein solution.*
Intravenous administration: 5%; 10% protein 
solution.**
Subcutaneous administration: 15%; 16% protein 
solution.*
* Indicated for primary immune deficiency.
** Indicated for primary immune deficiency and Kawasaki disease.
11.2.2 Blood coagulation factors
Complementary List
 coagulation factor VIII Powder for injection: 500 IU/vial.
 coagulation factor IX Powder for injection: 500 IU/vial, 1000 IU/vial.
11.3 Plasma substitutes
 dextran 70* Injectable solution: 6%.
* Polygeline, injectable solution, 3.5% is considered 
as equivalent.
12. CARDIOVASCULAR MEDICINES
12.1 Antianginal medicines
 bisoprolol* Tablet: 1.25 mg; 5 mg.
*  includes metoprolol and carvedilol as alternatives.
glyceryl trinitrate Tablet (sublingual): 500 micrograms.
 isosorbide dinitrate Tablet (sublingual): 5 mg.
verapamil Tablet: 40 mg; 80 mg (hydrochloride).
12.2 Antiarrhythmic medicines
 bisoprolol* Tablet: 1.25 mg; 5 mg.
*  includes metoprolol and carvedilol as alternatives.
digoxin Injection: 250 micrograms/ml in 2-ml ampoule.
Oral liquid: 50 micrograms/ml.
Tablet: 62.5 micrograms; 250 micrograms.
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12. CARDIOVASCULAR MEDICINES (continued)
epinephrine (adrenaline) Injection: 100 micrograms/ml (as acid tartrate or 
hydrochloride) in 10-ml ampoule.
lidocaine Injection: 20 mg (hydrochloride)/ml in 5-ml ampoule.
verapamil Injection: 2.5 mg (hydrochloride)/ml in 2-ml ampoule.
Tablet: 40 mg; 80 mg (hydrochloride).
Complementary List
amiodarone Injection: 50 mg/ml in 3-ml ampoule (hydrochloride).
Tablet: 100 mg; 200 mg; 400 mg (hydrochloride).
12.3 Antihypertensive medicines
 amlodipine Tablet: 5 mg (as maleate, mesylate or besylate).
 bisoprolol* Tablet: 1.25 mg; 5 mg.
*  includes metoprolol and carvedilol as alternatives.
 enalapril Tablet: 2.5 mg; 5 mg (as hydrogen maleate).
hydralazine* Powder for injection: 20 mg (hydrochloride) 
in ampoule.
Tablet: 25 mg; 50 mg (hydrochloride).
* Hydralazine is listed for use only in the acute management 
of severe pregnancy-induced hypertension. Its use in the 
treatment of essential hypertension is not recommended 
in view of the evidence of greater efficacy and safety of 
other medicines.
 hydrochlorothiazide Oral liquid: 50 mg/5 ml.
Solid oral dosage form: 12.5 mg; 25 mg.
methyldopa* Tablet: 250 mg.
* Methyldopa is listed for use only in the management 
of pregnancy-induced hypertension. Its use in the 
treatment of essential hypertension is not recommended 
in view of the evidence of greater efficacy and safety of 
other medicines.
Complementary List
sodium nitroprusside Powder for infusion: 50 mg in ampoule.
12.4 Medicines used in heart failure
 bisoprolol* Tablet: 1.25 mg; 5 mg.
*  includes metoprolol and carvedilol as alternatives.
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12. CARDIOVASCULAR MEDICINES (continued)
digoxin Injection: 250 micrograms/ml in 2-ml ampoule.
Oral liquid: 50 micrograms/ml.
Tablet: 62.5 micrograms; 250 micrograms.
 enalapril Tablet: 2.5 mg; 5 mg (as hydrogen maleate).
 furosemide Injection: 10 mg/ml in 2-ml ampoule.
Oral liquid: 20 mg/5 ml  [c]  .
Tablet: 40 mg.
 hydrochlorothiazide Oral liquid: 50 mg/5 ml.
Solid oral dosage form: 25 mg.
spironolactone Tablet: 25 mg.
Complementary List
dopamine Injection: 40 mg/ml (hydrochloride) in 5-ml vial.
12.5 Antithrombotic medicines
acetylsalicylic acid Tablet: 100 mg.
Complementary List
streptokinase Powder for injection: 1.5 million IU in vial.
12.6 Lipid-lowering agents
 simvastatin* Tablet: 5 mg; 10 mg; 20 mg; 40 mg.
* For use in high-risk patients.
13. DERMATOLOGICAL MEDICINES (topical)
13.1 Antifungal medicines
 miconazole Cream or ointment: 2% (nitrate).
selenium sulfide Detergent-based suspension: 2%.
sodium thiosulfate Solution: 15%.
terbinafine Cream: 1% or Ointment: 1% terbinafine 
hydrochloride.
13.2 Anti-infective medicines
mupirocin Cream (as mupirocin calcium): 2%.
Ointment: 2%.
potassium permanganate Aqueous solution: 1:10 000.
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13. DERMATOLOGICAL MEDICINES (topical) (continued)
silver sulfadiazine a Cream: 1%.
a  >2 months.
13.3 Anti-inflammatory and antipruritic medicines
 betamethasone a Cream or ointment: 0.1% (as valerate).
a  Hydrocortisone preferred in neonates.
 calamine Lotion.
 hydrocortisone Cream or ointment: 1% (acetate).
13.4 Medicines affecting skin differentiation and proliferation
benzoyl peroxide Cream or lotion: 5%.
coal tar Solution: 5%.
fluorouracil Ointment: 5%.
 podophyllum resin Solution: 10% to 25%.
salicylic acid Solution: 5%.
urea Cream or ointment: 5%; 10%.
13.5 Scabicides and pediculicides
 benzyl benzoate a Lotion: 25%.
a  >2 years.
permethrin Cream: 5%.
Lotion: 1%.
14. DIAGNOSTIC AGENTS
14.1 Ophthalmic medicines
fluorescein Eye drops: 1% (sodium salt).
 tropicamide Eye drops: 0.5%.
14.2 Radiocontrast media
 amidotrizoate Injection: 140 mg to 420 mg iodine (as sodium or 
meglumine salt)/ml in 20-ml ampoule.
barium sulfate Aqueous suspension.
 iohexol Injection: 140 mg to 350 mg iodine/ml in 5-ml; 
10-ml; 20-ml ampoules.
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14. DIAGNOSTIC AGENTS (continued)
Complementary List
barium sulfate  [c] Aqueous suspension.
 meglumine iotroxate Solution: 5 g to 8 g iodine in 100 ml to 250 ml.
15. DISINFECTANTS AND ANTISEPTICS
15.1 Antiseptics
 chlorhexidine Solution: 5% (digluconate).
 ethanol Solution: 70% (denatured).
 povidone iodine Solution: 10% (equivalent to 1% available iodine).
15.2 Disinfectants
 chlorine base compound Powder: (0.1% available chlorine) for solution.
 chloroxylenol Solution: 4.8%.
glutaral Solution: 2%.
16. DIURETICS
amiloride Tablet: 5 mg (hydrochloride).
 furosemide Injection: 10 mg/ml in 2-ml ampoule.
Oral liquid: 20 mg/5 ml  [c]  .
Tablet: 10 mg  [c]  ; 20 mg  [c]  ; 40 mg.
 hydrochlorothiazide Solid oral dosage form: 25 mg.
mannitol Injectable solution: 10%; 20%.
spironolactone Tablet: 25 mg.
Complementary List  [c] 
 hydrochlorothiazide Tablet (scored): 25 mg.
mannitol Injectable solution: 10%; 20%.
spironolactone Oral liquid: 5 mg/5 ml; 10 mg/5 ml; 25 mg/5 ml.
Tablet: 25 mg.
17. GASTROINTESTINAL MEDICINES
Complementary List  [c] 
 pancreatic enzymes Age-appropriate formulations and doses including 
lipase, protease and amylase.
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17. GASTROINTESTINAL MEDICINES (continued)
17.1 Antiulcer medicines
 omeprazole Powder for oral liquid: 20 mg; 40 mg sachets.
Solid oral dosage form: 10 mg; 20 mg; 40 mg.
 ranitidine Injection: 25 mg/ml (as hydrochloride) in 
2-ml ampoule.
Oral liquid: 75 mg/5 ml (as hydrochloride).
Tablet: 150 mg (as hydrochloride).
17.2 Antiemetic medicines
dexamethasone Injection: 4 mg/ml in 1-ml ampoule (as disodium 
phosphate salt).
Oral liquid: 0.5 mg/5 ml; 2 mg/5 ml.
Solid oral dosage form: 0.5 mg; 0.75 mg; 1.5 mg; 
4 mg.
metoclopramide a Injection: 5 mg (hydrochloride)/ml in 2-ml ampoule.
Oral liquid: 5 mg/5 ml  [c]  .
Tablet: 10 mg (hydrochloride).
a  Not in neonates.
ondansetron a Injection: 2 mg base/ml in 2-ml ampoule 
(as hydrochloride).
Oral liquid: 4 mg base/5 ml.
Solid oral dosage form: Eq 4 mg base; Eq 8 mg base; 
Eq 24 mg base.
a  >1 month.
17.3 Anti-inflammatory medicines
 sulfasalazine Retention enema.
Suppository: 500 mg.
Tablet: 500 mg.
Complementary List
 hydrocortisone Retention enema.
Suppository: 25 mg (acetate).
(the  only applies to hydrocortisone retention enema).
17.4 Laxatives
 senna Tablet: 7.5 mg (sennosides) (or traditional 
dosage forms).
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17. GASTROINTESTINAL MEDICINES (continued)
17.5 Medicines used in diarrhoea
17.5.1 Oral rehydration
oral rehydration salts Powder for dilution in 200 ml; 500 ml; 1 L.
glucose: 75 mEq
sodium: 75 mEq or mmol/L
chloride: 65 mEq or mmol/L
potassium: 20 mEq or mmol/L
citrate: 10 mmol/L
osmolarity: 245 mOsm/L
glucose: 13.5 g/L
sodium chloride: 2.6 g/L
potassium chloride: 1.5 g/L
trisodium citrate dihydrate*: 2.9 g/L
* trisodium citrate dihydrate may be replaced by 
sodium hydrogen carbonate (sodium bicarbonate) 
2.5 g/L. However, as the stability of this latter 
formulation is very poor under tropical conditions, 
it is recommended only when manufactured for 
immediate use.
17.5.2 Medicines for diarrhoea
zinc sulfate* Solid oral dosage form: 20 mg.
* In acute diarrhoea zinc sulfate should be used as an adjunct 
to oral rehydration salts.
18. HORMONES, OTHER ENDOCRINE MEDICINES AND CONTRACEPTIVES
18.1 Adrenal hormones and synthetic substitutes
fludrocortisone Tablet: 100 micrograms (acetate).
hydrocortisone Tablet: 5 mg; 10 mg; 20 mg.
18.2 Androgens
Complementary List
testosterone Injection: 200 mg (enanthate) in 1-ml ampoule.
18.3 Contraceptives
18.3.1 Oral hormonal contraceptives
 ethinylestradiol + 
 levonorgestrel
Tablet: 30 micrograms + 150 micrograms.
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18. HORMONES, OTHER ENDOCRINE MEDICINES AND CONTRACEPTIVES (continued)
 ethinylestradiol + 
 norethisterone
Tablet: 35 micrograms + 1 mg.
levonorgestrel Tablet: 30 micrograms; 750 micrograms (pack of 
two); 1.5 mg.
18.3.2 Injectable hormonal contraceptives
estradiol cypionate + 
medroxyprogesterone acetate
Injection: 5 mg + 25 mg.
medroxyprogesterone acetate Depot injection: 150 mg/ml in 1-ml vial.
norethisterone enantate Oily solution: 200 mg/ml in 1-ml ampoule.
18.3.3 Intrauterine devices
copper-containing device
18.3.4 Barrier methods
condoms
diaphragms
18.3.5 Implantable contraceptives
levonorgestrel-releasing 
implant
Two-rod levonorgestrel-releasing implant, each rod 
containing 75 mg of levonorgestrel (150 mg total).
18.4 Estrogens
18.5 Insulins and other medicines used for diabetes
 gliclazide* Solid oral dosage form: (controlled-release tablets) 
30 mg; 60 mg; 80 mg.
* glibenclamide not suitable above 60 years.
glucagon Injection: 1 mg/ml.
insulin injection (soluble) Injection: 40 IU/ml in 10-ml vial; 100 IU/ml in 
10-ml vial.
intermediate-acting insulin Injection: 40 IU/ml in 10-ml vial; 100 IU/ml in 
10-ml vial (as compound insulin zinc suspension or 
isophane insulin).
metformin Tablet: 500 mg (hydrochloride).
Complementary List  [c] 
metformin Tablet: 500 mg (hydrochloride).
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18. HORMONES, OTHER ENDOCRINE MEDICINES AND CONTRACEPTIVES (continued)
18.6 Ovulation inducers
Complementary List
clomifene Tablet: 50 mg (citrate).
18.7 Progestogens
 medroxyprogesterone 
acetate
Tablet: 5 mg.
18.8 Thyroid hormones and antithyroid medicines
levothyroxine Tablet: 25 micrograms  [c]  ; 50 micrograms; 
100 micrograms (sodium salt).
potassium iodide Tablet: 60 mg.
 propylthiouracil Tablet: 50 mg.
Complementary List  [c] 
Lugol’s solution Oral liquid: about 130 mg total iodine/ml.
potassium iodide Tablet: 60 mg.
propylthiouracil Tablet: 50 mg.
19. IMMUNOLOGICALS
19.1 Diagnostic agents
All tuberculins should comply with the WHO requirements for tuberculins.
tuberculin, purified protein 
derivative (PPD)
Injection.
19.2 Sera and immunoglobulins
All plasma fractions should comply with the WHO requirements.
anti-D immunoglobulin 
(human)
Injection: 250 micrograms in single-dose vial.
anti-rabies immunoglobulin 
(human)
Injection: 150 IU/ml in vial.
anti-tetanus immunoglobulin 
(human)
Injection: 500 IU in vial.
anti-venom immunoglobulin* Injection.
* Exact type to be defined locally.
diphtheria antitoxin Injection: 10 000 IU; 20 000 IU in vial.
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19. IMMUNOLOGICALS (continued)
19.3 Vaccines
Selection of vaccines from the Model List will need to be determined by each country 
after consideration of international recommendations, epidemiology and national 
priorities. The list below details the vaccines for which there is either a recommendation 
from the Strategic Advisory Group of Experts on Immunization (SAGE) (http://www.
who.int/immunization/sage_conclusions/en/index.html) and/or a WHO position paper 
(http://www.who.int/immunization/documents/positionpapers/en/index.html). This site 
will be updated as new position papers are published and contains the most recent 
information and recommendations.
All vaccines should comply with the WHO requirements for biological substances.
WHO noted the need for vaccines used in children to be polyvalent.
BCG vaccine
cholera vaccine
diphtheria vaccine
Haemophilus influenzae type b vaccine
hepatitis A vaccine
hepatitis B vaccine
influenza vaccine
Japanese encephalitis vaccine
measles vaccine
meningococcal meningitis vaccine
mumps vaccine
pertussis vaccine
pneumococcal vaccine
poliomyelitis vaccine
rabies vaccine
rotavirus vaccine
rubella vaccine
tetanus vaccine
typhoid vaccine
varicella vaccine
yellow fever vaccine
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20. MUSCLE RELAXANTS (PERIPHERALLY-ACTING) AND CHOLINESTERASE 
INHIBITORS
 atracurium Injection: 10 mg/ml (besylate).
neostigmine Injection: 500 micrograms in 1-ml ampoule; 2.5 mg 
(metilsulfate) in 1-ml ampoule.
Tablet: 15 mg (bromide).
suxamethonium Injection: 50 mg (chloride)/ml in 2-ml ampoule.
Powder for injection (chloride), in vial.
 vecuronium  [c] Powder for injection: 10 mg (bromide) in vial.
Complementary List
pyridostigmine Injection: 1 mg in 1-ml ampoule.
Tablet: 60 mg (bromide).
 vecuronium Powder for injection: 10 mg (bromide) in vial.
21. OPHTHALMOLOGICAL PREPARATIONS
21.1 Anti-infective agents
aciclovir Ointment: 3% W/W.
azithromycin Solution (eye drops): 1.5%.
 gentamicin Solution (eye drops): 0.3% (sulfate).
 ofloxacin Solution (eye drops): 0.3%.
 tetracycline Eye ointment: 1% (hydrochloride).
21.2 Anti-inflammatory agents
 prednisolone Solution (eye drops): 0.5% (sodium phosphate).
21.3 Local anaesthetics
 tetracaine a Solution (eye drops): 0.5% (hydrochloride).
a  Not in preterm neonates.
21.4 Miotics and antiglaucoma medicines
acetazolamide Tablet: 250 mg.
latanoprost Solution (eye drops): latanoprost 50 micrograms/mL
 pilocarpine Solution (eye drops): 2%; 4% (hydrochloride 
or nitrate).
 timolol Solution (eye drops): 0.25%; 0.5% (as 
hydrogen maleate).
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21. OPHTHALMOLOGICAL PREPARATIONS (continued)
21.5 Mydriatics
atropine* a Solution (eye drops): 0.1%; 0.5%; 1% (sulfate).
*  [c]   Or homatropine (hydrobromide) or cyclopentolate 
(hydrochloride).
a  >3 months.
Complementary List
epinephrine (adrenaline) Solution (eye drops): 2% (as hydrochloride).
21.6 Anti-vascular endothelial growth factor (VEGF) preparations
Complementary List
bevacizumab Injection: 25 mg/ml.
22. OXYTOCICS AND ANTIOXYTOCICS
22.1 Oxytocics
 ergometrine Injection: 200 micrograms (hydrogen maleate) in 
1-ml ampoule.
misoprostol Tablet: 200 micrograms.*
* For management of incomplete abortion and miscarriage, 
and for prevention of postpartum haemorrhage where 
oxytocin is not available or cannot be safely used.
Vaginal tablet: 25 micrograms.*
* Only for use for induction of labour where appropriate 
facilities are available.
oxytocin Injection: 10 IU in 1-ml.
Complementary List
mifepristone* – misoprostol*
Where permitted under  
national law and where 
culturally acceptable.
Tablet 200 mg – tablet 200 micrograms.
* Requires close medical supervision.
22.2 Antioxytocics (tocolytics)
nifedipine Immediate-release capsule: 10 mg.
23. PERITONEAL DIALYSIS SOLUTION
Complementary List
intraperitoneal dialysis 
solution (of appropriate 
composition)
Parenteral solution.
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24. MEDICINES FOR MENTAL AND BEHAVIOURAL DISORDERS
24.1 Medicines used in psychotic disorders
 chlorpromazine Injection: 25 mg (hydrochloride)/ml in 2-ml ampoule.
Oral liquid: 25 mg (hydrochloride)/5 ml.
Tablet: 100 mg (hydrochloride).
 fluphenazine Injection: 25 mg (decanoate or enantate) in 
1-ml ampoule.
 haloperidol Injection: 5 mg in 1-ml ampoule.
Tablet: 2 mg; 5 mg.
risperidone Solid oral dosage form: 0.25 mg to 6.0 mg.
Complementary List
chlorpromazine  [c] Injection: 25 mg (hydrochloride)/ml in 2-ml ampoule.
Oral liquid: 25 mg (hydrochloride)/5 ml.
Tablet: 10 mg; 25 mg; 50 mg; 100 mg (hydrochloride).
clozapine Solid oral dosage form: 25 to 200 mg.
haloperidol  [c] Injection: 5 mg in 1-ml ampoule.
Oral liquid: 2 mg/ml.
Solid oral dosage form: 0.5 mg; 2 mg; 5 mg.
24.2 Medicines used in mood disorders
24.2.1 Medicines used in depressive disorders
 amitriptyline Tablet: 25 mg; 75mg. (hydrochloride).
fluoxetine Solid oral dosage form: 20 mg (as hydrochloride).
Complementary List  [c] 
fluoxetine a Solid oral dosage form: 20 mg (as hydrochloride).
a  >8 years.
24.2.2 Medicines used in bipolar disorders
carbamazepine Tablet (scored): 100 mg; 200 mg.
lithium carbonate Solid oral dosage form: 300 mg.
valproic acid 
(sodium valproate)
Tablet (enteric-coated): 200 mg; 500 mg 
(sodium valproate).
24.3 Medicines for anxiety disorders
 diazepam Tablet (scored): 2 mg; 5 mg.
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24. MEDICINES FOR MENTAL AND BEHAVIOURAL DISORDERS (continued)
24.4 Medicines used for obsessive compulsive disorders
clomipramine Capsule: 10 mg; 25 mg (hydrochloride).
24.5 Medicines for disorders due to psychoactive substance use
nicotine replacement 
therapy (NRT)
Chewing gum: 2 mg; 4 mg (as polacrilex).
Transdermal patch: 5 mg to 30 mg/16 hrs; 7 mg to 
21 mg/24 hrs.
Complementary List
 methadone* Concentrate for oral liquid: 5 mg/ml; 10 mg/ml 
(hydrochloride).
Oral liquid: 5 mg/5 ml; 10 mg/5 ml (hydrochloride).
* The square box is added to include buprenorphine. The 
medicines should only be used within an established 
support programme.
25. MEDICINES ACTING ON THE RESPIRATORY TRACT
25.1 Antiasthmatic and medicines for chronic obstructive pulmonary disease
 beclometasone Inhalation (aerosol): 50 micrograms (dipropionate) 
per dose; 100 micrograms (dipropionate) per dose 
(as CFC free forms).
 budesonide  [c] Inhalation (aerosol): 100 micrograms per dose; 
200 micrograms per dose.
epinephrine (adrenaline) Injection: 1 mg (as hydrochloride or hydrogen 
tartrate) in 1-ml ampoule.
ipratropium bromide Inhalation (aerosol): 20 micrograms/metered dose.
 salbutamol Inhalation (aerosol): 100 micrograms (as sulfate) 
per dose.
Injection: 50 micrograms (as sulfate)/ml in 
5-ml ampoule.
Metered dose inhaler (aerosol): 100 micrograms 
(as sulfate) per dose.
Respirator solution for use in nebulizers: 5 mg 
(as sulfate)/ml.
26. SOLUTIONS CORRECTING WATER, ELECTROLYTE AND ACID–BASE 
DISTURBANCES
26.1 Oral
oral rehydration salts See section 17.5.1.
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26. SOLUTIONS CORRECTING WATER, ELECTROLYTE AND ACID–BASE 
DISTURBANCES (continued)
potassium chloride Powder for solution.
26.2 Parenteral
glucose Injectable solution: 5% (isotonic); 10% (hypertonic); 
50% (hypertonic).
glucose with sodium chloride Injectable solution: 4% glucose, 0.18% sodium 
chloride (equivalent to Na+ 30 mmol/L, 
Cl- 30 mmol/L).
Injectable solution: 5% glucose, 0.9% sodium 
chloride (equivalent to Na+ 150 mmol/L and 
Cl- 150 mmol/L); 5% glucose, 0.45% sodium 
chloride (equivalent to Na+ 75 mmol/L and 
Cl- 75 mmol/L)  [c]  .
potassium chloride Solution: 11.2% in 20-ml ampoule (equivalent to 
K+ 1.5 mmol/ml, Cl- 1.5 mmol/ml).
Solution for dilution: 7.5% (equivalent to  
K 1 mmol/ml and Cl 1 mmol/ml)  [c]  ; 15% 
(equivalent to K 2 mmol/ml and Cl 2 mmol/ml)  [c]  .
sodium chloride Injectable solution: 0.9% isotonic (equivalent to 
Na+ 154 mmol/L, Cl- 154 mmol/L).
sodium hydrogen carbonate Injectable solution: 1.4% isotonic (equivalent to 
Na+ 167 mmol/L, HCO3 - 167 mmol/L).
Solution: 8.4% in 10-ml ampoule (equivalent to 
Na+ 1000 mmol/L, HCO3 -1000 mmol/L).
 sodium lactate, 
compound solution
Injectable solution.
26.3 Miscellaneous
water for injection 2-ml; 5-ml; 10-ml ampoules.
27. VITAMINS AND MINERALS
ascorbic acid Tablet: 50 mg.
calcium Tablet: 500 mg (elemental).
cholecalciferol*  [c] Oral liquid: 400 IU/ml.
Solid oral dosage form: 400 IU; 1000 IU.
* Ergocalciferol can be used as an alternative.
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27. VITAMINS AND MINERALS (continued)
 ergocalciferol Oral liquid: 250 micrograms/ml (10 000 IU/ml).
Solid oral dosage form: 1.25 mg (50 000 IU).
iodine Capsule: 200 mg.
Iodized oil: 1 ml (480 mg iodine); 0.5 ml (240 mg 
iodine) in ampoule (oral or injectable); 0.57 ml 
(308 mg iodine) in dispenser bottle.
 nicotinamide Tablet: 50 mg.
pyridoxine Tablet: 25 mg (hydrochloride).
retinol Capsule: 50 000 IU; 100 000 IU; 200 000 IU 
(as palmitate).
Oral oily solution: 100 000 IU (as palmitate)/ml in 
multidose dispenser.
Tablet (sugar-coated): 10 000 IU (as palmitate).
Water-miscible injection: 100 000 IU (as palmitate) 
in 2-ml ampoule.
riboflavin Tablet: 5 mg.
sodium fluoride In any appropriate topical formulation.
thiamine Tablet: 50 mg (hydrochloride).
Complementary List
calcium gluconate Injection: 100 mg/ml in 10-ml ampoule.
28. EAR, NOSE AND THROAT MEDICINES  [c] 
acetic acid Topical: 2%, in alcohol.
 budesonide Nasal spray: 100 micrograms per dose.
 ciprofloxacin Topical: 0.3% drops (as hydrochloride).
 xylometazoline a Nasal spray: 0.05%.
a  Not in children less than 3 months.
29. SPECIFIC MEDICINES FOR NEONATAL CARE
29.1 Medicines administered to the neonate  [c] 
caffeine citrate Injection: 20 mg/ml (equivalent to 10 mg 
caffeine base/ml).
Oral liquid: 20 mg/ml (equivalent to 10 mg 
caffeine base/ml).
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29. SPECIFIC MEDICINES FOR NEONATAL CARE (continued)
Chlorhexidine Solution or gel: 7.1% (digluconate) delivering 4% 
chlorhexidine (for umbilical cord care)  [c]  .
Complementary List
 ibuprofen Solution for injection: 5 mg/ml.
 prostaglandin E Solution for injection:
Prostaglandin E1: 0.5 mg/ml in alcohol.
Prostaglandin E 2: 1 mg/ml.
surfactant Suspension for intratracheal instillation: 25 mg/ml 
or 80 mg/ml.
29.2 Medicines administered to the mother
dexamethasone Injection: 4 mg/ml dexamethasone phosphate (as 
disodium salt).
30. MEDICINES FOR DISEASES OF JOINTS
30.1 Medicines used to treat gout
allopurinol Tablet: 100 mg.
30.2 Disease-modifying agents used in rheumatoid disorders (DMARDs)
chloroquine Tablet: 100 mg; 150 mg (as phosphate or sulfate).
Complementary List
azathioprine Tablet: 50 mg.
hydroxychloroquine  [c] Solid oral dosage form: 200 mg (as sulfate).
methotrexate Tablet: 2.5 mg (as sodium salt).
penicillamine Solid oral dosage form: 250 mg.
sulfasalazine Tablet: 500 mg.
30.3 Juvenile joint diseases
acetylsalicylic acid* (acute or 
chronic use)
Suppository: 50 mg to 150 mg.
Tablet: 100 mg to 500 mg.
* For use for rheumatic fever, juvenile arthritis, 
Kawasaki disease.
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Table 1.1: Medicines with age or weight restrictions
atazanavir >25 kg
atropine >3 months
benzyl benzoate >2 years
betamethasone topical 
preparations
hydrocortisone preferred in neonates
cefazolin >1 month
ceftriaxone >41 weeks corrected gestational age
diloxanide >25 kg 
doxycycline >8 years (except for serious infections e.g. cholera)
efavirenz >3 years or >10 kg 
emtricitabine >3 months
fluoxetine >8 years 
ibuprofen >3 months (except IV form for patent ductus arteriosus)
mefloquine >5 kg or >3 months
metoclopramide Not in neonates
ondansetron >1 month
saquinavir >25 kg 
silver sulfadiazine >2 months
tetracaine Not in preterm neonates
trimethoprim >6 months
xylometazoline >3 months
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Table 1.2: Explanation of dosage forms
A. Principal dosage forms used in EML – oral administration
Term Definition
Solid oral  
dosage form
Refers to tablets or capsules or other solid dosage forms 
such as ‘melts’ that are immediate-release preparations. 
It implies that there is no difference in clinical efficacy or 
safety between the available dosage forms, and countries 
should therefore choose the form(s) to be listed depending 
on quality and availability.
The term ‘solid oral dosage form’ is never intended to allow 
any type of modified-release tablet.
Tablets Refers to:
•	 uncoated or coated (film-coated or sugar-coated) tablets 
that are intended to be swallowed whole;
•	 unscored and scored*;
•	 tablets that are intended to be chewed before being 
swallowed;
•	 tablets that are intended to be dispersed or dissolved in 
water or another suitable liquid before being swallowed;
•	 tablets that are intended to be crushed before being 
swallowed.
The term ‘tablet’ without qualification is never intended to 
allow any type of modified-release tablet.
Tablets (qualified) Refers to a specific type of tablet:
chewable – tablets that are intended to be chewed before 
being swallowed; 
dispersible – tablets that are intended to be dispersed in 
water or another suitable liquid before being swallowed; 
soluble – tablets that are intended to be dissolved in water 
or another suitable liquid before being swallowed; 
crushable – tablets that are intended to be crushed before 
being swallowed; 
scored – tablets bearing a break mark or marks where sub-
division is intended in order to provide doses of less than 
one tablet;
sublingual – tablets that are intended to be placed beneath 
the tongue.
* Scored tablets may be divided for ease of swallowing, provided that dose is a whole number of tablets.
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Term Definition
The term ‘tablet’ is always qualified with an additional term 
(in parentheses) in entries where one of the following 
types of tablet is intended: gastro-resistant (such tablets 
may sometimes be described as enteric-coated or as 
delayed-release), prolonged-release or another modified-
release form.
Capsules Refers to hard or soft capsules.
The term ‘capsule’ without qualification is never intended to 
allow any type of modified-release capsule.
Capsules (qualified) The term ‘capsule’ with qualification refers to gastro-
resistant (such capsules may sometimes be described as 
enteric-coated or as delayed-release), prolonged-release 
or another modified-release form.
Granules Preparations that are issued to patient as granules to be 
swallowed without further preparation, to be chewed, or to 
be taken in or with water or another suitable liquid.
The term ‘granules’ without further qualification is never 
intended to allow any type of modified-release granules.
Oral powder Preparations that are issued to patient as powder (usually 
as single-dose) to be taken in or with water or another 
suitable liquid.
Oral liquid Liquid preparations intended to be swallowed i.e. oral 
solutions, suspensions, emulsions and oral drops, including 
those constituted from powders or granules, but not those 
preparations intended for oromucosal administration 
e.g. gargles and mouthwashes.
Oral liquids presented as powders or granules may offer 
benefits in the form of better stability and lower transport 
costs. If more than one type of oral liquid is available on 
the same market (e.g. solution, suspension, granules for 
reconstitution), they may be interchanged and in such 
cases should be bioequivalent. It is preferable that oral 
liquids do not contain sugar and that solutions for children 
do not contain alcohol.
Table 1.2 continued
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B. Principal dosage forms used in EMLc – parenteral administration
Term Definition
Injection Refers to solutions, suspensions and emulsions including 
those constituted from powders or concentrated 
solutions.
Injection (qualified) Route of administration is indicated in parentheses 
where relevant.
Injection (oily) The term ‘injection’ is qualified by ‘(oily)’ in relevant 
entries.
Intravenous infusion Refers to solutions and emulsions including those 
constituted from powders or concentrated solutions.
C. Other dosage forms
Mode of administration Term to be used
To the eye Eye drops, eye ointments.
Topical For liquids: lotions, paints.
For semi-solids: cream, ointment.
Rectal Suppositories, gel or solution.
Vaginal Pessaries or vaginal tablets.
Inhalation Powder for inhalation, pressurized inhalation, nebulizer.
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Annex 2
4th WHO Model List of Essential Medicines for Children 
(April 2013)
Explanatory notes
This Model List is intended for use for children up to 12 years of age.
The core list presents a list of minimum medicine needs for a basic health-
care system, listing the most efficacious, safe and cost-effective medicines for 
priority conditions. Priority conditions are selected on the basis of current 
and estimated future public health relevance, and potential for safe and cost–
effective treatment.
The complementary list presents essential medicines for priority 
diseases, for which specialized diagnostic or monitoring facilities, and/or 
specialist medical care, and/or specialist training are needed. In case of doubt 
medicines may also be listed as complementary on the basis of consistent higher 
costs or less attractive cost-effectiveness in a variety of settings.
The square box symbol () is primarily intended to indicate similar 
clinical performance within a pharmacological class. The listed medicine should 
be the example of the class for which there is the best evidence for effectiveness 
and safety. In some cases, this may be the first medicine that is licensed for 
marketing; in other instances, subsequently licensed compounds may be safer or 
more effective. Where there is no difference in terms of efficacy and safety data, 
the listed medicine should be the one that is generally available at the lowest 
price, based on international drug price information sources.
Therapeutic equivalence is indicated only on the basis of reviews of 
efficacy and safety and when consistent with WHO clinical guidelines. National 
lists should not use a similar symbol and should be specific in their final 
selection, which would depend on local availability and price.
The format and numbering of the 18th WHO Model List of Essential 
Medicines have been retained but, as indicated in the text, some sections have 
been deleted because they contain medicines that are not relevant for children.
a  indicates that there is an age or weight restriction on use of the 
medicines; the details for each medicine are in Table 1.1 of Annex 1.
The presence of an entry on the Essential Medicines List carries no 
assurance as to pharmaceutical quality. It is the responsibility of the relevant 
national or regional drug regulatory authority to ensure that each product is of 
appropriate pharmaceutical quality (including stability) and that when relevant, 
different products are interchangeable.
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For recommendations and advice concerning all aspects of the quality 
assurance of medicines see the WHO Medicines web site http://www.who.int/
medicines/areas/quality_assurance.
Medicines and dosage forms are listed in alphabetical order within 
each section and there is no implication of preference for one form over 
another. Standard treatment guidelines should be consulted for information on 
appropriate dosage forms.
The main terms used for dosage forms in the Essential Medicines List can 
be found in Table 1.2 of Annex 1.
Definitions of many of these terms and pharmaceutical quality 
requirements applicable to the different categories are published in the current 
edition of The International Pharmacopoeia http://www.who.int/medicines/
publications/pharmacopoeia.
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1. ANAESTHETICS
1.1 General anaesthetics and oxygen
1.1.1 Inhalational medicines
halothane Inhalation.
isoflurane Inhalation.
nitrous oxide Inhalation.
oxygen Inhalation (medicinal gas).
1.1.2 Injectable medicines
ketamine Injection: 50 mg (as hydrochloride)/ml in 10-ml vial.
propofol * Injection: 10 mg/ml; 20 mg/ml.
* Thiopental may be used as an alternative depending on 
local availability and cost.
1.2 Local anaesthetics
 bupivacaine Injection: 0.25%; 0.5% (hydrochloride) in vial.
Injection for spinal anaesthesia: 0.5% 
(hydrochloride) in 4-ml ampoule to be mixed with 
7.5% glucose solution.
 lidocaine Injection: 1%; 2% (hydrochloride) in vial.
Injection for spinal anaesthesia: 5% (hydrochloride) 
in 2-ml ampoule to be mixed with 7.5% glucose 
solution.
Topical forms: 2% to 4% (hydrochloride). 
lidocaine + epinephrine 
(adrenaline)
Dental cartridge: 2% (hydrochloride) + epinephrine 
1:80 000.
Injection: 1%; 2% (hydrochloride or sulfate) + 
epinephrine 1:200 000 in vial.
1.3 Preoperative medication and sedation for short-term procedures 
atropine Injection: 1 mg (sulfate) in 1-ml ampoule.
 midazolam Injection: 1 mg/ml.
Oral liquid: 2 mg/ml.
Tablet: 7.5 mg; 15 mg.
morphine Injection: 10 mg (sulfate or hydrochloride) in 
1-ml ampoule.
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2. MEDICINES FOR PAIN AND PALLIATIVE CARE
2.1 Non-opioids and non-steroidal anti-inflammatory medicines (NSAIMs)
ibuprofen a Oral liquid: 200 mg/5 ml.
Tablet: 200 mg; 400 mg; 600 mg.
a  Not in children less than 3 months.
paracetamol* Oral liquid: 125 mg/5 ml.
Suppository: 100 mg.
Tablet: 100 mg to 500 mg.
* Not recommended for anti-inflammatory use due to lack of 
proven benefit to that effect.
2.2 Opioid analgesics
 morphine* Granules (slow release; to mix with water): 20 mg 
to 200 mg (morphine sulfate).
Injection: 10 mg (morphine hydrochloride or 
morphine sulfate) in 1-ml ampoule.
Oral liquid: 10 mg (morphine hydrochloride or 
morphine sulfate)/5 ml.
Tablet (slow release): 10 mg – 200mg (morphine 
hydrochloride or morphine sulfate).
Tablet (immediate release): 10 mg (morphine 
sulfate).
* Alternatives limited to hydromorphone and oxycodone.
2.3 Medicines for other symptoms common in palliative care
amitriptyline Tablet: 10 mg; 25 mg.
cyclizine Injection: 50 mg/ml.
Tablet: 50 mg.
dexamethasone Injection: 4 mg/ml in 1-ml ampoule (as disodium 
phosphate salt).
Oral liquid: 2 mg/5 ml.
Tablet: 2 mg.
diazepam Injection: 5 mg/ml.
Oral liquid: 2 mg/5 ml.
Rectal solution: 2.5 mg; 5 mg; 10 mg.
Tablet: 5 mg; 10 mg.
docusate sodium Capsule: 100 mg. 
Oral liquid: 50 mg/5 ml.
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2. MEDICINES FOR PAIN AND PALLIATIVE CARE (continued)
fluoxetine a Solid oral dosage form: 20 mg (as hydrochloride).
a  >8 years.
hyoscine hydrobromide Injection: 400 micrograms/ml; 600 micrograms/ml.
Transdermal patches: 1 mg/72 hours.
lactulose Oral liquid: 3.1–3.7 g/5 ml.
midazolam Injection: 1 mg/ml; 5 mg/ml.
Oral liquid: 2mg/ml.
Solid oral dosage form: 7.5 mg; 15 mg.
ondansetron a Injection: 2 mg base/ml in 2-ml ampoule 
(as hydrochloride).
Oral liquid: 4 mg base/5 ml.
Solid oral dosage form: Eq 4 mg base; Eq 8 mg base.
a  >1 month.
senna Oral liquid: 7.5 mg/5 ml. 
3. ANTIALLERGICS AND MEDICINES USED IN ANAPHYLAXIS
dexamethasone Injection: 4 mg/ml in 1-ml ampoule (as disodium 
phosphate salt).
epinephrine (adrenaline) Injection: 1 mg (as hydrochloride or hydrogen 
tartrate) in 1-ml ampoule.
hydrocortisone Powder for injection: 100 mg (as sodium succinate) 
in vial.
 loratadine * Oral liquid: 1 mg/ml.
Tablet: 10 mg.
* There may be a role for sedating antihistamines for limited 
indications.
 prednisolone Oral liquid: 5 mg/ml.
Tablet: 5 mg; 25 mg.
4. ANTIDOTES AND OTHER SUBSTANCES USED IN POISONINGS
4.1 Non-specific
charcoal, activated Powder.
4.2 Specific 
acetylcysteine Injection: 200 mg/ml in 10-ml ampoule.
Oral liquid: 10%; 20%.
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4. ANTIDOTES AND OTHER SUBSTANCES USED IN POISONINGS (continued)
atropine Injection: 1 mg (sulfate) in 1-ml ampoule.
calcium gluconate Injection: 100 mg/ml in 10-ml ampoule.
naloxone Injection: 400 micrograms (hydrochloride) in 
1-ml ampoule.
Complementary List
deferoxamine Powder for injection: 500 mg (mesilate) in vial.
dimercaprol Injection in oil: 50 mg/ml in 2-ml ampoule.
fomepizole Injection: 5 mg/ml (sulfate) in 20-ml ampoule or  
1 g/ml (base) in 1.5-ml ampoule.
sodium calcium edetate Injection: 200 mg/ml in 5-ml ampoule.
succimer Solid oral dosage form: 100 mg.
5. ANTICONVULSANTS/ANTIEPILEPTICS 
carbamazepine Oral liquid: 100 mg/5 ml.
Tablet (chewable): 100 mg; 200 mg.
Tablet (scored): 100 mg; 200 mg.
diazepam Gel or rectal solution: 5 mg/ml in 0.5 ml; 2-ml; 
4-ml tubes.
 lorazepam Parenteral formulation: 2 mg/ml in 1-ml ampoule; 
4 mg/ml in 1-ml ampoule.
phenobarbital Injection: 200 mg/ml (sodium).
Oral liquid: 15 mg/5 ml. 
Tablet: 15 mg to 100 mg.
phenytoin Injection: 50 mg/ml in 5-ml vial (sodium salt).
Oral liquid: 25 mg to 30 mg/5 ml.*
Solid oral dosage form: 25 mg; 50 mg; 100 mg 
(sodium salt).
Tablet (chewable): 50 mg.
* The presence of both 25 mg/5 ml and 30 mg/5 ml strengths 
on the same market would cause confusion in prescribing 
and dispensing and should be avoided.
valproic acid 
(sodium valproate)
Oral liquid: 200 mg/5 ml.
Tablet (crushable): 100 mg.
Tablet (enteric-coated): 200 mg; 500 mg 
(sodium valproate).
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5. ANTICONVULSANTS/ANTIEPILEPTICS (continued)
Complementary List
ethosuximide Capsule: 250 mg.
Oral liquid: 250 mg/5 ml.
6. ANTI-INFECTIVE MEDICINES
6.1 Anthelminthics 
6.1.1 Intestinal anthelminthics 
albendazole Tablet (chewable): 400 mg.
levamisole Tablet: 50 mg; 150 mg (as hydrochloride).
mebendazole Tablet (chewable): 100 mg; 500 mg.
niclosamide Tablet (chewable): 500 mg.
praziquantel Tablet: 150 mg; 600 mg.
pyrantel Oral liquid: 50 mg (as embonate or pamoate)/ml.
Tablet (chewable): 250 mg (as embonate or pamoate).
6.1.2 Antifilarials
albendazole Tablet (chewable): 400 mg.
diethylcarbamazine Tablet: 50 mg; 100 mg (dihydrogen citrate).
ivermectin Tablet (scored): 3 mg.
6.1.3 Antischistosomals and other antitrematode medicines 
praziquantel Tablet: 600 mg.
triclabendazole Tablet: 250 mg.
Complementary List
oxamniquine* Capsule: 250 mg.
Oral liquid: 250 mg/5 ml.
* Oxamniquine is listed for use when praziquantel treatment fails.
6.2 Antibacterials
6.2.1 Beta lactam medicines
amoxicillin Powder for oral liquid: 125 mg (as trihydrate)/5 ml; 
250 mg (as trihydrate)/5 ml.
Solid oral dosage form: 250 mg; 500 mg 
(as trihydrate).
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6. ANTI-INFECTIVE MEDICINES (continued)
amoxicillin + clavulanic acid Oral liquid: 125 mg amoxicillin + 31.25 mg 
clavulanic acid/5 ml AND 250 mg amoxicillin + 
62.5 mg clavulanic acid/5 ml.
Tablet: 500 mg (as trihydrate) + 125 mg (as 
potassium salt).
ampicillin Powder for injection: 500 mg; 1 g (as sodium salt) 
in vial.
benzathine benzylpenicillin Powder for injection: 900 mg benzylpenicillin 
(= 1.2 million IU) in 5-ml vial; 1.44 g benzylpenicillin 
(= 2.4 million IU) in 5-ml vial.
benzylpenicillin Powder for injection: 600 mg (= 1 million IU); 
3 g (= 5 million IU) (sodium or potassium salt) in vial.
cefalexin Powder for reconstitution with water: 125 mg/5 ml; 
250 mg/5 ml (anhydrous).
Solid oral dosage form: 250 mg (as monohydrate).
 cefazolin* a Powder for injection: 1 g (as sodium salt) in vial.
* For surgical prophylaxis.
a  >1 month.
ceftriaxone* a Powder for injection: 250 mg; 1 g (as sodium salt) 
in vial.
* Do not administer with calcium and avoid in infants with 
hyperbilirubinaemia.
a  >41 weeks corrected gestational age.
 cloxacillin Capsule: 500 mg; 1 g (as sodium salt).
Powder for injection: 500 mg (as sodium salt) in vial.
Powder for oral liquid: 125 mg (as sodium salt)/5 ml.
phenoxymethylpenicillin Powder for oral liquid: 250 mg (as potassium 
salt)/5 ml.
Tablet: 250 mg (as potassium salt).
procaine benzylpenicillin* Powder for injection: 1 g (=1 million IU); 3 g 
(=3 million IU) in vial.
* Procaine benzylpenicillin is not recommended as first-line 
treatment for neonatal sepsis except in settings with high 
neonatal mortality, when given by trained health workers in 
cases where hospital care is not achievable. 
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6. ANTI-INFECTIVE MEDICINES (continued)
Complementary List
cefotaxime* Powder for injection: 250 mg per vial (as sodium salt).
* 3rd generation cephalosporin of choice for use in 
hospitalized neonates.
ceftazidime Powder for injection: 250 mg or 1 g (as pentahydrate) 
in vial.
imipenem* + cilastatin* Powder for injection: 250 mg (as monohydrate) + 
250 mg (as sodium salt); 500 mg (as monohydrate) + 
500 mg (as sodium salt) in vial.
* Only listed for the treatment of life-threatening hospital-
based infection due to suspected or proven multidrug-
resistant infection. Meropenem is indicated for the treatment 
of meningitis and is licensed for use in children over the age of 
3 months.
6.2.2 Other antibacterials
azithromycin* Capsule: 250 mg; 500 mg (anhydrous).
Oral liquid: 200 mg/5 ml.
* Listed only for trachoma.
chloramphenicol Capsule: 250 mg.
Oily suspension for injection*: 0.5 g (as sodium 
succinate)/ml in 2-ml ampoule.
* Only for the presumptive treatment of epidemic meningitis 
in children older than 2 years.
Oral liquid: 150 mg (as palmitate)/5 ml.
Powder for injection: 1 g (sodium succinate) in vial.
ciprofloxacin Oral liquid: 250 mg/5 ml (anhydrous).
Solution for IV infusion: 2 mg/ml (as hyclate).
Tablet: 250 mg (as hydrochloride).
doxycycline a Oral liquid: 25 mg/5 ml; 50 mg/5 ml (anhydrous).
Solid oral dosage form: 50 mg; 100 mg (as hyclate).
a  Use in children <8 years only for life-threatening infections 
when no alternative exists.
erythromycin Powder for oral liquid: 125 mg/5 ml (as stearate or 
estolate or ethyl succinate).
Solid oral dosage form: 250 mg (as stearate or 
estolate or ethyl succinate). 
 gentamicin Injection: 10 mg; 40 mg (as sulfate)/ml in 2-ml vial.
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6. ANTI-INFECTIVE MEDICINES (continued)
metronidazole Injection: 500 mg in 100-ml vial.
Oral liquid: 200 mg (as benzoate)/5 ml.
Tablet: 200 mg to 500 mg.
nitrofurantoin Oral liquid: 25 mg/5 ml.
Tablet: 100 mg.
sulfamethoxazole + 
trimethoprim
Injection:
80 mg + 16 mg/ml in 5-ml ampoule;
80 mg + 16 mg/ml in 10-ml ampoule.
Oral liquid: 200 mg + 40 mg/5 ml.
Tablet: 100 mg + 20 mg; 400 mg + 80 mg.
trimethoprim a Oral liquid: 50 mg/5 ml.
Tablet: 100 mg; 200 mg.
a  >6 months.
Complementary List  
clindamycin Capsule: 150 mg (as hydrochloride).
Injection: 150 mg (as phosphate)/ml.
Oral liquid: 75 mg/5 ml (as palmitate).
vancomycin Powder for injection: 250 mg (as hydrochloride) in vial.
6.2.3 Antileprosy medicines
Medicines used in the treatment of leprosy should never be used except in combination. 
Combination therapy is essential to prevent the emergence of drug resistance. 
Colour-coded blister packs (MDT blister packs) containing standard two-medicine 
(paucibacillary leprosy) or three-medicine (multibacillary leprosy) combinations for 
adult and childhood leprosy should be used. MDT blister packs can be supplied free 
of charge through WHO.
clofazimine Capsule: 50 mg; 100 mg.
dapsone Tablet: 25 mg; 50 mg; 100 mg.
rifampicin Solid oral dosage form: 150 mg; 300 mg.
6.2.4 Antituberculosis medicines
WHO recommends and endorses the use of fixed-dose combinations and the 
development of appropriate new fixed-dose combinations, including modified 
dosage forms, non-refrigerated products and paediatric dosage forms of assured 
pharmaceutical quality.
ethambutol Oral liquid: 25 mg/ml.
Tablet: 100 mg; 400 mg (hydrochloride).
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6. ANTI-INFECTIVE MEDICINES (continued)
isoniazid Oral liquid: 50 mg/5 ml.
Tablet: 100 mg to 300 mg.
Tablet (scored): 50 mg. 
pyrazinamide Oral liquid: 30 mg/ml.
Tablet: 400 mg.
Tablet (dispersible): 150 mg.
Tablet (scored): 150 mg.
rifampicin Oral liquid: 20 mg/ml.
Solid oral dosage form: 150 mg; 300 mg.
Complementary List
Reserve second-line drugs for the treatment of multidrug-resistant tuberculosis (MDR-TB) 
should be used in specialized centres adhering to WHO standards for TB control. 
amikacin Powder for injection: 100 mg; 500 mg; 1 g (as sulfate) 
in vial.
capreomycin Powder for injection: 1 g (as sulfate) in vial.
cycloserine Solid oral dosage form: 250 mg.
ethionamide* Tablet: 125 mg; 250 mg.
* Protionamide may be used as an alternative.
kanamycin Powder for injection: 1 g (as sulfate) in vial.
levofloxacin* Tablet: 250 mg: 500 mg.
* Ofloxacin and moxifloxacin may be used as alternatives based 
on availability and programme considerations.
p-aminosalicylic acid Granules: 4 g in sachet.
Tablet: 500 mg.
streptomycin Powder for injection: 1 g (as sulfate) in vial.
6.3 Antifungal medicines
amphotericin B Powder for injection: 50 mg in vial (as sodium 
deoxycholate or liposomal complex).
 fluconazole Capsule: 50 mg.
Injection: 2 mg/ml in vial.
Oral liquid: 50 mg/5 ml.
flucytosine Capsule: 250 mg.
Infusion: 2.5 g in 250 ml.
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6. ANTI-INFECTIVE MEDICINES (continued)
griseofulvin Oral liquid: 125 mg/5 ml.
Solid oral dosage form: 125 mg; 250 mg.
nystatin Lozenge: 100 000 IU.
Oral liquid: 50 mg/5 ml; 100 000 IU/ml.
Tablet: 100 000 IU; 500 000 IU.
Complementary List
potassium iodide Saturated solution.
6.4 Antiviral medicines
6.4.1 Antiherpes medicines
aciclovir Oral liquid: 200 mg/5 ml.
Powder for injection: 250 mg (as sodium salt) in vial.
Tablet: 200 mg.
6.4.2 Antiretrovirals
Based on current evidence and experience of use, medicines in the following three 
classes of antiretrovirals are included as essential medicines for treatment and 
prevention of HIV (prevention of mother-to-child transmission and post-exposure 
prophylaxis). WHO emphasizes the importance of using these products in accordance 
with global and national guidelines. WHO recommends and endorses the use of fixed-
dose combinations and the development of appropriate new fixed-dose combinations, 
including modified dosage forms, non-refrigerated products and paediatric dosage 
forms of assured pharmaceutical quality. 
Scored tablets can be used in children and therefore can be considered for inclusion 
in the listing of tablets, provided that adequate quality products are available.
6.4.2.1 Nucleoside/Nucleotide reverse transcriptase inhibitors
abacavir (ABC) Oral liquid: 100 mg (as sulfate)/5 ml.
Tablet: 300 mg (as sulfate).
didanosine (ddI) Buffered powder for oral liquid: 100-mg; 167-mg; 
250-mg packets.
Capsule (unbuffered enteric-coated): 125 mg; 
200 mg; 250 mg; 400 mg.
Tablet (buffered chewable, dispersible): 25 mg; 
50 mg; 100 mg; 150 mg; 200 mg.
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6. ANTI-INFECTIVE MEDICINES (continued)
emtricitabine (FTC)* a Capsule: 200 mg.
Oral liquid: 10 mg/ml.
* FTC is an acceptable alternative to 3TC, based on 
knowledge of the pharmacology, the resistance patterns 
and clinical trials of antiretrovirals.
a  >3 months.
lamivudine (3TC) Oral liquid: 50 mg/5 ml.
Tablet: 150 mg.
stavudine (d4T) Capsule: 15 mg; 20 mg; 30 mg.
Powder for oral liquid: 5 mg/5 ml.
zidovudine (ZDV or AZT) Capsule: 100 mg; 250 mg.
Oral liquid: 50 mg/5 ml.
Solution for IV infusion injection: 10 mg/ml in 
20-ml vial.
Tablet: 300 mg.
6.4.2.2 Non‑nucleoside reverse transcriptase inhibitors
efavirenz (EFV or EFZ) a Capsule: 50 mg; 100 mg; 200 mg.
Oral liquid: 150 mg/5 ml.
Tablet: 600 mg.
a  >3 years or >10 kg.
nevirapine (NVP) Oral liquid: 50 mg/5 ml.
Tablet: 200 mg.
6.4.2.3 Protease inhibitors
Selection of protease inhibitor(s) from the Model List will need to be determined by 
each country after consideration of international and national treatment guidelines 
and experience. Ritonavir is recommended for use in combination as a pharmacological 
booster, and not as an antiretroviral in its own right. All other protease inhibitors should 
be used in boosted forms (e.g. with ritonavir).
atazanavir a Solid oral dosage form: 100 mg; 150 mg; 300 mg 
(as sulfate).
a  >25 kg.
lopinavir + ritonavir (LPV/r) Capsule: 133.3 mg + 33.3 mg. 
Oral liquid: 400 mg + 100 mg/5 ml.  
Tablet (heat stable): 100 mg + 25 mg; 
200 mg + 50 mg.
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6. ANTI-INFECTIVE MEDICINES (continued)
ritonavir Oral liquid: 400 mg/5 ml.
Solid oral dosage form: 100 mg.
Tablet (heat stable): 25 mg; 100 mg.
saquinavir (SQV) a Solid oral dosage form: 200 mg (as mesilate).
a  >25 kg.
FIXED‑DOSE COMBINATIONS
lamivudine + nevirapine + 
stavudine 
Tablet: 150 mg + 200 mg + 30 mg.
Tablet (dispersible): 30 mg + 50 mg + 6 mg; 60 mg + 
100 mg + 12 mg.
lamivudine + nevirapine + 
zidovudine
Tablet: 30 mg + 50 mg + 60 mg; 150 mg + 200 mg + 
300 mg.
lamivudine + zidovudine Tablet: 30 mg + 60 mg; 150 mg + 300 mg.
6.4.3 Other antivirals
oseltamivir* Capsule: 30 mg; 45 mg; 75 mg (as phosphate).
Oral powder: 12 mg/ml.
* Potentially severe or complicated illness due to confirmed 
or suspected influenza virus infection in accordance with 
WHO treatment guidelines.
ribavirin* Injection for intravenous administration: 800 mg 
and 1 g in 10-ml phosphate buffer solution.
Solid oral dosage form: 200 mg; 400 mg; 600 mg.
* For the treatment of viral haemorrhagic fevers only.
6.5 Antiprotozoal medicines
6.5.1 Antiamoebic and antigiardiasis medicines
diloxanide a Tablet: 500 mg (furoate).
a  >25 kg.
 metronidazole Injection: 500 mg in 100-ml vial.
Oral liquid: 200 mg (as benzoate)/5 ml.
Tablet: 200 mg to 500 mg.
6.5.2 Antileishmaniasis medicines 
amphotericin B Powder for injection: 50 mg in vial.
As sodium deoxycholate or liposomal complex. 
miltefosine Solid oral dosage form: 10 mg; 50 mg.
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6. ANTI-INFECTIVE MEDICINES (continued)
paromomycin Solution for intramuscular injection: 750 mg of 
paromomycin base (as the sulfate).
sodium stibogluconate or 
meglumine antimoniate
Injection: 100 mg/ml, 1 vial = 30 ml or 30%, 
equivalent to approximately 8.1% antimony 
(pentavalent) in 5-ml ampoule. 
6.5.3 Antimalarial medicines
6.5.3.1 For curative treatment
Medicines for the treatment of P. falciparum malaria cases should be used in 
combination. The list currently recommends combinations according to treatment 
guidelines. WHO recognizes that not all of the fixed dose combinations (FDCs) in the 
WHO treatment guidelines exist, and encourages their development and rigorous 
testing. WHO also encourages development and testing of rectal dosage formulations.
amodiaquine* Tablet: 153 mg or 200 mg (as hydrochloride).
* To be used in combination with artesunate 50 mg.
artemether* Oily injection: 80 mg/ml in 1-ml ampoule.
* For use in the management of severe malaria.
artemether + lumefantrine* Tablet: 20 mg + 120 mg.
Tablet (dispersible): 20 mg + 120 mg.
* Not recommended in the first trimester of pregnancy or in 
children below 5 kg.
artesunate* Injection: ampoules, containing 60 mg anhydrous 
artesunic acid with a separate ampoule of 5% 
sodium bicarbonate solution.
For use in the management of severe malaria.
Rectal dosage form: 50 mg; 200 mg capsules 
(for pre-referral treatment of severe malaria only; 
patients should be taken to an appropriate health 
facility for follow-up care).
Tablet: 50 mg.
* To be used in combination with either amodiaquine, 
mefloquine or sulfadoxine + pyrimethamine.
artesunate + amodiaquine* Tablet: 25 mg + 67.5 mg; 50 mg + 135 mg; 100 mg + 
270 mg.
* Other combinations that deliver the target doses required 
such as 153 mg or 200 mg (as hydrochloride) with 50 mg 
artesunate can be alternatives.
artesunate + mefloquine Tablet: 25 mg + 55 mg; 100 mg + 220 mg.
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6. ANTI-INFECTIVE MEDICINES (continued)
chloroquine* Oral liquid: 50 mg (as phosphate or sulfate)/5 ml.
Tablet: 100 mg; 150 mg (as phosphate or sulfate).
* For use only for the treatment of P. vivax infection.
doxycycline* Capsule: 100 mg (as hydrochloride or hyclate).
Tablet (dispersible): 100 mg (as monohydrate).
* For use only in combination with quinine.
mefloquine* Tablet: 250 mg (as hydrochloride). 
* To be used in combination with artesunate 50 mg.
primaquine* Tablet: 7.5 mg; 15 mg (as diphosphate).
* Only for use to achieve radical cure of P. vivax and P. ovale 
infections, given for 14 days.
quinine* Injection: 300 mg quinine hydrochloride/ml in 
2-ml ampoule.
Tablet: 300 mg (quinine sulfate) or 300 mg (quinine 
bisulfate).
* For use only in the management of severe malaria, and 
should be used in combination with doxycycline.
sulfadoxine + pyrimethamine* Tablet: 500 mg + 25 mg.
* Only in combination with artesunate 50 mg.
6.5.3.2 For prophylaxis
chloroquine* Oral liquid: 50 mg (as phosphate or sulfate)/5 ml.
Tablet: 150 mg (as phosphate or sulfate).
* For use only for the treatment of P. vivax infection.
doxycycline a Solid oral dosage form: 100 mg (as hydrochloride 
or hyclate).
a  >8 years.
mefloquine a Tablet: 250 mg (as hydrochloride).
a  >5 kg or >3 months.
proguanil* Tablet: 100 mg (as hydrochloride).
* For use only in combination with chloroquine.
6.5.4 Antipneumocystosis and antitoxoplasmosis medicines
pyrimethamine Tablet: 25 mg.
sulfadiazine Tablet: 500 mg.
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6. ANTI-INFECTIVE MEDICINES (continued)
sulfamethoxazole + 
trimethoprim
Injection:
80 mg + 16 mg/ml in 5-ml ampoule;
80 mg + 16 mg/ml in 10-ml ampoule.
Oral liquid: 200 mg + 40 mg/5 ml.
Tablet: 100 mg + 20 mg; 400 mg + 80 mg.
6.5.5 Antitrypanosomal medicines
6.5.5.1 African trypanosomiasis
Medicines for the treatment of 1st stage African trypanosomiasis.
pentamidine* Powder for injection: 200 mg (as isetionate) in vial.
* To be used for the treatment of Trypanosoma brucei 
gambiense infection.
suramin sodium* Powder for injection: 1 g in vial.
* To be used for the treatment of the initial phase of 
Trypanosoma brucei rhodesiense infection.
Medicines for the treatment of 2nd stage African trypanosomiasis
eflornithine* Injection: 200 mg (hydrochloride)/ml in 100-ml bottle.
* To be used for the treatment of Trypanosoma brucei 
gambiense infection.
nifurtimox* Tablet: 120 mg.
* Only to be used in combination with eflornithine, for the 
treatment of Trypanosoma brucei gambiense infection.
Complementary List
melarsoprol Injection: 3.6% solution in 5-ml ampoule (180 mg of 
active compound).
6.5.5.2 American trypanosomiasis
benznidazole Tablet: 12.5 mg; 100 mg.
Tablet (scored): 50 mg.
nifurtimox Tablet: 30 mg; 120 mg; 250 mg.
7. ANTIMIGRAINE MEDICINES
7.1 For treatment of acute attack 
ibuprofen Tablet: 200 mg; 400 mg.
paracetamol Oral liquid: 125 mg/5 ml.
Tablet: 300 mg to 500 mg.
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7. ANTIMIGRAINE MEDICINES (continued)
7.2 For prophylaxis
propranolol Tablet: 20 mg; 40 mg (hydrochloride).
8. ANTINEOPLASTICS AND IMMUNOSUPPRESSIVES 
8.1 Immunosuppressive medicines
Complementary List
azathioprine Powder for injection: 100 mg (as sodium salt) in vial.
Tablet (scored): 50 mg.
ciclosporin Capsule: 25 mg.
Concentrate for injection: 50 mg/ml in 1-ml ampoule 
for organ transplantation.
8.2 Cytotoxic and adjuvant medicines
Medicines listed below should be used according to protocols for treatment of 
the diseases.
Complementary List
ACUTE LYMPHOBLASTIC LEUKAEMIA
STEP 1
asparaginase Powder for injection: 10 000 IU in vial.
dexamethasone Oral liquid: 2 mg/5 ml.
mercaptopurine Tablet: 50 mg.
methotrexate Powder for injection: 50 mg (as sodium salt) in vial.
Tablet: 2.5 mg (as sodium salt).
methylprednisolone Injection: 40 mg/ml (as sodium succinate) in 1-ml 
single dose vial and 5-ml multidose vials; 80 mg/ml 
(as sodium succinate) in 1-ml single dose vial.
prednisolone Oral liquid: 5 mg/ml. 
vincristine Powder for injection: 1 mg; 5 mg (sulfate) in vial.
STEP 2
cyclophosphamide Powder for injection: 500 mg in vial.
cytarabine Powder for injection: 100 mg in vial.
daunorubicin Powder for injection: 50 mg (hydrochloride) in vial.
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8. ANTINEOPLASTICS AND IMMUNOSUPPRESSIVES (continued)
doxorubicin Powder for injection: 10 mg; 50 mg (hydrochloride) 
in vial.
hydrocortisone Powder for injection: 100 mg (as sodium succinate) 
in vial.
methotrexate Powder for injection: 50 mg (as sodium salt) in vial.
tioguanine Solid oral dosage form: 40 mg.
WILMS TUMOUR (NEPHROBLASTOMA)
STEP 1 & STEP 2
dactinomycin Powder for injection: 500 micrograms in vial.
daunorubicin Powder for injection: 50 mg (hydrochloride) in vial.
vincristine Powder for injection: 1 mg; 5 mg (sulfate) in vial.
BURKITT LYMPHOMA
STEP 1 & STEP 2
cyclophosphamide Powder for injection: 500 mg in vial.
cytarabine Powder for injection: 100 mg in vial.
doxorubicin Powder for injection: 10 mg; 50 mg (hydrochloride) in 
vial.
prednisolone Oral liquid: 5 mg/ml. 
vincristine Powder for injection: 1 mg; 5 mg (sulfate) in vial.
ADJUVANT MEDICINES
allopurinol Tablet: 100 mg; 300 mg.
mesna Injection: 100 mg/ml in 4-ml and 10-ml ampoules.
Tablet: 400 mg; 600 mg. 
 8.3 Hormones and antihormones 
 9. ANTIPARKINSONISM MEDICINES  
10. MEDICINES AFFECTING THE BLOOD
10.1 Antianaemia medicines 
ferrous salt Oral liquid: equivalent to 25 mg iron (as sulfate)/ml.
Tablet: equivalent to 60 mg iron.
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10. MEDICINES AFFECTING THE BLOOD (continued)
folic acid Tablet: 1 mg; 5 mg.
hydroxocobalamin Injection: 1 mg (as acetate, as hydrochloride or as 
sulfate) in 1-ml ampoule.
10.2 Medicines affecting coagulation 
phytomenadione Injection: 1 mg/ml; 10 mg/ml in 5-ml ampoule.
Tablet: 10 mg.
Complementary List
heparin sodium Injection: 1000 IU/ml; 5000 IU/ml in 1-ml ampoule.
protamine sulfate Injection: 10 mg/ml in 5-ml ampoule.
 warfarin Tablet: 0.5 mg; 1 mg; 2 mg; 5 mg (sodium salt).
10.3 Other medicines for haemoglobinopathies
Complementary List
deferoxamine* Powder for injection: 500 mg (mesilate) in vial.
* Deferasirox oral form may be an alternative, depending on 
cost and availability.
hydroxycarbamide Solid oral dosage form: 200 mg; 500 mg; 1 g.
11. BLOOD PRODUCTS OF HUMAN ORIGIN AND PLASMA SUBSTITUTES
11.1 Blood and blood components
In accordance with the World Health Assembly resolution WHA63.12, WHO recognizes 
that achieving self-sufficiency, unless special circumstances preclude it, in the supply of 
safe blood components based on voluntary, non-remunerated blood donation, and the 
security of that supply are important national goals to prevent blood shortages and 
meet the transfusion requirements of the patient population. All preparations should 
comply with the WHO requirements.
fresh–frozen plasma
platelets
red blood cells
whole blood
11.2 Plasma-derived medicinal products
All human plasma-derived medicines should comply with the WHO requirements.
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11. BLOOD PRODUCTS OF HUMAN ORIGIN AND PLASMA SUBSTITUTES (continued)
11.2.1 Human immunoglobulins
Complementary List
human normal 
immunoglobulin
Intramuscular administration: 16% protein solution.*
Intravenous administration: 5%; 10% protein 
solution.**
Subcutaneous administration: 15%; 16% protein 
solution.*
* Indicated for primary immune deficiency.
** Indicated for primary immune deficiency and Kawasaki disease.
11.2.2 Blood coagulation factors
Complementary List
 coagulation factor VIII Powder for injection: 500 IU/vial.
 coagulation factor IX Powder for injection: 500 IU/vial, 1000 IU/vial.
11.3 Plasma substitutes
 dextran 70*
Injectable solution: 6%.
* Polygeline, injectable solution, 3.5% is considered 
as equivalent.
12. CARDIOVASCULAR MEDICINES
 12.1 Antianginal medicines 
 12.2 Antiarrhythmic medicines 
12.3 Antihypertensive medicines 
 enalapril Tablet: 2.5 mg; 5 mg (as hydrogen maleate).
12.4 Medicines used in heart failure 
digoxin Injection: 250 micrograms/ml in 2-ml ampoule.
Oral liquid: 50 micrograms/ml.
Tablet: 62.5 micrograms; 250 micrograms.
furosemide Injection: 10 mg/ml in 2-ml ampoule.
Oral liquid: 20 mg/5 ml.
Tablet: 40 mg.
Complementary List
dopamine Injection: 40 mg (hydrochloride) in 5-ml vial.
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12. CARDIOVASCULAR MEDICINES (continued)
 12.5 Antithrombotic medicines 
12.6 Lipid-lowering agents
13. DERMATOLOGICAL MEDICINES (topical) 
13.1 Antifungal medicines
 miconazole Cream or ointment: 2% (nitrate).
terbinafine Cream: 1% or Ointment: 1% terbinafine 
hydrochloride.
13.2 Anti-infective medicines
mupirocin Cream (as mupirocin calcium): 2%.
Ointment: 2%.
potassium permanganate Aqueous solution: 1:10 000.
silver sulfadiazine a Cream: 1%.
a  >2 months.
13.3 Anti-inflammatory and antipruritic medicines
 betamethasone a Cream or ointment: 0.1% (as valerate).
a  Hydrocortisone preferred in neonates.
calamine Lotion.
hydrocortisone Cream or ointment: 1% (acetate).
13.4 Medicines affecting skin differentiation and proliferation
benzoyl peroxide Cream or lotion: 5%.
coal tar Solution: 5%.
 podophyllum resin Solution: 10% to 25%.
salicylic acid Solution: 5%.
urea Cream or ointment: 5%; 10%.
13.5 Scabicides and pediculicides
 benzyl benzoate a Lotion: 25%.
a  >2 years.
permethrin Cream: 5%.
Lotion: 1%.
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14. DIAGNOSTIC AGENTS
14.1 Ophthalmic medicines
fluorescein Eye drops: 1% (sodium salt).
 tropicamide Eye drops: 0.5%.
14.2 Radiocontrast media
Complementary List
barium sulfate Aqueous suspension.
15. DISINFECTANTS AND ANTISEPTICS
15.1 Antiseptics
 chlorhexidine Solution: 5% (digluconate).
Gel: 4%.
 ethanol Solution: 70% (denatured).
 povidone iodine Solution: 10% (equivalent to 1% available iodine).
15.2 Disinfectants 
 chlorine base compound Powder: (0.1% available chlorine) for solution.
 chloroxylenol Solution: 4.8%.
glutaral Solution: 2%.
16. DIURETICS
furosemide Injection: 10 mg/ml in 2-ml ampoule.
Oral liquid: 20 mg/5 ml.
Tablet: 10 mg; 20 mg; 40 mg.
Complementary List
 hydrochlorothiazide Tablet (scored): 25 mg.
mannitol Injectable solution: 10%; 20%.
spironolactone Oral liquid: 5 mg/5 ml; 10 mg/5 ml; 25 mg/5 ml.
Tablet: 25 mg.
17. GASTROINTESTINAL MEDICINES
Complementary List
 pancreatic enzymes Age-appropriate formulations and doses including 
lipase, protease and amylase.
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17. GASTROINTESTINAL MEDICINES (continued)
17.1 Antiulcer medicines
 omeprazole Powder for oral liquid: 20-mg; 40-mg sachets.
Solid oral dosage form: 10 mg; 20 mg; 40 mg.
 ranitidine Injection: 25 mg/ml (as hydrochloride) in 
2-ml ampoule.
Oral liquid: 75 mg/5 ml (as hydrochloride).
Tablet: 150 mg (as hydrochloride).
17.2 Antiemetic medicines 
dexamethasone Injection: 4 mg/ml in 1-ml ampoule (as disodium 
phosphate salt).
Oral liquid: 0.5 mg/5 ml; 2 mg/5 ml. 
Solid oral dosage form: 0.5 mg; 0.75 mg; 1.5 mg; 
4 mg.
metoclopramide a Injection: 5 mg (hydrochloride)/ml in 2-ml ampoule.
Oral liquid: 5 mg/5 ml.
Tablet: 10 mg (hydrochloride).
a  Not in neonates.
ondansetron a Injection: 2 mg base/ml in 2-ml ampoule 
(as hydrochloride).
Oral liquid: 4 mg base/5 ml.
Solid oral dosage form: Eq 4 mg base; Eq 8 mg base.
a  >1 month.
 17.3 Anti-inflammatory medicines 
17.4 Laxatives
Annex 2: 4th WHO Model List of Essential Medicines for Children
175
17. GASTROINTESTINAL MEDICINES (continued)
17.5 Medicines used in diarrhoea
17.5.1 Oral rehydration
oral rehydration salts Powder for dilution in 200 ml; 500 ml; 1 L.
glucose: 75 mEq
sodium:  75 mEq or mmol/L
chloride:  65 mEq or mmol/L
potassium:  20 mEq or mmol/L
citrate:  10 mmol/L
osmolarity:  245 mOsm/L 
glucose:  13.5 g/L
sodium chloride: 2.6 g/L
potassium chloride: 1.5 g/L
trisodium citrate dihydrate*: 2.9 g/L
* trisodium citrate dihydrate may be replaced by 
sodium hydrogen carbonate (sodium bicarbonate) 
2.5 g/L. However, as the stability of this latter 
formulation is very poor under tropical conditions, 
it is recommended only when manufactured for 
immediate use. 
17.5.2 Medicines for diarrhoea
zinc sulfate* Solid oral dosage form: 20 mg.  [c]  .
* In acute diarrhoea zinc sulfate should be used as an adjunct 
to oral rehydration salts.
18. HORMONES, OTHER ENDOCRINE MEDICINES AND CONTRACEPTIVES
18.1 Adrenal hormones and synthetic substitutes
fludrocortisone Tablet: 100 micrograms (acetate).
hydrocortisone Tablet: 5 mg; 10 mg; 20 mg.
 18.2 Androgens 
 18.3 Contraceptives 
 18.3.1 Oral hormonal contraceptives 
 18.3.2 Injectable hormonal contraceptives 
 18.3.3 Intrauterine devices 
 18.3.4 Barrier methods 
 18.3.5 Implantable contraceptives 
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18. HORMONES, OTHER ENDOCRINE MEDICINES AND CONTRACEPTIVES (continued)
 18.4 Estrogens 
18.5 Insulins and other medicines used for diabetes
glucagon Injection: 1 mg/ml.
insulin injection (soluble) Injection: 100 IU/ml in 10-ml vial. 
intermediate-acting insulin Injection: 100 IU/ml in 10-ml vial (as compound 
insulin zinc suspension or isophane insulin).
Complementary List
metformin Tablet: 500 mg (hydrochloride).
 18.6 Ovulation inducers 
 18.7 Progestogens 
18.8 Thyroid hormones and antithyroid medicines
levothyroxine Tablet: 25 micrograms; 50 micrograms; 
100 micrograms (sodium salt).
Complementary List
Lugol’s solution Oral liquid: about 130 mg total iodine/ml.
potassium iodide Tablet: 60 mg.
propylthiouracil Tablet: 50 mg.
19. IMMUNOLOGICALS
19.1 Diagnostic agents
All tuberculins should comply with the WHO requirements for tuberculins. 
tuberculin, purified protein 
derivative (PPD)
Injection.
19.2 Sera and immunoglobulins
All plasma fractions should comply with the WHO requirements 
anti-tetanus immunoglobulin 
(human)
Injection: 500 IU in vial.
anti-rabies immunoglobulin 
(human)
Injection: 150 IU/ml in vial.
anti-venom immunoglobulin* Injection.
* Exact type to be defined locally.
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19. IMMUNOLOGICALS (continued)
diphtheria antitoxin Injection: 10 000 IU; 20 000 IU in vial.
19.3 Vaccines
Selection of vaccines from the Model List will need to be determined by each country 
after consideration of international recommendations, epidemiology and national 
priorities. The list below details the vaccines for which there is either a recommendation 
from the Strategic Advisory Group of Experts on Immunization (SAGE) (http://www.
who.int/immunization/sage_conclusions/en/index.html) and/or a WHO position paper 
(http://www.who.int/immunization/documents/positionpapers/en/index.html). This site 
will be updated as new position papers are published and contains the most recent 
information and recommendations.
All vaccines should comply with the WHO requirements for biological substances.
WHO noted the need for vaccines used in children to be polyvalent.
BCG vaccine
cholera vaccine
diphtheria vaccine
Haemophilus influenzae type b vaccine
hepatitis A vaccine
hepatitis B vaccine
influenza vaccine
Japanese encephalitis vaccine
measles vaccine
meningococcal meningitis vaccine
mumps vaccine
pertussis vaccine
pneumococcal vaccine
poliomyelitis vaccine
rabies vaccine
rotavirus vaccine
rubella vaccine
tetanus vaccine
typhoid vaccine
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19. IMMUNOLOGICALS (continued)
varicella vaccine
yellow fever vaccine
20. MUSCLE RELAXANTS (PERIPHERALLY-ACTING) AND CHOLINESTERASE 
INHIBITORS
neostigmine Injection: 500 micrograms in 1-ml ampoule; 2.5 mg 
(metilsulfate) in 1-ml ampoule.
Tablet: 15 mg (bromide).
suxamethonium Injection: 50 mg (chloride)/ml in 2-ml ampoule.
Powder for injection: (chloride), in vial.
 vecuronium Powder for injection: 10 mg (bromide) in vial.
Complementary List
pyridostigmine Injection: 1 mg in 1-ml ampoule.
Tablet: 60 mg (bromide).
21. OPHTHALMOLOGICAL PREPARATIONS
21.1 Anti-infective agents
aciclovir Ointment: 3% W/W.
azithromycin Solution (eye drops): 1.5%
 gentamicin Solution (eye drops): 0.3% (sulfate).
 ofloxacin Solution (eye drops): 0.3%.
 tetracycline Eye ointment: 1% (hydrochloride).
21.2 Anti-inflammatory agents
 prednisolone Solution (eye drops): 0.5% (sodium phosphate).
21.3 Local anaesthetics
 tetracaine a Solution (eye drops): 0.5% (hydrochloride).
a  Not in preterm neonates.
 21.4 Miotics and antiglaucoma medicines 
21.5 Mydriatics
atropine* a Solution (eye drops): 0.1%; 0.5%; 1% (sulfate).
* Or homatropine (hydrobromide) or cyclopentolate 
(hydrochloride).
a  >3 months.
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21. OPHTHALMOLOGICAL PREPARATIONS (continued)
Complementary List
epinephrine (adrenaline) Solution (eye drops): 2% (as hydrochloride).
 22. OXYTOCICS AND ANTIOXYTOCICS 
 22.1 Oxytocics 
 22.2 Antioxytocics (tocolytics) 
23. PERITONEAL DIALYSIS SOLUTION
Complementary List
intraperitoneal dialysis 
solution (of appropriate 
composition)
Parenteral solution.
24. MEDICINES FOR MENTAL AND BEHAVIOURAL DISORDERS
24.1 Medicines used in psychotic disorders 
Complementary List
chlorpromazine Injection: 25 mg (hydrochloride)/ml in 2-ml ampoule.
Oral liquid: 25 mg (hydrochloride)/5 ml.
Tablet: 10 mg; 25 mg; 50 mg; 100 mg (hydrochloride).
haloperidol Injection: 5 mg in 1-ml ampoule.
Oral liquid: 2 mg/ml.
Solid oral dosage form: 0.5 mg; 2 mg; 5 mg.
24.2 Medicines used in mood disorders
24.2.1 Medicines used in depressive disorders
Complementary List
fluoxetine a Solid oral dosage form: 20 mg (as hydrochloride).
a  >8 years.
24.2.2 Medicines used in bipolar disorders 
24.3 Medicines for anxiety disorders 
24.4 Medicines used for obsessive compulsive disorders 
24.5 Medicines for disorders due to psychoactive substance use 
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25. MEDICINES ACTING ON THE RESPIRATORY TRACT
25.1 Antiasthmatic medicines
 budesonide Inhalation (aerosol): 100 micrograms per dose; 
200 micrograms per dose.
epinephrine (adrenaline) Injection: 1 mg (as hydrochloride or hydrogen 
tartrate) in 1-ml ampoule.
 salbutamol Injection: 50 micrograms (as sulfate)/ml in 
5-ml ampoule.
Metered dose inhaler (aerosol): 100 micrograms 
(as sulfate) per dose.
Respirator solution for use in nebulizers: 5 mg 
(as sulfate)/ml.
26. SOLUTIONS CORRECTING WATER, ELECTROLYTE AND ACID–BASE 
DISTURBANCES
26.1 Oral
oral rehydration salts See section 17.5.1. 
potassium chloride Powder for solution.
26.2 Parenteral
glucose Injectable solution: 5% (isotonic); 10% (hypertonic); 
50% (hypertonic).
glucose with sodium chloride Injectable solution: 5% glucose, 0.9% sodium 
chloride (equivalent to Na+ 150 mmol/L and 
Cl- 150 mmol/L); 5% glucose, 0.45% sodium chloride 
(equivalent to Na+ 75 mmol/L and Cl- 75 mmol/L).
potassium chloride Solution for dilution: 7.5% (equivalent to  
K+ 1 mmol/ml and Cl 1 mmol/ml); 15% (equivalent 
to K+ 2 mmol/ml and Cl 2 mmol/ml).
sodium chloride Injectable solution: 0.9% isotonic (equivalent to 
Na+ 154 mmol/L, Cl- 154 mmol/L).
sodium hydrogen carbonate Injectable solution: 1.4% isotonic (equivalent to 
Na+ 167 mmol/L, HCO3 - 167 mmol/L).
Solution: 8.4% in 10-ml ampoule (equivalent to 
Na+ 1000 mmol/L, HCO3 -1000 mmol/L).
 sodium lactate, 
compound solution
Injectable solution.
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26. SOLUTIONS CORRECTING WATER, ELECTROLYTE AND ACID–BASE 
DISTURBANCES (continued)
26.3 Miscellaneous
water for injection 2-ml; 5-ml; 10-ml ampoules.
27. VITAMINS AND MINERALS 
ascorbic acid Tablet: 50 mg.
cholecalciferol* Oral liquid: 400 IU/ml.
Solid oral dosage form: 400 IU; 1000 IU.
* Ergocalciferol can be used as an alternative.
iodine Capsule: 200 mg.
Iodized oil: 1 ml (480 mg iodine); 0.5 ml (240 mg 
iodine) in ampoule (oral or injectable); 0.57 ml 
(308 mg iodine) in dispenser bottle.
pyridoxine Tablet: 25 mg (hydrochloride).
retinol Capsule: 100 000 IU; 200 000 IU (as palmitate).
Oral oily solution: 100 000 IU (as palmitate)/ml in 
multidose dispenser.
Tablet (sugar-coated): 10 000 IU (as palmitate).
Water-miscible injection: 100 000 IU (as palmitate) 
in 2-ml ampoule.
riboflavin Tablet: 5 mg.
sodium fluoride In any appropriate topical formulation.
thiamine Tablet: 50 mg (hydrochloride).
Complementary List
calcium gluconate Injection: 100 mg/ml in 10-ml ampoule.
28. EAR, NOSE AND THROAT MEDICINES 
acetic acid Topical: 2%, in alcohol.
 budesonide Nasal spray: 100 micrograms per dose.
 ciprofloxacin Topical: 0.3% drops (as hydrochloride).
 xylometazoline a Nasal spray: 0.05%.
a  Not in children less than 3 months.
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29. SPECIFIC MEDICINES FOR NEONATAL CARE 
29.1 Medicines administered to the neonate 
caffeine citrate Injection: 20 mg/ml (equivalent to 10 mg 
caffeine base/ml).
Oral liquid: 20 mg/ml (equivalent to 10 mg 
caffeine base/ml).
chlorhexidine Solution or gel: 7.1% (digluconate) delivering 4% 
chlorhexidine (for umbilical cord care).
Complementary List
 ibuprofen Solution for injection: 5 mg/ml.
 prostaglandin E Solution for injection: 
Prostaglandin E1: 0.5 mg/ml in alcohol.
Prostaglandin E2: 1 mg/ml.
surfactant Suspension for intratracheal instillation: 25 mg/ml 
or 80 mg/ml.
30. MEDICINES FOR DISEASES OF JOINTS
 30.1 Medicines used to treat gout  
30.2 Disease-modifying agents used in rheumatoid disorders (DMARDs)
Complementary List
hydroxychloroquine Solid oral dosage form: 200 mg (as sulfate).
methotrexate Tablet: 2.5 mg (as sodium salt).
30.3 Juvenile joint diseases
acetylsalicylic acid* (acute or 
chronic use)
Suppository: 50 mg to 150 mg.
Tablet: 100 mg to 500 mg.
* For use for rheumatic fever, juvenile arthritis, 
Kawasaki disease.
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Annex 3
The Anatomical Therapeutic Chemical (ATC) 
Classification System
The following list provides the corresponding Anatomical Therapeutic Chemical 
(ATC) classification codes for all items on the 18th WHO Model List of Essential 
Medicines and the 4th WHO Model List of Essential Medicines for Children, 
sorted by ATC code number.
ATC code ATC group/medicine or item Section
A ALIMENTARY TRACT AND METABOLISM
A02 Drugs for acid related disorders
A02B Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD)
A02BA H2-receptor antagonists
A02BA02 ranitidine 17.1
A02BC Proton pump inhibitors
A02BC01 omeprazole 17.1
A03 Drugs for functional gastrointestinal disorders
A03B Belladonna and derivatives, plain
A03BA Belladonna alkaloids, tertiary amines
A03BA01 atropine 1.3; 4.2
A03BB Belladonna alkaloids, semisynthetic, quaternary ammonium compounds
A03BB01 hyoscine butylbromide* 2.3
A03F Propulsives
A03FA Propulsives
A03FA01 metoclopramide 2.3; 17.2
A04 Antiemetics and antinauseants
A04A Antiemetics and antinauseants
A04AA Serotonin (5HT3) antagonists
A04AA01 ondansetron 17.2
A04AD Other antiemetics
A04AD01 hyoscine hydrobromide* 2.3
184
W
H
O
 T
ec
hn
ic
al
 R
ep
or
t S
er
ie
s N
o.
 9
85
, 2
01
4
The Selection and Use of Essential Medicines   Report of the 19th WHO Expert Committee
ATC code ATC group/medicine or item Section
A06 Laxatives
A06A Laxatives
A06AA Softeners, emollients
A06AA02 docusate sodium  2.3
A06AB Contact laxatives
A06AB06 senna glycosides* 17.4
A06AD Osmotically acting laxatives
A06AD11 lactulose  2.3
A07 Antidiarrheals, intestinal antiinflammatory/antiinfective agents
A07A Intestinal antiinfectives
A07AA Antibiotics
A07AA06 paromomycin 6.5.2
A07B Intestinal adsorbents
A07BA Charcoal preparations
A07BA01 medicinal charcoal* 4.1
A07C Electrolytes with carbohydrates
A07CA Oral rehydration salt formulations* 17.5.1; 26.1
A07DA Antipropulsives
A07DA03 loperamide  2.3
A07E Intestinal antiinflammatory agents
A07EA Corticosteroids for local use
A07EA02 hydrocortisone 17.3
A07EC Aminosalicylic acid and similar agents
A07EC01 sulfasalazine 17.3; 30.2
A09 Digestives, incl. enzymes
A09A Digestives, incl. enzymes
A09AA Enzyme preparations
A09AA02 multienzymes (lipase, protease, etc.)* 17
A10 Drugs used in diabetes
A10A Insulins and analogues
A10AB Insulins and analogues for injection, fast-acting
A10AB insulin injection (soluble)* 18.5
A10AC Insulins and analogues for injection, intermediate-acting
A10AC insulin, intermediate-acting* 18.5
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A10B Blood glucose lowering drugs, excl. insulins
A10BA Biguanides
A10BA02 metformin 18.5
A10BB Sulfonamides, urea derivatives
A10BB01 glibenclamide 18.5
A10BB09 gliclazide 18.5
A11 Vitamins
A11C Vitamin A and D, incl. combinations of the two
A11CA Vitamin A, plain
A11CA01 retinol 27
A11CC Vitamin D and analogues
A11CC01 ergocalciferol 27
A11CC05 colecalciferol* 27
A11D Vitamin B1, plain and in combination with vitamin B6 and B12
A11DA Vitamin B1, plain
A11DA01 thiamine 27
A11G Ascorbic acid (vitamin C), incl. combinations
A11GA Ascorbic acid (vitamin C), plain
A11GA01 ascorbic acid 27
A11H Other plain vitamin preparations
A11HA Other plain vitamin preparations
A11HA01 nicotinamide 27
A11HA02 pyridoxine 27
A11HA04 riboflavin 27
A12 Mineral supplements
A12A Calcium
A12AA Calcium
A12AA03 calcium gluconate 4.2; 27
A12C Other mineral supplements
A12CB Zinc
A12CB01 zinc sulfate 17.5.2
A12CD Fluoride
A12CD01 sodium fluoride 27
A12CX Other mineral products* 27
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B BLOOD AND BLOOD FORMING ORGANS
B01 Antithrombotic agents
B01A Antithrombotic agents
B01AA Vitamin K antagonists
B01AA03 warfarin 10.2
B01AB Heparin group
B01AB01 heparin* 10.2
B01AC Platelet aggregation inhibitors excl. heparin
B01AC06 acetylsalicylic acid 7.1; 12.5; 30.3
B01AD Enzymes
B01AD01 streptokinase 12.5
B02 Antihemorrhagics
B02A Antifibrinolytics
B02AA Amino acids
B02AA02 tranexamic acid 10.2
B02B Vitamin K and other hemostatics
B02BA Vitamin K
B02BA01 phytomenadione 10.2
B02BD Blood coagulation factors
B02BD01 coagulation factor IX, II, VII and X in combination* 11.2.2
B02BD02 coagulation factor VIII* 11.2.2
B03 Antianemic preparations
B03A Iron preparations* 10.1
B03AD Iron in combination with folic acid* 10.1
B03B Vitamin B12 and folic acid
B03BA Vitamin B12 (cyanocobalamin and analogues)
B03BA03 hydroxocobalamin 10.1
B03BB Folic acid and derivatives
B03BB01 folic acid 10.1
B05 Blood substitutes and perfusion solutions
B05A Blood and related products
B05A platelet concentrates 11.1
B05A whole blood* 11.1
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B05AA Blood substitutes and plasma protein fractions
B05AA05 dextran* 11.3
B05AX Other blood products
B05AX01 red blood cells* 11.1
B05AX03 fresh frozen plasma* 11.1
B05B I.V. solutions
B05BA Solutions for parenteral nutrition
B05BA03 carbohydrates* 26.2
B05BA03 glucose 26.2
B05BB Solutions affecting the electrolyte balance
B05BB01 electrolytes* 26.2
B05BB02 electrolytes with carbohydrates* 26.2
B05BB02 glucose with sodium chloride 26.2
B05BC Solutions producing osmotic diuresis
B05BC01 mannitol 16
B05D Peritoneal dialytics
B05DA Isotonic solutions* 23
B05X I.V. solution additives
B05XA Electrolyte solutions
B05XA01 potassium chloride 26.1; 26.2
B05XA02 sodium bicarbonate* 26.2
B05XA03 sodium chloride 26.2
B05XA05 magnesium sulfate 5
C CARDIOVASCULAR SYSTEM
C01 Cardiac therapy
C01A Cardiac glycosides
C01AA Digitalis glycosides
C01AA01 simvastatin 12.6
C01AA05 digoxin 12.2; 12.4
C01B Antiarrhythmics, class I and III
C01BB Antiarrhythmics, class Ib
C01BB01 lidocaine 12.2
C01BD Antiarrhythmics, class III
C01BD01 amiodarone 12.2
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C01C Cardiac stimulants excl. cardiac glycosides
C01CA Adrenergic and dopaminergic agents
C01CA04 dopamine 12.4
C01CA24 epinephrine (adrenaline) 3; 12.2; 25.1
C01D Vasodilators used in cardiac diseases
C01DA Organic nitrates
C01DA02 glyceryl trinitrate 12.1
C01DA08 isosorbide dinitrate 12.1
C02 Antihypertensives
C02A Antiadrenergic agents, centrally acting
C02AB Methyldopa
C02AB01 methyldopa (levorotatory)* 12.3
C02D Arteriolar smooth muscle, agents acting on
C02DB Hydrazinophthalazine derivatives
C02DB02 hydrazaline 12.3
C02DD Nitroferricyanide derivatives
C02DD01 nitroprusside* 12.3
C03 Diuretics
C03A Low-ceiling diuretics, thiazides
C03AA Thiazides, plain
C03AA03 hydrochlorothiazide 12.3; 12.4; 16
C03C High-ceiling diuretics
C03CA Sulfonamides, plain
C03CA01 furosemide 12.4; 16
C03D Potassium-sparing agents
C03DA Aldosterone antagonists
C03DA01 spironolactone 16; 12.4
C03DB Other potassium-sparing agents
C03DB01 amiloride 16
C07 Beta blocking agents
C07A Beta blocking agents
C07AA Beta blocking agents, non-selective
C07AA05 propranolol 7.2
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C07AB Beta blocking agents, selective
C07AB07 bisoprolol 12.1; 12.2; 
12.3; 12.4
C08 Calcium channel blockers
C08C Selective calcium channel blockers with mainly vascular effects
C08CA Dihydropyridine derivatives
C08CA01 amlodipine 12.3
C08CA05 nifedipine 22.2
C08D Selective calcium channel blockers with direct cardiac effects
C08DA Phenylalkylamine derivatives
C08DA01 verapamil 12.1; 12.2
C09 Agents acting on the renin-angiotensin system
C09A ACE inhibitors, plain
C09AA ACE inhibitors, plain
C09AA02 enalapril 12.3; 12.4
D DERMATOLOGICALS
D01 Antifungals for dermatological use
D01A Antifungals for topical use
D01AA Antibiotics
D01AA01 nystatin 6.3
D01AC Imidazole and triazole derivatives
D01AC02 miconazole 13.1
D01AE Other antifungals for topical use
D01AE12 salicylic acid 13.4
D01AE13 selenium sulfide 13.1
D01B Antifungals for systemic use
D01BA Antifungals for systemic use
D01BA01 griseofulvin 6.3
D01BA02 terbinafine 13.1
D02 Emollients and protectives
D02A Emollients and protectives
D02AB Zinc products* 13.3
D02AB Calamine lotion 13.3
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D02AE Carbamide products
D02AE01 carbamide* 13.5
D05 Antipsoriatics
D05A Antipsoriatics for topical use
D06 Antibiotics and chemotherapeutics for dermatological use
D06A Antibiotics for topical use
D06AX Other antibiotics for topical use
D06AX09 mupirocin 13.2
D06B Chemotherapeutics for topical use
D06BA Sulfonamides
D06BA01 silver sulfadiazine 13.2
D06BB Antivirals
D06BB04 podophyllotoxin* 13.5
D07 Corticosteroids, dermatological preparations
D07A Corticosteroids, plain
D07AA Corticosteroids, weak (group I)
D07AA02 hydrocortisone 13.3
D07AC Corticosteroids, potent (group III)
D07AC01 betamethasone 13.3
D08 Antiseptics and disinfectants
D08A Antiseptics and disinfectants
D08AC Biguanides and amidines
D08AC02 chlorhexidine 15.1; 29.1
D08AE Phenol and derivatives
D08AE05 chloroxylenol 15.2
D08AG Iodine products
D08AG02 povidone-iodine* 15.1
D08AX Other antiseptics and disinfectants* 15
D08AX06 potassium permanganate 13.2
D08AX08 ethanol 15.1
D10 Anti-acne preparations
D10A Anti-acne preparations for topical use
D10AE Peroxides
D10AE01 benzoyl peroxide 13.4
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G GENITO URINARY SYSTEM AND SEX HORMONES
G01 Gynecological antiinfectives and antiseptics
G01A Antiinfectives and antiseptics, excl. combinations with corticosteroids
G01AF Imidazole derivatives
G01AF02 clotrimazole 6.3
G02 Other gynecologicals
G02A Oxytocics
G02AB Ergot alkaloids
G02AB03 ergometrine 22.1
G02AD Prostaglandins
G02AD06 misoprostol 22.1
G02B Contraceptives for topical use
G02BA Intrauterine contraceptives
G02BA02 plastic IUD with copper* 18.3.3
G02BA03 plastic IUD with progesteron* 18.3.5
G02BB Intravaginal contraceptives* 18.3.4
G03 Sex hormones and modulators of the genital system
G03A Hormonal contraceptives for systemic use
G03AA Progestogens and estrogens, fixed combinations
G03AA05 norethisterone and estrogen* 18.3.1
G03AA08 medroxyprogesterone and estrogen* 18.3.2
G03AB Progestogens and estrogens, sequential preparations
G03AB03 levonorgestrel and estrogen* 18.3.1
G03AC Progestogens
G03AC01 norethisterone* 18.3.2
G03AC03 levonorgestrel 18.3.1
G03AC06 medroxyprogesterone* 18.3.2; 18.7
G03B Androgens
G03BA 3-oxoandrosten (4) derivatives
G03BA03 testosterone 18.2
G03G Gonadotropins and other ovulation stimulants
G03GB Ovulation stimulants, synthetic
G03GB02 clomifene 18.6
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G03X Other sex hormones and modulators of the genital system
G03XB Antiprogesterons
G03XB01 mifepristone 22.1
H SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX 
HORMONES AND INSULINS
H01 Pituitary, hypothalamic hormones and analogues
H01B Posterior pituitary lobe hormones
H01BB Oxytocin and analogues
H01BB02 oxytocin 22.1
H02 Corticosteroids for systemic use
H02A Corticosteroids for systemic use, plain
H02AA Mineralocorticoids
H02AA02 fludrocortisone 18.1
H02AB Glucocorticoids
H02AB02 dexamethasone 2.3; 3; 8.3; 
17.2; 29.2
H02AB04 methylprednisolone 8.3
H02AB06 prednisolone 3; 8.3
H02AB09 hydrocortisone 3; 8.3
H03 Thyroid therapy
H03A Thyroid preparations
H03AA Thyroid hormones
H03AA01 levothyroxine sodium* 18.8
H03B Antithyroid preparations
H03BA Thiouracils
H03BA02 propylthiouracil 18.8
H03C Iodine therapy
H03CA Iodine therapy* 18.8
H04 Pancreatic hormones
H04A Glycogenolytic hormones
H04AA Glycogenolytic hormones
H04AA01 glucagon 18.5
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J ANTIINFECTIVES FOR SYSTEMIC USE
J01 Antibacterials for systemic use
J01A Tetracyclines
J01AA Tetracyclines
J01AA02 doxycycline 6.2.2; 6.5.3.1; 
6.5.3.2
J01B Amphenicols
J01BA Amphenicols
J01BA01 chloramphenicol 6.2.2
J01C Beta-lactam antibacterials, penicillins
J01CA Penicillins with extended spectrum
J01CA01 ampicillin 6.2.1
J01CA04 amoxicillin 6.2.1
J01CE Beta-lactamase sensitive penicillins
J01CE01 benzylpenicillin 6.2.1
J01CE02 phenoxymethylpenicillin 6.2.1
J01CE08 benzathine benzylpenicillin 6.2.1
J01CE09 procaine benzylpenicillin 6.2.1
J01CF Beta-lactamase resistant penicillins
J01CF02 cloxacillin 6.2.1
J01CR Combinations of penicillins, incl. beta-lactamase inhibitors
J01CR02 amoxicillin and enzyme inhibitor* 6.2.1
J01D Other beta-lactam antibacterials
J01DB First-generation cephalosporins
J01DB01 cefalexin 6.2.1
J01DB04 cefazolin 6.2.1
J01DD Third-generation cephalosporins
J01DD01 cefotaxime 6.2.1
J01DD02 ceftazidime 6.2.1
J01DD04 ceftriaxone 6.2.1
J01DD08 cefixime 6.2.1
J01DH Carbapenems
J01DH5 imipenem and enzyme inhibitor* 6.2.1
J01E Sulfonamides and trimethoprim
J01EA Trimethoprim and derivatives
J01EA01 trimethoprim 6.2.2
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J01EC Intermediate-acting sulfonamides
J01EC02 sulfadiazine 6.5.4
J01EE Combinations of sulfonamides and trimethoprim, incl. derivatives
J01EE01 sulfamethoxazole + trimethoprim 6.2.2; 6.5.4
J01F Macrolides, lincosamides and streptogramins
J01FA Macrolides
J01FA01 erythromycin 6.2.2
J01FA09 clarithromycin 6.2.2
J01FA10 azithromycin 6.2.2; 21.1
J01FF Lincosamides
J01FF01 clindamycin 6.2.2
J01G Aminoglycoside antibacterials
J01GA Streptomycins
J01GA01 streptomycin 6.2.4
J01GB Other aminoglycosides
J01GB03 gentamicin 6.2.2
J01GB04 kanamycin 6.2.4
J01GB06 amikacin 6.2.4
J01M Quinolone antibacterials
J01MA Fluoroquinolones
J01MA01 ofloxacin 6.2.4; 21.1
J01MA12 levofloxacin 6.2.4
J01MA02 ciprofloxacin 6.2.2
J01X Other antibacterials
J01XA Glycopeptide antibacterials
J01XA01 vancomycin 6.2.2
J01XD Imidazole derivatives
J01XD01 metronidazole 6.2.2; 6.5.1
J01XE Nitrofuran derivatives
J01XE01 nitrofurantoin 6.2.2
J01XX Other antibacterials
J01XX04 spectinomycin 6.2.2
J02 Antimycotics for systemic use
J02A Antimycotics for systemic use
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J02AA Antibiotics
J02AA01 amphotericin B 6.3; 6.5.2
J02AC Triazole derivatives
J02AC01 fluconazole 6.3
J02AX Other antimycotics for systemic use
J02AX01 flucytosine 6.3
J04 Antimycobacterials
J04A Drugs for treatment of tuberculosis
J04AA Aminosalicylic acid and derivatives
J04AA01 p-aminosalicylic acid* 6.2.4
J04AB Antibiotics
J04AB01 cycloserine 6.2.4
J04AB02 rifampicin 6.2.3; 6.2.4
J04AB04 rifabutin 6.2.4
J04AB30 capreomycin 6.2.4
J04AC Hydrazides
J04AC01 isoniazid 6.2.4
J04AD Thiocarbamide derivatives
J04AD03 ethionamide 6.2.4
J04AD01 protionamide 6.2.4
J04AK Other drugs for treatment of tuberculosis
J04AK01 pyrazinamide 6.2.4
J04AK02 ethambutol 6.2.4
J04AM Combinations of drugs for treatment of tuberculosis* 6.2.4
J04AM02 rifampicin and isoniazid* 6.2.4
J04AM03 ethambutol and isoniazid* 6.2.4
J04AM05 rifampicin, pyrazinamide and isoniazid* 6.2.4
J04AM06 rifampicin, pyrazinamide, ethambutol and isoniazid* 6.2.4
J04B Drugs for treatment of lepra
J04BA Drugs for treatment of lepra
J04BA01 clofazimine 6.2.3
J04BA02 dapsone 6.2.3
J05 Antivirals for systemic use
J05A Direct acting antivirals
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J05AB Nucleosides and nucleotides excl. reverse transcriptase inhibitors
J05AB01 aciclovir 6.4.1
J05AB04 ribavirin 6.4.3
J05AE Protease inhibitors
J05AE01 saquinavir (SQV) 6.4.2.3
J05AE02 indinavir (IDV) 6.4.2.3
J05AE03 ritonavir (r) 6.4.2.3
J05AE08 atazanavir 6.4.2.3
J05AE30 lopinavir + ritonavir (LPV/r)* 6.4.2.3
J05AF Nucleoside and nucleotide reverse transcriptase inhibitors
J05AF01 zidovudine (ZDV or AZT) 6.4.2.1
J05AF02 didanosine (ddI) 6.4.2.1
J05AF04 stavudine (d4T) 6.4.2.1
J05AF05 lamivudine (3TC) 6.4.2.1
J05AF06 abacavir (ABC) 6.4.2.1
J05AF07 tenofovir disoproxil fumarate 6.4.2.1
J05AF09 emtricitabine 6.4.2.1
J05AG Non-nucleoside reverse transcriptase inhibitors
J05AG01 nevirapine (NVP) 6.4.2.2
J05AG03 efavirenz (EFV or EFZ) 6.4.2.2
J05AH Neuraminidase inhibitors
J05AH02 oseltamivir 6.4.3
J05AR Antivirals for treatment of HIV infections, combinations
J05AR01 lamivudine + zidovudine (ZDV or AZT) 6.4.2
J05AR03 emtricitabine + tenofovir 6.4.2
J05AR05 lamivudine + nevirapine + zidovudine 6.4.2
J05AR06 efavirenz + emtricitabine + tenofovir 6.4.2
J05AR07 lamivudine + nevirapine + stavudine 6.4.2
J06 Immune sera and immunoglobulins
J06A Immune sera
J06AA Immune sera
J06AA01 diphtheria antitoxin 19.2
J06AA03 snake venom antiserum* 19.2
J06B Immunoglobulins
J06BA Immunoglobulins, normal human
J06BA01 immunoglobulins, normal human, for extravascular admin* 11.2.1
J06BA02 immunoglobulins, normal human, for intravascular admin* 11.2.1
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J06BB Specific immunoglobulins
J06BB01 anti-D immunoglobulin (human) 19.2
J06BB02 antitetanus immunoglobulin (human) 19.2
J06BB05 rabies immunoglobulin 19.2
J07 Vaccines
J07A Bacterial vaccines
J07AE Cholera vaccines 19.3
J07AF Diphtheria vaccines
J07AF01 diphtheria toxoid* 19.3
J07AH Meningococcal vaccines* 19.3
J07AJ Pertussis vaccines
J07AJ01 pertussis vaccine 19.3
J07AL Pneumococcal vaccines
J07AL01 pneumococcus, purified polysaccharides antigen* 19.3
J07AM Tetanus vaccines
J07AM01 tetanus toxoid* 19.3
J07AN Tuberculosis vaccines
J07AN01 tuberculosis, live attenuated* 19.3
J07AP Typhoid vaccines
J07AP typhoid vaccine 19.3
J07B Viral vaccines
J07BA Encephalitis vaccines
J07BA02 encephalitis, Japanese, inactivated, whole virus 19.3
J07BB Influenza vaccines
J07BB influenza vaccine 19.3
J07BC Hepatitis vaccines
J07BC01 hepatitis B vaccine 19.3
J07BC02 hepatitis A vaccine 19.3
J07BD Measles vaccine*
J07BD01 measles vaccine, live attenuated* 19.3
J07BE Mumps vaccines
J07BE01 mumps vaccine, live attenuated* 19.3
J07BF Poliomyelitis vaccine 19.3
J07BG Rabies vaccine 19.3
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J07BH Rota virus diarrhea vaccines* 19.3
J07BJ Rubella vaccines 19.3
J07BK Varicella zoster vaccines* 19.3
J07BL Yellow fever vaccines 19.3
J07C Bacterial and viral vaccines, combined
J07CA Bacterial and viral vaccines, combined* 19.3
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L01 Antineoplastic agents
L01A Alkylating agents
L01AA Nitrogen mustard analogues
L01AA01 cyclophosphamide 8.2
L01AA02 chlorambucil 8.2
L01AA06 ifosfamide 8.2
L01AX Other alkylating agents
L01AX04 dacarbazine 8.2
L01B Antimetabolites
L01BA Folic acid analogues
L01BA01 methotrexate 8.2; 30.2
L01BB Purine analogues
L01BB02 mercaptopurine 8.2
L01BB03 tioguanine 8.2
L01BC Pyrimidine analogues
L01BC01 cytarabine 8.2
L01BC02 fluorouracil 8.2; 13.4
L01C Plant alkaloids and other natural products
L01CA Vinca alkaloids and analogues
L01CA01 vinblastine 8.2
L01CA02 vincristine 8.2
L01CB Podophyllotoxin derivatives
L01CB01 etoposide 8.2
L01CD Taxanes
L01CD01 paclitaxel 8.2
L01CD02 docetaxel 8.2
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L01D Cytotoxic antibiotics and related substances
L01DA Actinomycines
L01DA01 dactinomycin 8.2
L01DB Anthracyclines and related substances
L01DB01 doxorubicin 8.2
L01DB02 daunorubicin 8.2
L01DC Other cytotoxic antibiotics
L01DC01 bleomycin 8.2
L01X Other antineoplastic agents
L01XA Platinum compounds
L01XA02 carboplatin 8.2
L01XB Methylhydrazines
L01XB01 procarbazine 8.2
L01X Other antineoplastic agents
L01XC Monoclonal antibodies
L01XC07 bevacizumab 21.6
L01XX Other antineoplastic agents
L01XX02 asparaginase 8.2
L01XX05 hydroxycarbamide 8.2; 10.3
L01XX09 miltefosine 6.5.2
L02 Endocrine therapy
L02B Hormone antagonists and related agents
L02BA Anti-estrogens
L02BA01 tamoxifen 8.3
L03 Immunostimulants
L03A Immunostimulants
L03AB Interferons
L03AB10 peginterferon alfa-2b* 6.4.3
L03AB11 peginterferon alfa-2a* 6.4.3
L04 Immunosuppressants
L04A Immunosuppressants
L04AD Calcineurin inhibitors
L04AD01 ciclosporin 8.1
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L04AX Other immunosuppressants
L04AX01 azathioprine 8.1; 30.2
M MUSCULO-SKELETAL SYSTEM
M01 Antiinflammatory and antirheumatic products
M01A Antiinflammatory and antirheumatic products, non-steroids
M01AE Propionic acid derivatives
M01AE01 ibuprofen 2.1; 29
M01C Specific antirheumatic agents
M01CC Penicillamine and similar agents
M01CC01 penicillamine 4.2; 30.2
M03 Muscle relaxants
M03A Muscle relaxants, peripherally acting agents
M03AA Curare alkaloids
M03AA01 alcuronium 20
M03AB Choline derivatives
M03AB01 suxamethonium 20
M03AC Other quaternary ammonium compounds
M03AC03 vecuronium 20
M03AC04 atracurium 20
M04 Antigout preparations
M04A Antigout preparations
M04AA Preparations inhibiting uric acid production
M04AA01 allopurinol 8.2; 30.1
N NERVOUS SYSTEM
N01 Anesthetics
N01A Anesthetics, general
N01AB Halogenated hydrocarbons
N01AB01 halothane 1.1.1
N01AB06 isoflurane 1.1.1
N01AX Other general anesthetics
N01AX03 ketamine 1.1.2
N01AX10 propofol 1.1.2
N01AX13 nitrous oxide 1.1.1
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N01B Anesthetics, local
N01BB Amides
N01BB01 bupivacaine 1.2
N01BB02 lidocaine 1.2
N01BB52 lidocaine, combinations* 1.2
N02 Analgesics
N02A Opioids
N02AA Natural opium alkaloids
N02AA01 morphine 1.3; 2.2
N02AA03 hydromorphone 2.2
N02AA05 oxycodone 2.2
N02B Other analgesics and antipyretics
N02BA Salicylic acid and derivatives
N02BA01 acetylsalicylic acid 2.1; 7.1
N02BE Anilides
N02BE01 paracetamol 2.1; 7.1
N03 Antiepileptics
N03A Antiepileptics
N03AA Barbiturates and derivatives
N03AA02 phenobarbital 5
N03AB Hydantoin derivatives
N03AB02 phenytoin 5
N03AD Succinimide derivatives
N03AD01 ethosuximide 5
N03AF Carboxamide derivatives
N03AF01 carbamazepine 5; 24.2.2
N03AG Fatty acid derivatives
N03AG01 valproic acid 5; 24.2.2
N04 Anti-parkinson drugs
N04A Anticholinergic agents
N04AA Tertiary amines
N04AA02 biperiden 9
N04B Dopaminergic agents
N04BA Dopa and dopa derivatives
N04BA02 levodopa and decarboxylase inhibitor* 9
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ATC code ATC group/medicine or item Section
N05 Psycholeptics
N05A Antipsychotics
N05AA Phenothiazines with aliphatic side-chain
N05AA01 chlorpromazine 24.1
N05AB Phenothiazines with piperazine structure
N05AB02 fluphenazine 24.1
N05AH Diazepines, oxazepines, thiazepines and oxepines
N05AH02 clozapine 24.1
N05AD Butyrophenone derivatives
N05AD01 haloperidol 2.3; 24.1
N05AN Lithium
N05AN01 lithium* 24.2.2
N05AX Other antipsychotics
N05AX08 risperidone 24.1
N05B Anxiolytics
N05BA Benzodiazepine derivatives
N05BA01 diazepam 2.3; 5; 24.3
N05BA06 lorazepam 5
N05C Hypnotics and sedatives
N05CD Benzodiazepine derivatives
N05CD08 midazolam 1.3
N06 Psychoanaleptics
N06A Antidepressants
N06AA Non-selective monoamine reuptake inhibitors
N06AA04 clomipramine 24.4
N06AA09 amitriptyline 2.3; 24.2.1
N06AB Selective serotonin reuptake inhibitors
N06AB03 fluoxetine 24.2.1
N06B Psychostimulants, agents used for ADHD and nootropics
N06BC Xanthine derivatives
N06BC01 caffeine citrate 29
N07 Other nervous system drugs
N07A Parasympathomimetics
N07AA Anticholinesterases
N07AA01 neostigmine 20
N07AA02 pyridostigmine 20
Annex 3: The Anatomical Therapeutic Chemical (ATC) Classification System
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N07B Drugs used in addictive disorders
N07BA Drugs used in nicotine dependence
N07BA01 nicotine replacement therapy* 24.5
N07BC Drugs used in opioid dependence
N07BC02 methadone 24.5
P ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS
P01 Antiprotozoals
P01A Agents against amoebiasis and other protozoal diseases
P01AB Nitroimidazole derivatives
P01AB01 metronidazole 6.5.1
P01AC Dichloroacetamide derivatives
P01AC01 diloxanide 6.5.1
P01B Antimalarials
P01BA Aminoquinolines
P01BA01 chloroquine 2.4; 6.5.3.1; 
6.5.3.2
P01BA02 hydroxychloroquine 30.2
P01BA03 primaquine 6.5.3.1
P01BA06 amodiaquine 6.5.3.1
P01BB Biguanides
P01BB01 proguanil 6.5.3.2
P01BC Methanolquinolines
P01BC01 quinine 6.5.3.1
P01BC02 mefloquine 6.5.3.1; 
6.5.3.2
P01BD Diaminopyrimidines
P01BD01 pyrimethamine 6.5.4
P01BD51 pyrimethamine, combinations* 6.5.3.1
P01BE Artemisinin and derivatives
P01BE02 artemether 6.5.3.1
P01BE03 artesunate 6.5.3.1
P01BF01 artemether and lumefantrine  6.5.3.1
P01BF02 artesunate and mefloquine 6.5.3.1
P01BF03 artesunate and amodiaquine 6.5.3.1
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P01C Agents against leishmaniasis and trypanosomiasis
P01CA Nitroimidazole derivatives
P01CA02 benznidazole 6.5.5.2
P01CB Antimony compounds
P01CB01 meglumine antimoniate 6.5.2
P01CB02 sodium stibogluconate 6.5.2
P01CC Nitrofuran derivatives
P01CC01 nifurtimox 6.5.5.1; 
6.5.5.2
P01CD Arsenic compounds
P01CD01 melarsoprol 6.5.5.1
P01CX Other agents against leishmaniasis and trypanosomiasis
P01CX01 pentamidine isethionate* 6.5.4; 6.5.5.1
P01CX02 suramin sodium 6.5.5.1
P01CX03 eflornithine 6.5.5.1
P02 Anthelmintics
P02B Antitrematodals
P02BA Quinoline derivatives and related substances
P02BA01 praziquantel 6.1.1; 6.1.3
P02BA02 oxamniquine 6.1.3
P02BX Other antitrematodal agents
P02BX04 triclabendazole 6.1.3
P02C Antinematodal agents
P02CA Benzimidazole derivatives
P02CA01 mebendazole 6.1.1
P02CA03 albendazole 6.1.1; 6.1.2
P02CB Piperazine and derivatives
P02CB02 diethylcarbamazine 6.1.2
P02CC Tetrahydropyrimidine derivatives
P02CC01 pyrantel 6.1.1
P02CE Imidazothiazole derivatives
P02CE01 levamisole 6.1.1
P02CF Avermectines
P02CF01 ivermectin 6.1.2
Annex 3: The Anatomical Therapeutic Chemical (ATC) Classification System
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P02D Anticestodals
P02DA Salicylic acid derivatives
P02DA01 niclosamide 6.1.1
P03 Ectoparasiticides, incl. scabicides, insecticides and repellents
P03A Ectoparasiticides, incl. scabicides
P03AC Pyrethrines, incl. synthetic compounds
P03AC04 permethrin 13.5
P03AX Other ectoparasiticides, incl. scabicides
P03AX01 benzyl benzoate 13.6
R RESPIRATORY SYSTEM
R01 Nasal preparations
R01A Decongestants and other nasal preparations for topical use
R01AA Sympathomimetics, plain
R01AA07 xylometazoline 28
R01AD Corticosteroids
R01AD05 budesonide 28
R03 Drugs for obstructive airway diseases
R03A Adrenergics, inhalants
R03AC Selective beta-2-adrenoreceptor agonists
R03AC02 salbutamol 25.1
R03B Other drugs for obstructive airway diseases, inhalants
R03BA Glucocorticoids
R03BA01 beclometasone 25.1
R03BB Anticholinergics
R03BB01 ipratropium bromide 25.1
R03C Adrenergics for systemic use
R03CA Alpha- and beta-adrenoreceptor agonists
R03CA02 ephedrine 1.2
R03CC Selective beta-2-adrenoreceptor agonists
R03CC02 salbutamol 25.1
R05 Cough and cold preparations
R05D Cough suppressants, excl. combinations with expectorants
R05DA Opium alkaloids and derivatives
R05DA04 codeine 2.2
206
W
H
O
 T
ec
hn
ic
al
 R
ep
or
t S
er
ie
s N
o.
 9
85
, 2
01
4
The Selection and Use of Essential Medicines   Report of the 19th WHO Expert Committee
ATC code ATC group/medicine or item Section
R06 Antihistamines for systemic use
R06A Antihistamines for systemic use
R06AE Piperazine derivatives
R06AE3 cyclizine 2.3
R06AX Other antihistamines for systemic use
R06AX13  loratadine  3
R07 Other respiratory system products
R07A Other respiratory system products
R07AA Lung surfactants 29
S SENSORY ORGANS
S01 Ophthalmologicals
S01A Antiinfectives
S01AA Antibiotics
S01AA09 tetracycline 21.1
S01AA11 gentamicin 21.1
S01AD Antivirals
S01AD03 aciclovir 21.1
S01B Antiinflammatory agents
S01BA Corticosteroids, plain
S01BA04 prednisolone 21.2
S01E Antiglaucoma preparations and miotics
S01EA Sympathomimetics in glaucoma therapy
S01EA01 epinephrine 21.5
S01EB Parasympathomimetics
S01EB01 pilocarpine 21.4
S01EC Carbonic anhydrase inhibitors
S01EC01 acetazolamide 21.4
S01ED Beta blocking agents
S01ED01 timolol 21.4
S01EE Prostaglandin analogues
S01EE01 latanoprost  21.4
Annex 3: The Anatomical Therapeutic Chemical (ATC) Classification System
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S01F Mydriatics and cycloplegics
S01FA Anticholinergics
S01FA01 atropine 21.5
S01FA06 tropicamide 14.1
S01H Local anesthetics
S01HA Local anesthetics
S01HA03 tetracaine 21.3
S01J Diagnostic agents
S01JA Colouring agents
S01JA01 fluorescein 14.1
S02 Otologicals
S02A Antiinfectives
S02AA Antiinfectives
S02AA10 acetic acid 28
S02AA15 ciprofloxacin 28
V VARIOUS
V03 All other therapeutic products
V03A All other therapeutic products
V03AB Antidotes
V03AB03 edetates* 4.2
V03AB06 thiosulfate* 4.2; 13.1
V03AB08 sodium nitrite 4.2
V03AB09 dimercaprol 4.2
V03AB14 protamine* 10.2
V03AB15 naloxone 4.2
V03AB17 methylthioninium chloride (methylene blue) 4.2
V03AB23 acetylcysteine 4.2
V03AB31 potassium ferric hexacyanoferrate (II) -2H2O (Prussian blue) 4.2
V03AB34 fomepizole  4.2
V03AC Iron chelating agents
V03AC01 deferoxamine 4.2; 10.3
V03AF Detoxifying agents for antineoplastic treatment
V03AF01 mesna 8.2
V03AF03 calcium folinate 8.2
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V03AN Medical gases
V03AN01 oxygen 1.1.1
V04 Diagnostic agents
V04C Other diagnostic agents
V04CF Tuberculosis diagnostics
V04CF01 tuberculin, purified protein derivative (PPD) - BCG* 19.1
V07 All other non-therapeutic products
V07A All other non-therapeutic products
V07AB Solvents and diluting agents, incl. irrigating solutions* 26.3
V07AB Water for Injection 26.3
V07AV Technical disinfectants* 15.2
V08 Contrast media
V08A X-ray contrast media, iodinated
V08AA Watersoluble, nephrotropic, high osmolar X-ray contrast media
V08AA01 diatrizoic acid* 14.2
V08AB Watersoluble, nephrotropic, low osmolar X-ray contrast media
V08AB02 iohexol 14.2
V08AC Watersoluble, hepatotropic X-ray contrast media
V08AC02 iotroxic acid* 14.2
V08B X-ray contrast media, non-iodinated
V08BA Barium sulfate containing X-ray contrast media
V08BA01 barium sulfate with suspending agents* 14.2
* Medicine or item name differs slightly from the name used.
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abacavir (ABC) J05AF06 6.4.2.1
acetazolamide S01EC01 21.4
acetic acid S02AA10 28
acetylcysteine V03AB23 4.2
acetylsalicylic acid B01AC06 7.1; 12.5; 30.3
acetylsalicylic acid N02BA01 2.1; 7.1
aciclovir J05AB01 6.4.1
aciclovir S01AD03 21.1
albendazole P02CA03 6.1.1; 6.1.2
alcuronium M03AA01 20
allopurinol M04AA01 8.2; 30.1
amikacin J01GB06 6.2.4
amiloride C03DB01 16
amiodarone C01BD01 12.2
amitriptyline N06AA09 2.3; 24.2.1
amlodipine C08CA01 12.3
amodiaquine P01BA06 6.5.3.1
amoxicillin J01CA04 6.2.1
amoxicillin and enzyme inhibitor* J01CR02 6.2.1
amphotericin B J02AA01 6.3; 6.5.2
ampicillin J01CA01 6.2.1
anti-D immunoglobulin (human) J06BB01 19.2
antitetanus immunoglobulin (human) J06BB02 19.2
artemether P01BE02 6.5.3.1
artemether and lumefantrine P01BF01 6.5.3.1
artesunate P01BE03 6.5.3.1
artesunate and amodiaquine P01BF03 6.5.3.1
artesunate and mefloquine P01BF02 6.5.3.1
ascorbic acid A11GA01 27
asparaginase L01XX02 8.2
atazanavir J05AE08 6.4.2.3
atracurium M03AC04 20
atropine A03BA01 1.3; 4.2
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Medicine or item as in EML ATC code Section
atropine S01FA01 21.5
azathioprine L04AX01 8.1; 30.2
azithromycin J01FA10 6.2.2; 21.1
bacterial and viral vaccines, combined* J07CA 19.3
barium sulfate with suspending agents* V08BA01 14.2
beclometasone R03BA01 25.1
benzathine benzylpenicillin J01CE08 6.2.1
benznidazole P01CA02 6.5.5.2
benzoyl peroxide D10AE01 13.5
benzyl benzoate P03AX01 13.6
benzylpenicillin J01CE01 6.2.1
betamethasone D07AC01 13.3
bevacizumab  L01XC07  21.6
biperiden N04AA02 9
bisoprolol C07AB07 12.1; 12.2; 12.3; 12.4
bleomycin L01DC01 8.2
budesonide R01AD05 28
bupivacaine N01BB01 1.2
caffeine citrate N06BC01 29
calamine lotion D02AB 13.3
calcium folinate V03AF03 8.2
calcium gluconate A12AA03 4.2; 27
capreomycin J04AB30 6.2.4
carbamazepine N03AF01 5; 24.2.2
carbamide* D02AE01 13.5
carbohydrates* B05BA03 26.2
carboplatin L01XA02 8.2
cefalexin J01DB01 6.2.1
cefazolin J01DB04 6.2.1
cefixime J01DD08 6.2.1
cefotaxime J01DD01 6.2.1
ceftazidime J01DD02 6.2.1
ceftriaxone J01DD04 6.2.1
chlorambucil L01AA02 8.2
chloramphenicol J01BA01 6.2.2
chlorhexidine D08AC02 15.1; 29.1
chloroquine P01BA01 2.4; 6.5.3.1; 6.5.3.2
chloroxylenol D08AE05 15.2
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chlorpromazine N05AA01 24.1
cholera vaccines J07AE 19.3
ciclosporin L04AD01 8.1
ciprofloxacin J01MA02 6.2.2
ciprofloxacin S02AA15 28
clarithromycin J01FA09 6.2.2
clindamycin J01FF01 6.2.2
clofazimine J04BA01 6.2.3
clomifene G03GB02 18.6
clomipramine N06AA04 24.4
clotrimazole G01AF02 6.3
cloxacillin J01CF02 6.2.1
clozapine N05AH02 24.1
coagulation factor IX, II, VII and X 
in combination*
B02BD01 11.2.2
coagulation factor VIII* B02BD02 11.2.2
codeine R05DA04 2.2
colecalciferol* A11CC05 27
Combinations of drugs for treatment 
of tuberculosis*
J04AM 6.2.4
cyclizine R06AE3 2.3
cyclophosphamide L01AA01 8.2
cycloserine J04AB01 6.2.4
cytarabine L01BC01 8.2
dacarbazine L01AX04 8.2
dactinomycin L01DA01 8.2
dapsone J04BA02 6.2.3
daunorubicin L01DB02 8.2
deferoxamine V03AC01 4.2; 10.3
dexamethasone H02AB02 2.3; 3; 8.3; 17.2; 29.2
dextran* B05AA05 11.3
diatrizoic acid* V08AA01 14.2
diazepam N05BA01 2.3; 5; 24.3
didanosine (ddI) J05AF02 6.4.2.1
diethylcarbamazine P02CB02 6.1.2
digoxin C01AA05 12.2; 12.4
diloxanide P01AC01 6.5.1
dimercaprol V03AB09 4.2
diphtheria antitoxin J06AA01 19.2
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Medicine or item as in EML ATC code Section
diphtheria toxoid* J07AF01 19.3
docetaxel L01CD02 8.2
docusate sodium  A06AA02 2.3
dopamine C01CA04 12.4
doxorubicin L01DB01 8.2
doxycycline J01AA02 6.2.2; 6.5.3.1; 6.5.3.2
edetates* V03AB03 4.2
efavirenz (EFV or EFZ) J05AG03 6.4.2.2
efavirenz + emtricitabine + tenofovir J05AR06 6.4.2
eflornithine P01CX03 6.5.5.1
electrolytes with carbohydrates* B05BB02 26.2
electrolytes* B05BB01 26.2
emtricitabine J05AF09 6.4.2.1
emtricitabine + tenofovir J05AR03 6.4.2
enalapril C09AA02 12.3; 12.4
encephalitis, Japanese, inactivated, 
whole virus
J07BA02 19.3
ephedrine R03CA02 1.2
epinephrine S01EA01 21.5
epinephrine (adrenaline) C01CA24 3; 12.2; 25.1
ergocalciferol A11CC01 27
ergometrine G02AB03 22.1
erythromycin J01FA01 6.2.2
ethambutol J04AK02 6.2.4
ethambutol and isoniazid* J04AM03 6.2.4
ethanol D08AX08 15.1
ethionamide J04AD03 6.2.4
ethosuximide N03AD01 5
etoposide L01CB01 8.2
fluconazole J02AC01 6.3
flucytosine J02AX01 6.3
fludrocortisone H02AA02 18.1
fluorescein S01JA01 14.1
fluorouracil L01BC02 8.2; 13.4
fluoxetine N06AB03 24.2.1
fluphenazine N05AB02 24.1
folic acid B03BB01 10.1
fomepizole  V03AB34 4.2
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fresh frozen plasma* B05AX03 11.1
furosemide C03CA01 12.4; 16
gentamicin J01GB03 6.2.2
gentamicin S01AA11 21.1
glibenclamide A10BB01 18.5
gliclazide A10BB09 18.5
glucagon H04AA01 18.5
glucose* B05BA03 26.2
glucose with sodium chloride* B05BB02 26.2
glyceryl trinitrate C01DA02 12.1
griseofulvin D01BA01 6.3
haloperidol N05AD01 2.3; 24.1
halothane N01AB01 1.1.1
heparin* B01AB01 10.2
hepatitis A vaccine J07BC02 19.3
hepatitis B vaccine J07BC01 19.3
hydrazaline C02DB02 12.3
hydrochlorothiazide C03AA03 12.3; 12.4; 16
hydrocortisone A07EA02 17.3
hydrocortisone D07AA02 13.3
hydrocortisone H02AB09 3; 8.3
hydromorphone N02AA03 2.2
hydroxocobalamin B03BA03 10.1
hydroxycarbamide L01XX05 8.2; 10.3
hydroxychloroquine P01BA02 30.2
hyoscine butylbromide* A03BB01 2.3
hyoscine hydrobromide* A04AD01 2.3
ibuprofen M01AE01 2.1; 29
ifosfamide L01AA06 8.2
imipenem and enzyme inhibitor* J01DH5 6.2.1
immunoglobulins, normal human, for 
extravascular admin*
J06BA01 11.2.1
immunoglobulins, normal human, for 
intravascular admin*
J06BA02 11.2.1
indinavir (IDV) J05AE02 6.4.2.3
influenza vaccine J07BB 19.3
insulin injection (soluble)* A10AB 18.5
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insulin, intermediate-acting* A10AC 18.5
Intravaginal contraceptives* G02BB 18.3.4
Iodine therapy* H03CA 18.8
iohexol V08AB02 14.2
iotroxic acid* V08AC02 14.2
ipratropium bromide R03BB01 25.1
Iron in combination with folic acid* B03AD 10.1
Iron preparations* B03A 10.1
isoflurane N01AB06 1.1.1
isoniazid J04AC01 6.2.4
isosorbide dinitrate C01DA08 12.1
Isotonic solutions* B05DA 23
ivermectin P02CF01 6.1.2
kanamycin J01GB04 6.2.4
ketamine N01AX03 1.1.2
lactulose  A06AD11 2.3
lamivudine (3TC) J05AF05 6.4.2.1
lamivudine + nevirapine + stavudine J05AR07 6.4.2
lamivudine + nevirapine + zidovudine J05AR05 6.4.2
lamivudine + zidovudine (ZDV or AZT) J05AR01 6.4.2
latanoprost  S01EE01 21.4
levamisole P02CE01 6.1.1
levodopa and decarboxylase inhibitor* N04BA02 9
levofloxacin J01MA12 6.2.4
levonorgestrel G03AC03 18.3.1
levonorgestrel and estrogen* G03AB03 18.3.1
levothyroxine sodium* H03AA01 18.8
lidocaine C01BB01 12.2
lidocaine N01BB02 1.2
lidocaine, combinations* N01BB52 1.2
lithium* N05AN01 24.2.2
loperamide  A07DA03 2.3
lopinavir + ritonavir (LPV/r)* J05AE30 6.4.2.3
loratadine  R06AX13  3
lorazepam N05BA06 5
Lung surfactants R07AA 29.1
magnesium sulfate B05XA05 5
mannitol B05BC01 16
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measles vaccine, live attenuated* J07BD01 19.3
mebendazole P02CA01 6.1.1
medicinal charcoal* A07BA01 4.1
medroxyprogesterone and estrogen* G03AA08 18.3.2
medroxyprogesterone* G03AC06 18.3.2; 18.7
mefloquine P01BC02 6.5.3.1; 6.5.3.2
meglumine antimoniate P01CB01 6.5.2
melarsoprol P01CD01 6.5.5.1
meningococcal vaccines* J07AH 19.3
mercaptopurine L01BB02 8.2
mesna V03AF01 8.2
metformin A10BA02 18.5
methadone N07BC02 24.5
methotrexate L01BA01 8.2; 30.2
methyldopa (levorotatory)* C02AB01 12.3
methylprednisolone Ho2AB04 8.3
methylthioninium chloride (methylene blue) V03AB17 4.2
metoclopramide A03FA01 2.3; 17.2
metronidazole J01XD01 6.2.2; 6.5.1
metronidazole P01AB01 6.5.1
miconazole D01AC02 13.1
midazolam N05CD08 1.3
mifepristone G03XB01 22.1
miltefosine L01XX09 6.5.2
misoprostol G02AD06 22.1
morphine N02AA01 1.3; 2.2
multienzymes (lipase, protease, etc.)* A09AA02 17
mumps vaccine, live attenuated* J07BE01 19.3
mupirocin D06AX09 13.2
naloxone V03AB15 4.2
neostigmine N07AA01 20
nevirapine (NVP) J05AG01 6.4.2.2
niclosamide P02DA01 6.1.1
nicotinamide A11HA01 27
nicotine replacement therapy* N07BA01 24.5
nifedipine C08CA05 22.2
nifurtimox P01CC01 6.5.5.1; 6.5.5.2
nitrofurantoin J01XE01 6.2.2
nitroprusside* C02DD01 12.3
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nitrous oxide N01AX13 1.1.1
norethisterone and estrogen* G03AA05 18.3.1
norethisterone* G03AC01 18.3.2
nystatin D01AA01 6.3
ofloxacin J01MA01 6.2.4; 21.1
omeprazole A02BC01 17.1
ondansetron A04AA01 17.2
oral rehydration salt formulations* A07CA 17.5.1; 26.1
oseltamivir J05AH02 6.4.3
other antiseptics and disinfectants* D08AX 15.2
other mineral products* A12CX 27
oxamniquine P02BA02 6.1.3
oxycodone N02AA05 2.2
oxygen V03AN01 1.1.1
oxytocin H01BB02 22.1
paclitaxel L01CD01 8.2
p-aminosalicylic acid* J04AA01 6.2.4
paracetamol N02BE01 2.1; 7.1
paromomycin A07AA06 6.5.2
peginterferon alfa-2a* L03AB11 6.4.3
peginterferon alfa-2b* L03AB10 6.4.3
penicillamine M01CC01 4.2; 30.2
pentamidine isethionate* P01CX01 6.5.4; 6.5.5.1
permethrin P03AC04 13.6
pertussis vaccine J07AJ01 19.3
phenobarbital N03AA02 5
phenoxymethylpenicillin J01CE02 6.2.1
phenytoin N03AB02 5
phytomenadione B02BA01 10.2
pilocarpine S01EB01 21.4
plastic IUD with copper* G02BA02 18.3.3
plastic IUD with progesteron* G02BA03 18.3.5
platelet concentrates B05A 11.1
pneumococcus, purified 
polysaccharides antigen*
J07AL01 19.3
podophyllotoxin* D06BB04 13.5
poliomyelitis vaccine J07BF 19.3
potassium chloride B05XA01 26.1; 26.2
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potassium ferric hexacyanoferrate (II) -2H2O 
(Prussian blue)
V03AB31 4.2
potassium permanganate D08AX06 13.2
povidone-iodine* D08AG02 15.1
praziquantel P02BA01 6.1.1; 6.1.3
prednisolone H02AB06 3; 8.3
prednisolone S01BA04 21.2
primaquine P01BA03 6.5.3.1
procaine benzylpenicillin J01CE09 6.2.1
procarbazine L01XB01 8.2
proguanil P01BB01 6.5.3.2
propofol N01AX10 1.1.2
propranolol C07AA05 7.2
propylthiouracil H03BA02 18.8
protamine* V03AB14 10.2
protionamide J04AD01 6.2.4
pyrantel P02CC01 6.1.1
pyrazinamide J04AK01 6.2.4
pyridostigmine N07AA02 20
pyridoxine A11HA02 27
pyrimethamine P01BD01 6.5.4
pyrimethamine, combinations* P01BD51 6.5.3.1
quinine P01BC01 6.5.3.1
rabies immunoglobulin J06BB05 19.2
rabies vaccine J07BG 19.3
ranitidine A02BA02 17.1
red blood cells* B05AX01 11.1
retinol A11CA01 27
ribavirin J05AB04 6.4.3
riboflavin A11HA04 27
rifabutin J04AB04 6.2.4
rifampicin J04AB02 6.2.3; 6.2.4
rifampicin and isoniazid* J04AM02 6.2.4
rifampicin, pyrazinamide and isoniazid* J04AM05 6.2.4
rifampicin, pyrazinamide, ethambutol 
and isoniazid*
J04AM06 6.2.4
risperidone N05AX08 24.1
ritonavir (r) J05AE03 6.4.2.3
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Medicine or item as in EML ATC code Section
rota virus diarrhea vaccines* J07BH 19.3
rubella vaccines J07BJ 19.3
salbutamol R03AC02 25.1
salbutamol R03CC02 25.1
salicylic acid D01AE12 13.5
saquinavir (SQV) J05AE01 6.4.2.3
selenium sulfide D01AE13 13.1
senna glycosides* A06AB06 17.4
silver sulfadiazine D06BA01 13.2
simvastatin C01AA01 12.6
snake venom antiserum* J06AA03 19.2
sodium bicarbonate* B05XA02 26.2
sodium chloride B05XA03 26.2
sodium fluoride A12CD01 27
sodium nitrite V03AB08 4.2
sodium stibogluconate P01CB02 6.5.2
Solvents and diluting agents, incl. 
irrigating solutions*
V07AB 26.3
spectinomycin J01XX04 6.2.2
spironolactone C03DA01 16; 12.4
stavudine (d4T) J05AF04 6.4.2.1
streptokinase B01AD01 12.5
streptomycin J01GA01 6.2.4
sulfadiazine J01EC02 6.5.4
sulfamethoxazole + trimethoprim J01EE01 6.2.2; 6.5.4
sulfasalazine A07EC01 17.3; 30.2
suramin sodium P01CX02 6.5.5.1
suxamethonium M03AB01 20
tamoxifen L02BA01 8.3
Technical disinfectants* V07AV 15.2
tenofovir disoproxil fumarate J05AF07 6.4.2.1
terbinafine D01BA02 13.1
testosterone G03BA03 18.2
tetanus toxoid* J07AM01 19.3
tetracaine S01HA03 21.3
tetracycline S01AA09 21.1
thiamine A11DA01 27
thiosulfate* V03AB06 4.2; 13.1
Annex 4: Alphabetical list of essential medicines (with ATC classification code numbers)
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timolol S01ED01 21.4
tioguanine L01BB03 8.2
tranexamic acid B02AA02 10.2
triclabendazole P02BX04 6.1.3
trimethoprim J01EA01 6.2.2
tropicamide S01FA06 14.1
tuberculin, purified protein derivative 
(PPD) - BCG*
V04CF01 19.1
tuberculosis, live attenuated* J07AN01 19.3
typhoid vaccine J07AP 19.3
valproic acid N03AG01 5; 24.2.2
vancomycin J01XA01 6.2.2
varicella zoster vaccines* J07BK 19.3
vecuronium M03AC03 20
verapamil C08DA01 12.1; 12.2
vinblastine L01CA01 8.2
vincristine L01CA02 8.2
warfarin B01AA03 10.2
Water for Injection V07AB 26.3
whole blood* B05A 11.1
xylometazoline R01AA07 28
yellow fever vaccines J07BL 19.3
zidovudine (ZDV or AZT) J05AF01 6.4.2.1
Zinc products* D02AB 13.3
zinc sulfate A12CB01 17.5.2
* Medicine or item name differs slightly from the name used.
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